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Recent advancement in the field of drug formulation and discovery of gold(I) compounds 
is leading to the innovation of new and unusual gold(I) molecules with linear structure 
and geometry around the cation. The gold(I) dithiocarbamate complexes, (2-17), (18-22), 
(23-26), (27-30) and (31-34), type ([Au(R3P)(R2NCS2)] (where R2= dimethyl, diethyl and 
dibenzyl) were prepared by the reaction of R3PAuCl compound with sodium 
dimethyldithiocarbamate monohydrate and sodium diethyl dithiocarbamate trihydrate and 
dibenzyldithiocarbamate, respectively. The precusors have been prepared by the reaction 
of (CH3)2SAuCl (1) with equimolar amount of R3P.  In addition, the complexes of 
gold(I) phosphine (35-37), gold(I) carbene (38-50), gold(I) thione (51-55) and gold(I) 
carbene (56-65) have been prepared. These complexes were characterized by FT-IR, 1H, 
13C, 31P, 77Se NMR spectroscopy and elemental analysis. Complexes 27, 39, 44, 46, 48, 
49, 54, 55, 56, 61, 63 and 65 were characterized by X-ray diffraction analysis, showing 





19.56 ± 0.85, 29.25 ± 1.81 and 34.42 ± 1.02 μM) showed potent in vitro cytotoxicity 
one-to-two fold higher than cisplatin (IC50 42.2 ± 2.01 μM) against A549 (human lung 
carcinoma). Furthermore, complex 48 (IC50 27.97 ± 1.67) showed better in vitro 
cytotoxicity than cisplatin (IC50 32.04 ± 2.12 μM) against HCCT15. All other studied 
complexes exhibited similar and moderate to lower in vitro cytotoxicity against A549, 
HCT15 (human colon cancer) and HeLa (human cervical cancer) cell lines.  
The interactions of the synthesized [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3  
complexes, (DACH=cis-1,2-diaminocyclohexane), with enriched (13C,15N) thiourea and 
1,3-diazinane-2-thione  ligands were investigated. The progress of these reactions was 
monitored with NMR (1H, 13C and 15N) and UV-Vis spectroscopy as well as square wave 
stripping voltammetry. The kinetics of the substitution reactions between the 
above-mentioned complexes with thione ligands were studied in aqueous solutions 
containing 30 mM KCl, which is used to suppress hydrolysis of the chloride complex. 
The reactions were followed under pseudo first-order conditions as a function of ligand 
concentration, pH and temperature in the range of 15-37 °C. The activation parameters 
(ΔH#, ΔS#) were calculated from Eyring plot and the negative values of ∆S≠ lend support 
for an associative mechanism. The kinetic data also indicate a relatively higher reactivity 
of [Au(cis-DACH)Cl2]Cl than [Au(cis-DACH)2]Cl3 towards the thiones. 
The interaction of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 complexes [where 
cis-DACH: is cis-1,2-diaminocyclohexane] with  enriched (13C,15N) KCN were carried 
out in CD3OD and D2O, respectively. The reaction pathways of these complexes were 
studied by 1H, 13C, 15N NMR, UV spectrophotometry and electrochemistry. The kinetic 





M-1s-1, ∆H≠ = 11 kJmol-1, ∆S≠ = -185 JK-1mol-1,  and Ea = 13 kJ mol-1 with SWV peak 
+1.35 V, whereas the kinetic data for the reaction of cyanide ion with 
[Au(cis-DACH)Cl2]Cl  are found to be k = 148 M-1s-1, ∆H≠ = 39 kJmol-1, ∆S≠ = -80 
JK-1mol-1, and Ea= 42 kJmol-1  along with SWV peak +0.82 V, indicating the much 
higher reactively of [Au(cis-DACH)Cl2]Cl toward cyanide ligand than 
[Au(cis-DACH)2]Cl3. The interaction of these complexes with potassium cyanide 
resulted in an unstable [Au(13CN)4]¯ specie, which readily underwent reductive 
elimination reaction to generate [Au(13CN)2] ̅ and cyanogen (NCCN).  
Kinetic measurements revealed the rate constants of the interaction between 
[Au(cis-DACH)Cl2]Cl with Tu and DIAZ are 49.50; 121.70 and 24.31; 46.65 M-1s-1, 
respectively, at 288 K and 310 K. Similarly, the rate constants for [Au(cis-DACH)2]Cl3 
with Tu and DIAZ are found to be 41.88; 64.86 and 21.68; 40.89 M-1s-1, respectively at 
288 K and 310 K. [Au(cis-DACH)Cl2]Cl reacted faster towards thione ligands than 
[Au(cis-DACH)2]Cl3 complex; also Tu reacted faster than DIAZ towards these 
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آدم أحمد عبدهللا سليمان            السم الكامل:             ا   
مع  ( المشتقة من القطات الفوسفينات1اصطناع وتقييم  تضاد السرطان لمعقدات الذهب)+ عنوان الرسالة: 
( المشتقة من القطة 3ودراسة تفاعالت معقدات الذهب)+ ثنائية الكبريت كاربومات
 بعض الجزيئات الحيوية لهكسان الحلقي معاثنائى أمين -2,1
علوم الكيمياء                     التخصص:   
2016مايو تاريخ الدرجة العلمية:                     
عقدات  ختراع مادي الى أ( 1التقدم المتزايد حديثا في مجال صناعة أدوية السرطان مع أكتشاف معقدات الذهب)+
(  1)+( جديدة ذات تركيبة خطية حول أيون الذهب المركزي. حضرت مجموعات متسلسلة من معقدات الذهب1ذهب)+
ثنائي ايثيل الكاربومات و-ثنائي ميثيل ثنائي كبريتتقة من القطات (  مش34-31( و)30-27(، )26-23(، )22-18(، )17-2)
االضافة الي القطات فوسفينات مختلفة. هذه المعقدات آنفة الكاربومات ب-ثنائي بنزيل ثنائي كبريتالكاربومات و-ثنائي كبريت
ومات الكارب ( المشتق من كلوريد وثالثي ألكيل/اريل الفوسفين مع القطات1الذكر تم تحضيرها من تفاعل مركب الذهب)+
كبريتيد كلوريد  ( حضر من تفاعل مركب ثنائي ميثيل1المذكورة سابقا. المركب االولي ثالثي ألكيل/أريل فوسفين كلوريد الذهب)+
                                                                                           ( مع مختلف القطات آحادية وثنائية الفوسفين.1الذهب)+
ربينات  سيلونات (، كا37-35( )1باالضافة الي هذه المعقدات تم تحضير معقدات أخرى وهي فوسفينات الذهب)+  
فوسفينات احادية  وثنائية ب( المرتبطة 1( وكاربينات الذهب)+55-51( )1(، ثيونات الذهب)+50-39( )1الذهب)+
ى المغنطيسى ألنوية      مطيافية االشعة تحت الحمراء والرنين النوودرست خصائص هذه المعقدات بواسطة (.    65-56)
 ورات.نية  للبلالهيدروجين والكربون والفسفور والسيلينيوم باالضافة الي تحليل العناصر ومطيافية حيود االشعة السي
يود حمطيافية  درست خصائصها بواسطة 65و 63, 61, 56, 55, 54, 49, 48 ,46, 44, 39, 27المعقدات باالرقام 
 المركزي. ( 1)+االشعة السينية  وقد أظهرت تركيبة هندسية خطية حول أيون الذهب
أجريت دراسة فاعلية هذه المعقدات مختبريا علي ثالثة انواع من خاليا السرطان المصنعة  وهي سرطان الرئة 
من تلك التي  خلية سرطان الرئة أكثروية جدا ضد فاعلية ق 20-22والقولون وعنق الرحم. أظهرت المعقدات باالرقام 





(. بينما المعقدات االخري اعطت فاعلية اقل من تلك التي 2من معقد السيس بالتين)+ كثرضد خلية سرطان القولون أ
 ( ضد خاليا سرطان الرئة والقولون وعنق الرحم.2وجدت لمعقد  السيس بالتين)+
لهكسان الحلقي ودرست تفاعالتها  مع ثنائي أمين ا-2,1( المشتقة من 3من جهة أخرى حضرت معقدات الذهب)+
لبنفسجية االشعة فوق ا-يون بواسطة مطيافية الضوء المرئيث-2-ثنائي ازانين-3,1يد والثيويوريا والقطات السيان
 ة. جة المربعوالرنين النووي المغنطيسي ألنوية الهيدروجين والكربون والنتروجين باالضافة الي فولتية تعرية المو
ي الكاذبة في لنفة الذكر، عن طريق الرتبة األو( مع الالقطات اآل3درست حركية تفاعالت االستبدال لمعقدات الذهب)+
 30علي كلوريد البوتاسيوم بتركير  ي محاليلها المائية، والتي احتوتف درجة مئوية  15-37ات حرارة تترواح بين درج
 مليموالر لمنع ايونات كلوريد هذه المعقدات من التحلل.
لمعقدات الحراري واالنتروبيا لهذه ا طاقات المحتوىالي حركية التنشيط لحسبت معدالت سرعة التفاعل باالضافة 
لهكسان الحلقي ثنائي أمين ا-2,1( المشتقة من 3باستخدام معادلة ارينج. اوضحت الدراسة بان معقدات الذهب)+
 لتي الاثيون من تلك -2-ثنائي ازانين-3,1المرتبطة بأيونات الكلوريد أسرع تفاعال تجاه القطات السيانيد والثيويوريا و
ضحت الدراسة ان ثيون. كما او-2-ثنائي ازانين-3,1تحتوي علي الكلوريد وكذلك  السيانيد  اسرع من الثيويوريا و
 ( في وجود هذة الالقطات.1معقدات الذهب)+ ( غير مستقرة حينما تختزل الى3ب)+معقدات الذه
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1.1. Gold(III) complexes 
 
Gold was discovered as shining yellow chunks, its symbol derived from Latin name 
Aurum. In early civilizations, humans almost spontaneously attribute a high value to gold 
associating it with power of beauty. In the ancient time 2500 BC, Chinese and Arab have 
used gold in medicine. Gold possesses special characteristic features that make it unique, 
such as high chemical and thermal stability, mechanical softness and high electrical 
conductivity. Gold(III) has electronic configuration d8 ([Xe]4f145d8) and forms 
diamagnetic four coordinate 16e- species with predominantly square-planar geometry 
analogue to Pt(II) complexes. Five coordinate gold(III) complexes are rare [1-2].   
 The unexpected disclosure of cisplatin by Rosenberg in 1965 proclaimed another region 
of anticancer medication research on metal-based medication [3]. Cisplatin has been a 
standout amongst the best chemotherapies in the most recent 30 years, and has been 
utilized to treat various sorts of tumor diseases. In spite of having great usefulness as a 
chemotherapeutic, cisplatin has downsides; tumors regularly create imperviousness to the 
medication, and patients routinely encounter serious symptoms over the span of treatment 





enhance these constraints. Common problems include cumulative toxicities of 
nephrotoxicity and cytotoxicity [5–8]. Notwithstanding the genuine symptoms, the 
remedial adequacy is additionally constrained by regular or treatment-impelled resistance 
tumor cells. These drawbacks have given the inspiration to select chemotherapeutic 
procedures. To stay away from the issue of medication resistance in cisplatin, gold(III)_ 
based compounds have been outlined as a potential distinct option for cisplatin [9–13].  
Gold(III) derivatives have significantly pulled in researcher's consideration in the most 
recent decade for their exceptional cytotoxic activities. It is a metal ion which normally has 
a four-coordinate, square-planar geometry and anticipated to emulate the structure and 
electronic properties of platinum(II). Late studies have demonstrated that few gold(III) 
compounds are exceptionally cytotoxic against various tumor cells [10, 14–16], including 
some which are active even against the cisplatin-resistance cell lines [17–19]. A few lines 
of confirmation propose that gold (III) complexes produce their anti-proliferative impacts 
through innovative and nonconventional modes of activity. Case in point, the speculation 
that their biological impacts are mediated by an antimitochondrial mechanism rather than 
by direct DNA damage, as it is the situation for cisplatin and its analogs, has increased 
much credit amid the most recent couple of decades [12].  
The stringent relationship to Pt(II) complexes makes Au(III) compounds great possibility 
for improvement and testing as anticancer medications, despite the fact that the generally 
high kinetic lability and the normally high redox possibilities have to a great extent ruined 
such investigations. These drawbacks can be dodged by shaping gold(III) derivatives with 
one or more multi-dentate nitrogen ligands to upgrade the strength and stability of gold(III) 





good antitumor properties both in-vitro and in vivo, have bringing new enthusiasm up in 
this research field [23–25].  
 A number of structurally analogues of cisplatin [26] have been tested, later utilized in 
clinical practice [27], one of these is trans-1,2-diaminocyclohexane dichloridoplatinum(II) 
(DACH) [28]. Since the molecule is chiral, the pertinence of stereochemistry has been 
addressed by researchers [29]. The ligand DACH has three isomeric structures: (1R, 
2R-DACH) (trans-DACH), (lS, 2S-DACH) (trans-DACH) and (1R,2S-DACH) 
(cis-DACH). Disregarding conflicting perspectives [30 –34], the agreement is that the (R, 
R) isomer is more active than the (S,S) isomer [35-36], in spite of the fact that activity has 
additionally been shown for the (R, S) isomer [37]. As the stereochemistry of the 
complexes, the DACH platinum compounds of Pt(IR,2R-DACH) and Pt(1S,2S-DACH) 
have a higher antitumor activity than Pt(1R,2S-DACH) complex [38–40]. 
1.2 Gold(I) complexes 
 
Gold(I) has d10 electron configuration which is divided into three distinct classes of 
co-ordination environments:  linear two coordination, so far the most important 
co-ordination environment along with trigonal three-coordination and tetrahedral 
four-coordination. 
 Gold(I) is a soft cation with susceptibility for soft ligands such as: cyanide, thiolate, halide 
(e.g. iodide), and phosphine to form stable species of AuX2-, and AuL2+, respectively [41–
43]. During the last two decades, a large variety of gold(I) and gold(III) compounds have 
been reported to possess anti-proliferative properties in vitro against several human tumor 





The recent literature shows a high number of papers reporting gold(I) phosphine 
complexes with sulphur ligands with application in catalysis, biological activities, 
luminescence, and the medical field. Moreover, the aurophilic interaction is well known in 
gold compounds containing P-, S-, and N- ligands [44–48], Fortman et al. studied 
thermodynamics of ligand exchange reactions in [(tht)AuCl] (tht= tetrahydrothiophene) 
with a series of tertiary phosphines and phosphites. They found that P─Au bond formed to 
be largely dependent on electronics parameters of phosphorus donor, whereas steric of 
ligand seems to play only a minor role in affecting enthalpy and BDE (bond disassociation 
energy). The phosphite ligands bind more weakly to Au centre than phosphine [49]. 
Gold(I) can be oxidized to gold(III) in vivo e.g. by myeloperoxidase system in white cells,  
that may be  responsible for side-effects of gold(I) drugs [50]. On the other hand, gold(I) 
predominates the biochemistry of gold compounds, which is stabilized via π-acceptor 
ligands.  
Auranofin is the first gold(I) phosphine lipophilic complex utilized into clinical practice 
for the treatment of rheumatoid arthritis. Also some of mixed ligands phosphine and 
thiolate gold(I) complexes have been tremendously shown to induce cell death, with 
varying characteristics depending on the cell type such as:  solganol, myocrisin, 






Scheme 1: Some gold(I) complexes are used in rheumatic arthritis treatment. 
 
These complexes and other gold(I) compounds including phosphine ligands such as Gopl 




Scheme 2: Gold(I) phosphine anticancer drug (GoPl) 
Gold(I) N-heterocyclic carbene (NHC) complexes were obtained in good yields from the 
corresponding silver complexes by treatment with [AuCl(PPh3)]. These complexes have 
been characterized by 1H, 13C-NMR, IR spectroscopy and elemental analysis. Au-NHC 
complexes were evaluated for their in vitro antimicrobial activity against a variety of 
Gram-positive and Gram-negative bacteria and fungal species [53]. 
A series of gold(I) phosphine complexes containing naphtha-imide ligand have been 





anti-proliferative effects in MCF-7 breast cancer cells and HT-29 colon carcinoma cells 
[54]. 
In this thesis, I would like to explore the nature of bonding in Au(III) cis-DACH type 
complexes and to study their stability, when exposed to cyanide, thiones.  Cyanide occurs 
naturally and blood of smokers contains high amount of SCN¯. Myeloperoxidase (MPO) 
converts SCN¯ to cyanide.  1H, 13C, and 15N solution NMR were used to study these 
interactions. In addition, different types of [(R3P-Au-S2CNR], gold(I)_carbene with 
selones, gold(I)_ter-t-butylphosine with thione, and gold(I)_carbene with phosphine 
complexes were synthesized, and then were characterize by using 1H, 13C, 31P solution 
and solid NMR. 
 
 1.3 RESEARCH OBJECTIVES 
 
1. Preparation of the two complexes, [cis-1,2-(DACH)AuCl2]Cl and [cis-1,2-
(DACH)2Au]Cl3. 
2. Study of interactions of the complexes prepared in objective 1 with thiones such 
as IMT, DIAZ, and DIAP along with thiourea and cyanide using UV 
spectroscopy, 1H NMR, 13C NMR, and 15N NMR.  
3. Study of interactions of these complexes with labeled nucleobases: Guanine (8-
13C, 7, 9 15N2), Adenine (8-13C, 6-amino and 1, 9 15N2), Cytosine (2,4-13C2, 15N3) 






4. Synthesis of complexes of the type [R3P-Au-PR3]+ and [R3P-Au-S2CNR2], where 






phenyl]-1-phenylethylamine, (3-diphenylphosphino)propylamine, 2-(D-i-propyl- 
phosphino)ethylamine, and 3-(D-i-propylphosphino)propylamine and NR2CS2¯ =   
 dimethyldithiocarbamate (DMTC), diethyldithiocarbamate (DETC), and 
dibenzyldithiocarbamate (DBTC). 
5. Characterization of gold(I) phosphine complexes using 1H, 13C, 31P NMR, IR, 
elemental analysis, and single crystal X-ray. 
6. Study of their cytotoxic activity against A549 (human lung cancer), MCF7 (human 












2.1. Gold(III) complexes 
 
Since early 1990s, the chemistry of gold has been a well-established area of research.   
The metal and its complexes have special characteristic features that make them suitable 
for several research fields. For instance, a huge number of these complexes have antitumor 
action with positive results [55, 56]. Recently, using various Au(III) complexes with novel 
functionality has elicited more interest due to their distinct physical and chemical 
properties, stability under physiological conditions, and outstanding cytotoxic effects 
[57,58]. Cis-diamminedichloridoplatinum(II) (cisplatin) is one of the most widely used 
anticancer drugs today. However, platinum compounds possessing the 
1,2-diaminocyclohexane (DACH) carrier ligand offer advantages over cisplatin with 
regard to bioavailability, activity and decreased renal toxicity [59].  Furthermore, success 
of oxaliplatin, (1R,2R-DACH)PtC2O4 complex, raised considerable research interest over 






2.1.1. Complexes formed from (C, N) donor ligands 
Bugarčić et. al. [61] recently have studied the kinetics of the substitution reactions of 
gold(III) compounds bearing 3-azapentane-1,5-diamine, 2,2′,6′,2′′-terpyridine, 
2.2′-bipyridine and 1,2-diaminocyclohexaneligands associated with biologically 
applicable ligands, for example, L-histidine (L-His), inosine (Ino), inosine-5′- 
monophosphate (5′-IMP) and guanosine-5′-monophosphate (5′-GMP). Their outcomes 
demonstrated that the [Au(terpyridine)Cl]2+ complex is the most reactive one, which was 
affirmed by (DFT) computations [61].  The nucleophiles reactivity order are: L-His > 
5′-GMP > 5′-IMP > Ino.  
As per the deliberate activation parameters, all studied reactions affiliated an associative 
substitution mechanism. The outcomes show strong association between the reactivity of 
these complexes toward biological pertinent ligands and their chemical and electronic 
characteristics. Hence, the binding of gold(III) compounds to 5′-GMP, constituent of 
DNA, is exceptionally compelling since this connection is thought to be in charge of their 
anticancer activity.  
Over the past several years, significant effort has been devoted to study the antitumor 
activity of platinum-DACH complexes, whereas, gold-DACH complexes [62] have 
generally little consideration despite the fact that gold(III) has a genuinely rich biological 
nature. For instance, it has redox activity, can be facilitated by amino acids and proteins 
[63]. As on account of cisplatin, the anticancer activity of platinum–DACH is associted by 
some toxicity. The rise of resistance and low water solubility that can influence the 
pharmacokinetics are extra components that should be enhanced in the mission for more 





Promising results were obtained with a class of gold(III) compounds with 
2-(dimethylamino)methylphenyl ligand synthesized in such an approach to settle gold in 
its +3 oxidation state. These compounds showed cytotoxic impacts against a few human 
tumor cell lines, tantamount to, or more noteworthy than cis-platin [65]. 
In recent literature Messori et al. brought up the in vitro test of a series of gold(III) 
compounds, such as [Au(en)2]Cl3 against the A2780 ovarian malignancy cell line and a 
cisplatin safe variation [10, 65]. A number of other gold(III) compounds have been 
prepared and their cytotoxicity has been assessed. Calamai et al. studied gold(III) 
compounds containing no less than two gold-chloride bonds in cis-position [66, 67]. 
Arsenijevic et al [68] studied the kinetics of the reaction of [Au(en)Cl2]Cl, [Au(bipy)Cl2]Cl 
and [Au(DACH)Cl2]Cl with 5’-GMP. They observed the spectral changes upon mixing of 
the complex with the 5’-GMP in λmax in the range (280─350 nm). All kinetics 
measurements were performed under pseudo-first order conditions. The activation 
parameters suggest an associative mechanism. They measured their reactions at three 
different temperatures and reported the rate constants and activation parameters. 
In biological systems, the imidazole group of histidine is frequently found in combination 
with copper ions, but also with nickel and zinc ions whereas the cobalt ion, in vitamin B12, 
is coordinated to the benzimidazole group [69, 70]. In the blue copper protein, the Cu(II) is 
ligated in a distorted-tetrahedral arrangement of two histidine nitrogens, a cysteine thiolate 
sulfur and a methionine thioether sulfur [71]. For the modeling of this active site, 





Imidazole as shown below is a planar 5-membered aromatic molecule [72]. The electrons 
in the unhybridized p-orbital of N1 form part of the aromatic sextet.  The all-electron 
computation for the imidazole [73] molecule was reported previously, and the net charges 









Scheme 3. Basic imidazole structure (both N1 and N3 has one lone pair each). 
 
The nitrogen atoms in imidazole are in two different environments. The N1 electrons are 
not available for bonding, since the aromicity of the imidazole molecule will be 
compromised, unless this nitrogen deprotonates and has an available pair of electrons.  
The N3 nitrogen displays fractionally negative σ and π electron charges, indicating that it is 
a modest σ-donor and a weak π-acceptor when involved in bonding.  Therefore, the 
imidazole molecule presents a single energetically favorable coordination site for a metal 
ion, namely the unshared electron pair on N3. 
A metal ion can bind at N3, thereby forming a metal ion complex containing a neutral 
imidazole.  In fact, there are extensive studies of biological systems with the imidazole 
core, especially with N-alkylated derivatives, and these models display the coordination 
of the N3 nitrogen to the metal ions [69, 70, 73-74].  However, the neutral imidazole can 





Megumu et al. [75] have already studied the interactions of imidazole with Cd2+ in 
solution.  Barbarossou et al. [76] have studied the interaction of the mononucleotides 
guanosine-5'- monophosphate (5'-GMP2-) and inosine-5'-monophosphate (5'-IMP2-) with 
Na+, Ba2+, and Cd2+ by 15N and 113Cd CP MAS NMR spectra in the solid state at natural 
abundance. The 15N CP MAS NMR spectrum of Cd(5'-GMP)·5H2O shows sharp single 
resonances for all the purine nitrogens in agreement with the X-ray structure, which 
demonstrates the presence of one nucleotide and one metal ion per crystal unit [77].  The 
X-ray structure is typical for transition and heavy metal complexes with a 1:1 ratio of metal 
to guanosine-5'-monophosphate monomeric structure with the general formula 
[M(5'-GMP)(H2O)5]·nH2O. The common features of this type of structure are the M-N (7) 
metal bonding and three intramolecular hydrogen bonds; one between a water molecule 
and O(6) and two between water molecules and phosphate oxygens. The N(7) resonance 
absorption in Cd2+ complex is strongly shielded by -29.6 and -31.9 ppm compared to that 
of the Na+ and Ba2+ complexes, respectively. This demonstrates significantly different 
binding modes to N(7), although X-ray structural data have been interpreted in terms of 
direct metal ion-N(7) interaction for Na+, Ba2+, and Cd2+ complexes [78-79].  
Unambiguous demonstration of a direct Cd-N coordination bond is provided by the 113Cd 
CP MAS NMR spectrum, which indicates the presence of an asymmetric 1:1:1 triplet due 
to (113Cd, 14N) indirect and residual dipolar spin-spin interactions [80–82]. 
2.1.2 Complexes formed from (N, S) donor ligands 
Thiolate complexes are of great importance from a bioinorganic point of view, mainly 
due to the presence of thiolate donors in the coordination sphere of many metal ions in 





Complexes of heterocyclic thiones such as imidazolidine-2-thione (Imt), diazinane- 
2-thione (Diaz) and their derivatives with transition metals are of interest in bioinorganic 
chemistry because of the search for simple model compounds for metal proteins [84–86].  
In view of this, copper(I) [89], silver(I) [88, 89],  gold(I) [90–92], mercury(II) [93, 94] and 
cadmium(II) [95] complexes with thiones have been widely studied in recent years. the 
coordination chemistry of >C=S ligands with d10 metal ions have been investigated in an 
attempt to assess their mode of binding and to study their physical properties [96–97]. In 
biological systems, the imidazole group of histidine is frequently found in combination 
with copper ions, but also with nickel and zinc ions whereas the cobalt ion in vitamin B12 is 
coordinated to the benzimidazole group [69, 70].  In the blue copper protein, the Cu(II) is 
ligated, in a distorted-tetrahedral arrangement to two histidine nitrogens, a cysteine thiolate 
sulfur and a methionine thioether sulfur [96].  For the modeling of this active site, 
imidazole- and thioether containing ligands are relevant. Mononuclear Au(III) compounds 
of the peptides H-His-Met-OH (D) and H-Gly-Gly-Met-OH (T) were structurally 
characterized by IR, MS and NMR [86]. In Au(III) complexes with dipeptides, Au(III) is 
bonded to S of imidazole, N of methionine and histidine ligands shaping macrochelate 
rings [98].  
The dithiocarbamate gold(III) compounds have additionally been analyzed lately [99]. 
Dimethyl dithiocarbamate (DMDT) which forms [(DMDT)AuX2] demonstrate more 
cytotoxic action than cisplatin even toward human tumor cell lines naturally impervious to 
cisplatin itself.  
Dinger and Henderson [100] have additionally shown the potential pharmacological action 





benzylamine compounds, these compounds showed better cytotoxic action in vitro. These 
compounds were assessed against the P388 leukemia cell line, and subsequently their 
potential activity against human tumors requires further examination. 
El-Maythalony et al. monitored the interaction of auricyanide [Au(CN)4]- with biologically 
important thiols, thioether and selenoether using 1H and 13 C NMR and UV spectroscopy. 
These ligands include L-cysteine, glutathione, captopril, L-methionine and 
DL-seleno-methionine. They pointed out L-cysteine reaction mechanism with [Au(CN)4]‾ 
was found to be dependent on reactants mole ratio. While L-methionine was completely 
inert toward auricyanide, DL-Se-methionine showed some reactivity with [Au(CN)4]‾  
after raising solution pH to 12 that facilitated cyanide exchange [101]. 
Kouroulis et al. showed that the reaction of tetrachloroauric(III) with the thioamides 
ligands leads to the desulfuration of these ligands. They demonstrated that the reaction of 
HAuCl4 with 2-mercapto-nicotinic acid, leads to of 2-sulfonate-nicotinine with the 
synchronous oxidation of the sulfur molecule. While the reactions of the gold(I) complex 
[Au(Ph3P)Cl] (Ph3P = triphenylphosphine) with the thioamides, 2-mercapto- thiazolidine 
(mtzdH), 2-mercapto-benzothiazole (mbztH) and 5-chloro-2-mercapto- benzothiazole 
(ClmbztH) in the presence of potassium hydroxide brought about the arrangement of the 
gold(I) complexes without ligand desulfuration and were investigated by spectroscopic 
methods such as FT-IR, far-FT-IR, 1H-NMR and X-ray crystallography. These complexes 














Scheme 4: Thioamide ligands. 
 
Glišić et al. used spectroscopic (1H-NMR and UV-vis) and electrochemical (CV) 
techniques to study the interaction of Gly-Met dipeptide with [Au(en)Cl2]+ complex 
resulting  Gly-Met sulfoxide, formed by the oxidation of methionine residue with 
[Au(en)Cl2]+. The formation of Gly-Met sulfoxide proceeds through two steps including 
the monodentate coordination of thioether sulfur atom of methionine residue and release of 
en ligand from Au(III). In addition, the obtained kinetic data showed that oxidation of 
methionine residue in Gly-Met was 200 times slower in comparison to the same process 
with [AuCl4] ‾ complex.  The variation in the oxidation rate of Gly-Met between these two 









Scheme 5: Oxidation of methionine residue in Gly-Met dipeptide in the presence of 
[Au(en)Cl2]+ [103]. 
 
Chi et al. prepared a series of new potential anticancer Au(III) complexes such as 
[(PipDTC)AuCl2] with macro-cyclic amine-based dithiocarbamate ligands. These 
complexes were characterized by elemental analysis, IR, UV, NMR, conductivity 
measurements and X-ray diffraction analysis. They have selective cytotoxic effects against 
a panel of human cancer cells lines. All these complexes show higher cytotoxicity than 
cisplatin against all examined cell lines. The nature of cyclic amine and the number of 





In 2012, a series of new gold(III)-dithiocarbamato (dtc) complexes of oligopeptides as 
promising potential anticancer drugs were synthesized to obtain metal peptidomimetics 
compounds. In vitro cytotoxicity studies pointed  out some of them to be the most  
effective toward the four evaluated human tumor cell lines (PC3, 2008, C13, and L540), 
for which the IC50 values were lower than cisplatin [105]. 
In 2014, M. D. Ðurović et al. studied the effect of tridentate, nitrogen donor ligands on 
stability of gold(III) complexes under physiochemical conditions. They have monitored 
the interaction of [Au(terpy)Cl]2+ (terpy = 2.2’:6, 2” terpyridine), [Au(bpma)Cl]2+ (bpma = 
bis(pyridyl-methyl)amine), [Au(dien)Cl]2+  (dien=diethylenetriamine) and [AuCl4]‾  with 
biological thiols, L-cysteine (L-Cys), glutathione (GSH) and L-methionine (L-Met) using 
UV-Vis and 1H NMR spectroscopy techniques, cyclic voltammetry and ESI-MS. The 
obtained second-order rate constants were determined at different initial concentrations of 
reactants, chloride ions, pH and constant ionic strength [106]. 
2.2 Gold(I) Complexes 
 
2.2.1 Complexes formed from (P, S, Se) donor ligands 
 
Dithiocarbamates are versatile ligands used in a wide range of application such as 
medicine, industry, agriculture and catalysis. Recently, gold(I) phosphine complexes have 
exhibited promising results as novel antitumor drugs against a wide variety of different 
malignancies. 
Scheffler et al. reported a series of chlorido gold(I) phosphine complexes (Cl-Au-PR3) R= 





nuclear uptake in HT-29 colon carcinoma and MCF-7 breast cancer cells. These complexes 
showed significant cytotoxicity results [107]. Four-coordinate gold(I) complexes,  
containing mono-phosphine ligands, these complexes showed strongly luminescence in 
liquid nitrogen and weakly at room temperature in addition to  high cytotoxicity against a 
panel of cancer cell lines [108]. 
Gold(I) thiolate complexes are used extensively in medicine. For instance, gold(I) 
thiosemicarbazone complexes exhibited high efficacy as antimalarial agent [109]. In 
addition, a series of gold(I) complexes with mixed phosphine and dithiocarbamate ligands 
have been synthesized. The stability of these complexes depends on the nature of 
phosphine used. Bis(phenylphosphino) ligands, with alkyls higher than ethyl give stable 
gold(I) complexes in solution (Scheme 6). All these complexes showed promising 






























Scheme 6: Gold(I) with monophosphosphine and dithiocarbamte complexes (1-3), gold(I) 
with (bis-phosphino)alkyl and dithiocarbamate complexes(4-12)[110]. 
 
Jamaludin et al. [111] reported three R3PAu[S2CN(ipr)CH2CH2OH] complexes, where R is 
Ph(1), Cy(2) and Et (3). They showed influence of substituted phosphine on in vitro 
cytotoxic activity against breast cancer cell line and death of cell pathways. They found 
that complex (1) is the most efficient even more than cisplatin and fallows apoptotic 








Figure 2.1. Signaling pathway of apoptosis induced by 1, 2 and 3. This diagram collates 
and summarizes the results of the PCR array analysis, caspase activity study, DNA 
fragmentation and ROS production measurements [111]. 
Recently, phosphinogold(I) organoselenium complexes have emerged as a new area in 
drugs delivery and medicinal applications due to the facts that selenopropteins play 
important role in the metabolism and antioxidant [112–114]. A series of 
organoselenogold(I) complexes (Scheme 7) were reported to have antimalarial activity. 






Scheme 7: Mono- and binuclear gold(I)phosphine complexes containing monoanionic 
seleno-and thiosemicarbazone ligands [115]. 
 
Abdulah et al. reviewed important biological roles of selenium in cancer prevention 
worldwide. They reported that the first clinical trials with Se to induce DNA damage and 
repair  were performed in China [116].   
Al-Maythalony et al. reported Hg(SeCN)2 and Cd(SeCN)2 complexes with histidine and 
glycine, they studied their anti-bacterial activities and they found that histidine ligates 
more strongly than glycine.  Cd(II) complexes have exhibited significant antimicrobial 
activity [117]. Isab et al. demonstrated that Me3PAu+ moiety coordinates more strongly to 
Se containing ligands than Et3PAu+ and Ph3PAu+ moieties, therefore, Me3PAu+ with 
selenium ligands lend to less side effects as anticancer agents [118]. 
Gold complexes bearing N-Heterocyclic carbene (NHC) ligands have been extensively 





soluble NHC complexes with coinage metals (Cu, Ag, Au) have been prepared and their 
biological activity evaluated against A549 lung cancer, HCT-15 colon cell line and 
selenocystiene TrxR (Scheme 8). Au and Ag complexes were found more active than Cu 
complexes [122]. 
2.2.2 Complexes fromed from (P, C, N) donor ligands 
 





Messori et al. synthesized a series of Au(I)- NHC compounds. They further functionalized 
these compounds as useful actively esters to enhance their cytotoxicity and selectivity 
towards human ovarian cancer A2780 cells and HEK-293T cells (Scheme 9). The 
functionalized compounds exposed promising anti-proliferate properties and significant 
selectivity to these cells (Scheme 10) [123]. 













Scheme 10. Synthesis of different Au(I)-NHC compounds through reaction of activated 
ester moiety. 
Two novel Au(I)-NHC complexes with high solubility in physiological media have been 
prepared (Scheme 11). These complexes completely overcome the resistance of 
cisplatinum against A2780 cell line, and their activity against three types of proteins were 
observed [123]. 





The high in vitro and in vivo proficiency binuclear gold(I) complex )1-PF6) with mixed 
diphosphine and bis-(NHC) ligands, with selective thiol reactivity has been prepared 
(Figure 2.2). Bis-(N-heterocyclic carbene) to enhance thiol stability and biphosphine to 
tune thiol reactivity. The stability of this complex allows selective inhibition of thioredoxin 
reductase (TrxR) without reacting with blood thiol. In vitro studies were performed against 
cancer stem cells and in vivo against tumor HeLa xenograft in mice and mouse B16- F10 
melanoma [124]. 
 












SYNTHESIS, ANTI-CANCER EVALAUTION OF NEW 
MIXED-LIGAND GOLD(I) COMPLEXES WITH 
DITHIOCARBAMATES AND PHOSPHINES 
 
 3.1 EXPERIMENTAL SECTION 
 
 3.1.1 Materials and Instrumentation  
All solvents are analytical grade used without further purification. (1R, 2R)-N, 
N-Bis[2-(diphenylphosphino)benzyl]cyclohexane 1,2-diamine, 
bis[2-(dicyclophosphino)ethyl]amine, bis[(2-diphenylphosphino)ethyl]ammonium 








tri(o-methoxyphenyl)phosphine and 2-(di-isopropylphosphino)ethylamine, 
bis(2-cyanoethyl)phenyl phosphine were purchased from Stream Chemicals Inc. 
(Newburyport, Massachusetts, United States). Dimethylsulfide, sodium 
tetrachloroaurate(III), ethanol, diethyl ether, dichloromethane from Fluka AG (St. Gallen, 
Switzerland).  
1H and 13C NMR spectra were recorded on a JEOL-LA 500 NMR spectrophotometer, 
operating at 500.0 and 125.65 MHz, respectively, corresponding to a magnetic field of 
11.74 T. The spectral conditions included 32 k data points, a 3.2 s acquisition time, and a 
5.75 μs pulse width. 13C NMR spectra were obtained with 1H broadband decoupling and 
following spectral conditions: 32 k data points, a 1 s acquisition time, a 2.5 s pulse delay, 
and a 5.12 μs pulse width. 31P NMR spectra were obtained at 200.0 MHz, with phosphoric 
acid as an external standard. All spectra were recorded at 297 K in CDCl3 using 
tetramethylsilane (TMS) as an internal standard. 
Elemental analyses were obtained on Perkin Elmer Series 11 (CHNS/O), Analyzer 2400. 
The solid state FT-IR spectra of the free ligands and their gold(I) complexes were recorded 
on a Perkin Elmer FT-IR 180 spectrophotometer, using KBr pellets over the range 4000- 
400 cm-1. Single crystal X-ray crystallography.  
3.2 Synthesis of binuclear Gold(I) complexes with mixed bis-phosphine 
and dithiocarbamate ligands 
 
3.2.1 [Au2((1R,2R)-N,N-Bis[2-(diphenylphosphino)benzyl]cyclohexane-1,2-di




























 Complex (1) was synthesized by a modified previously reported method [125]. In a fume 
hood, dimethylsulfide was added dropwise with stirring to reduce a yellow ethanolic 
NaAuCl4.3H2O solution at 0-5 ºC until a white precipitate was formed. The product was 
washed twice with ethanol (5 mL) and three times with diethyl ether (10 mL), then dried in 
the dark and stored in fridge. The yield was 0.268 g (91%). Anal. calc. for C2H6SAuCl= 
294.55 g/mol: C, 8.35; H 2.13. Found: C, 8.12; H, 1.83. 1H NMR (CDCl3, ppm), δ 2.75 (s, 
6H). 13C NMR (CDCl3, ppm) δ 25.3. 
  
 [C44H44Au2Cl2N2P2] (2) 
 Precursor (1) (295 mg, 1 mmol) in 5 mL of dichloromethane was added dropwise to a 
solution of (1R,2R)-N,N-Bis[2-(diphenylphosphino)-benzyl]cyclohexane-1,2-diamine 
(331.4 mg, 0.5 mmol) in 10 mL of dichloromethane. A clear colorless solution appeared 
and was stirred for 30 min; then, the solvent was concentrated by low evaporation at room 
temperature. The dichloro(bisphosphino)digold(I) intermediate (2), was obtained as a 
white solid, recrystallized from acetone /dichloromethane and dried overnight in vacuum. 
The yield was 0.479 g (85%). M.P. 127-130 ̊C. Anal. calc. for C44H44Au2Cl2N2P2 (1127.62 
g/mol): C, 46.42; H, 3.39; N, 2.41. Found: C, 46.87; H, 3.93; N, 2.48. IR (cm-1) ν(N-H) 
3442, ν(=CH) 3055, ν(CH2) 2923asym, 2854sym, ν(C-H) 1436bend, ν(Ar-C=C) 1633, ν(N-C) 
1478. 1H NMR (CDCl3, ppm) δ 9.06 (s, NH); 4.79, 4.54 (d, C(1)H, H’); 4.11 (m, C(2)H, 
H’); 2.31, 2.14 (m, C(3)H);  1.86, 1.32 (m, C(4)H); 6.77-8.25 (m, 28H, C6H5). 13C NMR 
(CDCl3, ppm) δ 46.22 C(1); 63.89, 59.05 C(2); 29.68, 29.40; C(3); 23.64, 22.97 C(4); 





[Au2(C44H44N2P2)(C2H6NCS2)2] (3)  
This complex was prepared by a previously reported method [126], intermediate (2) (281.9 
mg, 0.25 mmol) in 10 mL of dichloromethane was added to sodium 
dimethyldithiocarbamate monohydrate (72 mg, 0.5 mmol) in 10 mL of ethanol at room 
temperature with continuous stirring for 2h. The mixture was filtered, and the clear pale 
yellow solution was stored for low evaporation. A yellow solid was obtained, 
recrystallized from acetone/dichloromethane and dried overnight in vacuum. The yield 
0.263 g (81%). M.P. 110-112 ̊C. Anal. calc. for C50H56Au2N4P2S4 (1297.15 g/mol): C, 
46.32; H, 4.31; N, 4.21; S, 9.79. Found: C, 46.29; H, 4.35; N, 4.31; S, 9.88. IR (cm-1) 
ν(N-H) 3434, ν(CH) 2923; ν(CH2) 2925asym, 2852sym, ν(C-H) 1435bend; ν(Ar-C=C) 1629; 
ν(N-C) 1478; ν(C=S) 1099. 1H NMR (CDCl3, ppm) δ 1.61 (s, NH); 4.00, 3.81 (d, C(1)H, 
H’); 3.46 (m, C(2)H, H’); 2.13, 1.62 (m, C(3)H);  1.26, 1.10 (m, C(4)H); 4.35(s, 
C(6)H);6.80-7.58 (m, 28H, C6H5). 13C NMR (CDCl3, ppm) δ 49.56 C(1); 59.10 C(2); 
31.58, 30.93; C(3); 24.84, 22.64 C(4); 207.37 (C=S); 45.37 C(6); 127.24-134.66 C(C6H5). 
31P NMR (CDCl3, ppm) δ 29.77. 
 
[Au2(C44H44N2P2)(C4H10NCS2)2] (4) 
This complex was synthesized with sodium diethyldithiocarbamate trihydrate (112.7 mg, 
0.5 mmol) by steps similar to (3). An orange solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.291 g (86%). M.P. 
99-101 ºC. Anal. calc. for C54H64 Au2N4P2S4 (1353.25 g/mol): C, 47.63; H, 4.65; N, 4.03; 
S, 9.21. Found: C, 47.92; H, 4.76; N, 4.14; S, 9.47. IR (cm-1) ν(N-H) 3424, ν(=CH2) 3052; 





1H NMR (CDCl3, ppm) δ 2.35 (s, NH); 4.07, 3.89 (d, C(1)H, H’); 3.74 (m, C(2)H, H’); 
2.08, 1.78 (m, C(3)H);1.49, 1.02 (m, C(4)H); 4.19 (q, C(6)H); 1.30 (q, C(7)H); 6.74-8.03 
(m, 28H, C6H5). 13C NMR (CDCl3, ppm) δ 50.78 C(1); 61.21 C(2); 30.93 C(3); 24.85 C(4); 
205.71 (C=S); 49.31 C(6); 12.28 C(7) 126.71-145 C(C6H5). 31P NMR (CDCl3, ppm) δ 
26.80. 
 
 [Au2(C44H44N2P2)(C14H14NCS2)2] (5) 
This complex was synthesized with sodium dibenzyldithiocarbamate trihydrate (153.6 mg, 
0.5 mmol) by steps similar to (3). A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.348 g (87%). M.P. 
101-103 ºC. Anal. calc. for C74H72 Au2N4P2S4 (1601.53 g/mol): C, 55.13; H, 4.21; N, 3.11; 
S, 7.78. Found: C, 55.49; H, 4.53; N, 3.49; S, 8.00. IR (cm-1) ν(N-H) 3418, ν(=CH2) 3047, 
ν(CH2) 2920, 2848sym; ν(C-H) 1443bend, ν(Ar-C=C) 1639, ν(N-C) 1203, ν(C=S) 1099. 1H 
NMR (CDCl3, ppm) δ 2.62 (s, NH); 4.90, 4.45 (d, C(1)H, H’); 4.22 (m, C(2)H, H’); 2.81, 
1.99 (m, C(3)H); 1.59, 1.16 (m, C(4)H); 5.24, 5.07 (d, C(6)H); 6.81-7.91 (m, 38H, C6H5). 
13C NMR (CDCl3, ppm) δ 51.19 C(1); 63.99 C(2); 29.40 C(3); 24.01 C(4); 198.54 (C=S); 









3.2.2 [Au2(Bis[(2-diphenylphosphino)ethyl]ammonium chloride)Cl2] with 
dialkyl and diaryldithiocarbamates (6-9) 
 
[Au2(C28H30ClNP2)Cl2] (6)  
This complex was synthesized with bis[(2-diphenylphosphino)ethyl]ammonium chloride 
(239 mg, 0.5 mmol) by a procedure similar to (2).  A white solid was obtained, 
recrystallized from acetone/dichloromethane and dried overnight in vacuum. Yield 0.391 g 
(83%). M.P. 159-161 ºC. Anal. calc. for C28H30Au2Cl3NP2 (942.78 g/mol): C, 35.11; H, 
2.99; N, 1.31. Found: C, 35.67; H, 3.20; N, 1.48. IR (cm-1) ν(N-H) 3429, ν(=CH) 3051, 
ν(CH2) 2936, ν(C-H) 1315bend, ν(Ar-C=C) 1625, ν(N-C) 1435. 1H NMR (CDCl3, ppm) δ 
10.10(s, NH); 3.67, 3.17 (m, C(1)H, H’); 2.81, 2.16 (m, C(2)H, H’); 7.42-7.70 (m, 20H, 
C6H5). 13C NMR (CDCl3, ppm) δ 44.04 C(1), 25.18 C(2),126.98-133.45 C(C6H5). 31P 

























 This complex was synthesized with sodium dimethyldithiocarbamate monohydrate (71.6 
mg, 0.5 mmol) by a procedure similar to (3). A yellow solid was obtained, it was 
recrystallized from acetone/dichloromethane and dried overnight in vacuum. Yield 0.225 g 
(81%). M.P. 99-101 ºC. Anal. calc. for C34H42Au2ClN3P2S4 (1112.31 g/mol): C, 36.33; H, 
3.45; N, 3.31; S, 11.21. Found: C, 36.71; H, 3.80; N, 3.77; S, 11.53. IR (cm-1) ν(N-H) 3420, 
ν(=CH2) 3045, ν(CH2) 2920, ν(C-H) 1242bend, ν(Ar-C=C) 1629, ν(N-C) 1490, ν(C=S) 
1108. 1H NMR (CDCl3, ppm) δ 9.45 (s, NH); 3.92, 3.21 (m, C(1)H, H’); 2.99, 2.10 (m, 
C(2)H, H’), 3.56(s, C(4)H), 7.50-7.75 (m, 20H, C6H5). 13C NMR (CDCl3, ppm) δ 43.81 
C(1), 22.68 C(2), 201.49 C=S(3), 45.66 C(4), 124.63-132.69 C(C6H5). 31P NMR (CDCl3, 
ppm) δ 27.50. 
 
[Au2(C28H30ClNP2)(C4H10NCS2)2] (8) 
This complex was synthesized with sodium diethyldithiocarbamate trihydrate (112.7 mg, 
0.5 mmol) by a procedure similar to (3). An orange solid was obtained, it was recrystallized 
from acetone/dichloromethane and dried overnight in vacuum. Yield 0.248 g (85%). M.P. 
95-97 ºC. Anal. calc. for C38H50Au2ClN3P2S4 (1168.42 g/mol): C, 38.93; H, 4.00; N, 3.32; 
S, 10.41. Found: C, 39.06; H, 4.31; N, 3.59; S, 10.97. IR (cm-1) ν(N-H) 3425, ν(=CH2) 
3049, ν(CH2) 2970, ν(CH2) 2825sym,ν(C-H) 1262bend, ν(Ar-C=C) 1624, ν(N-C) 1480, 
ν(C=S) 1103. 1H NMR (CDCl3, ppm) δ 9.45 (s, NH); 3.92, 3.12 (m, C(1)H, H’); 2.56, 2.43 
(m, C(2)H, H’), 3.55 (s, C(4)H), 1.26 (s, C(5)H), 7.28-7.75 (m, 20H, C6H5). 13C NMR 
(CDCl3, ppm) δ 42.34 C(1), 27.36 C(2), 200.09 C=S(3), 52.32 C(4), 11.29 C(5), 






This complex was synthesized with sodium dibenzyldithiocarbamate trihydrate (153.6 mg, 
0.5 mmol) by a procedure similar to (3).  A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.291 g (82%). M.P. 93-95 
ºC. Anal. calc. for C58H58Au2ClN3P2S4 (1416.69 g/mol): C, 38.69; H, 3.93; N, 2.32; S, 
8.75. Found: C, 39.17; H, 4.12; N, 2.96; S, 9.05. IR (cm-1) ν(N-H) 3425, ν(=CH2) 3049, 
ν(CH2) 2970, ν(CH2) 2825sym,ν(C-H) 1256bend, ν(Ar-C=C) 1624, ν(N-C) 1480, ν(C=S) 
1103. 1H NMR (CDCl3, ppm) δ 9.03 (s, NH); 3.64, 3.19 (m, C(1)H, H’); 2.65, 2.18 (m, 
C(2)H, H’), 5.08, 4.47 (d, C(4)H), 7.30-7.76 (m, 30H, C6H5). 13C NMR (CDCl3, ppm) δ 
44.12 C(1), 25.81 C(2), 209.55 C=S(3), 58.72 C(4), 127.83-135.68 C(C6H5). 31P NMR 




































 [Au2(C28H53NP2)Cl2] (10) 
 This complex was synthesized with bis[2-(dicyclophosphino)ethyl]amine (23 3 mg, 0.5 
mmol) by a procedure similar to (2).  A white solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.195 g (84%). Anal. calc. 
for C28H53Au2Cl2NP2 (930.51 g/mol): C, 35.71; H, 5.34; N, 1.21. Found: C, 36.14; H, 5.74; 
N, 1.50. IR (cm-1) ν(N-H) 3434, ν(CH2) 2934asym, ν(CH2) 2847sym, ν(C-H) 1342bend, ν(N-C) 
1446. 1H NMR (CDCl3, ppm) δ 1.76 (s, NH); 3.94, 3.87 (m, C(1)H, H’); 2.51, 2.18 (m, 
C(2)H, H’); 3.47 (m, C(3) H,H’), 1.90 (m, C(4)H), 1.71 (m, C(5)H,H’), 1.35 (m, 
C(6)H,H’). 13C NMR (CDCl3, ppm) δ 46.23 C(1), 29.97 C(2), 34.47 C(3), 29.16 C(4,4’), 
26.48 C(5,5’), 25.57 C(6). 31P NMR (CDCl3, ppm) δ -11.26. 
 
[Au2(C28H53NP2)(C2H6NCS2)2] (11) 
This complex was synthesized with sodium dimethyldithiocarbamate monohydrate (71.6 
mg, 0.5 mmol) by a procedure similar to (3). A light yellow solid was obtained, 
recrystallized from acetone/dichloromethane and dried overnight in vacuum. Yield 0.245 g 
(89%). Anal. calc. for C34H65Au2N3P2S4 (1100.04 g/mol): C, 36.73; H, 5.31; N, 3.33. 
Found: C, 37.12; H, 5.95; N, 3.81. IR (cm-1) ν(N-H) 3420, ν(CH2) 2920, ν(C-H) 1242bend, 
ν(N-C) 1449, ν(C=S) 1108. 1H NMR (CDCl3, ppm) δ 1.56 (s, NH); 3.88, 3.74 (m, C(1)H, 
H’); 3.35, 2.64 (m, C(2)H, H’); 3.48 (m, C(3) H,H’), 1.87 (m, C(4)H,H’), 1.45 (m, 
C(5)H,H’), 1.29 (m, C(6)H,). 13C NMR (CDCl3, ppm) δ 45.10 C(1), 30.10 C(2), 34.80 
C(3), 29.82 C(4,4’), 26.21 C(5,5’), 25.82 C(6), 202.64 C=S(7), 45.23 C(8). 31P NMR 






[Au2(C28H53NP2)(C4H10NCS2)2] (12)  
This complex was synthesized with sodium diethyldithiocarbamate trihydrate (112.7 mg, 
0.5 mmol) by a procedure similar to (3).  A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.254 g (88%). Anal. calc. 
for C38H73Au2N3P2S4 (1156.15 g/mol): C, 39.21; H, 5.91; N, 3.29; S, 10.49. Found: C, 
39.74; H, 6.36; N, 3.63; S, 11.09. IR (cm-1) ν(N-H) 3436, ν(CH2) 293, ν(C-H) 1242bend, 
ν(N-C) 1446, ν(C=S) 1118. 1H NMR (CDCl3, ppm) δ 1.70 (s, NH); 3.88, 3.02 (m, C(1)H, 
H’), 2.02 (m, C(2)H, H’), 3.25 (m, C(3) H,H’), 1.84 (m, C(4)H,H’), 1.46 (m, C(5)H,H’), 
1.21 (m, C(6)H). 13C NMR (CDCl3, ppm) δ 47.03 C(1), 31.98 C(2), 34.45 C(3), 28.42 
C(4,4’), 26.64 C(5,5’), 25.74 C(6), 205.90 C=S(7), 49.02 C(8), 12.02 C(9). 31P NMR 
(CDCl3, ppm) δ 39.18. 
 
[Au2(C28H53NP2)(C14H14NCS2)2] (13) 
This complex was synthesized with sodium dibenzyldithiocarbamate trihydrate (153.6 mg, 
0.5 mmol) by a procedure similar to (3).  A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in a vacuum. Yield 0.305 g (87%). Anal. 
calc. for C58H81Au2N3P2S4 (1404.42 g/mol): C, 49.21; H, 5.21; N, 2.29; S, 8.81. Found: C, 
49.60; H, 5.81; N, 2.99; S, 9.13. IR (cm-1) ν(N-H) 3425, ν(CH2) 2970, ν(C-H) 1256bend, 
ν(Ar-C=C) 1624, ν(N-C) 1480, ν(C=S) 1103. 1H NMR (CDCl3, ppm) δ 1.67 (s, NH); 3.07 
(m, C(1)H, H’), 2.02 (m, C(2)H, H’), 3.14 (m, C(3) H,H’), 1.84 (m, C(4)H,H’), 1.45 (m, 
C(5)H,H’), 1.26 (m, C(6)H). 13C NMR (CDCl3, ppm) δ 47.30 C(1), 29.53 C(2), 34.52 C(3), 
28.54 C(4,4’), 26.63 C(5,5’), 25.70 C(6), 210.11 C=S(7), 55.81 C(8), 127.81-135.94 


























This complex was synthesized with (1S,2S)-N,N-bis[2-(diphenylphosino)benzyl]- 
cyclohexane 1,2-diamine (331.4 mg, 0.5 mmol) by steps similar to (2). A white solid was 
obtained, recrystallized from acetone/dichloromethane and dried overnight in a vacuum. 
Yield 0.451 g (80%). Anal. calc. for C44H44Au2Cl2N2P2 (1127.62 g/mol): C, 46.31; H, 
3.41; N, 2.11. Found: C, 46.87; H, 3.93; N, 2.48. IR (cm-1) ν(N-H) 3445, ν(=CH) 3057, 
ν(CH2) 2921asym, 2855sym, ν(C-H) 1439bend, ν(Ar-C=C) 1630, ν(N-C) 1481. 1H NMR 
(CDCl3, ppm) δ 9.45 (s, NH); 4.65, 4.50 (d, C(1)H, H’); 4.15 (m, C(2)H, H’); 2.35, 2.17 
(m, C(3)H); 1.83, 1.30 (m, C(4)H); 6.65-8.30 (m, 28H, C6H5). 13C NMR (CDCl3, ppm) δ 
45.22 C(1), 62.85 C(2), 29.40 C(3), 23.65 C(4), 128.18-162.65 C(C6H5). 31P NMR (CDCl3, 
ppm) δ -13.25. 
 
[Au2(C44H44N2P2)(C2H6NCS2)2] (15) 
This complex was synthesized with sodium dimethyldithiocarbamate monohydrate (71.6 
mg, 0.5 mmol) by steps similar to (3). Pale yellow solid was obtained, recrystallized from 
acetone/dichloromethane and it was dried overnight in vacuum. Yield 0.256 g (79%). 
Anal. calc. for C50H56Au2N4P2S4 (1297.15 g/mol): C, 46.29; H, 4.35; N, 4.31; S, 9.88. 
Found: C, 46.00; H, 4.11; N, 4.09; S, 9.53. IR (cm-1) ν(N-H) 3430, ν(CH) 2920; ν(CH2) 
2923asym, 2855sym, ν(C-H) 1445bend; ν(Ar-C=C) 1632; ν(N-C) 1488; ν(C=S) 1035. 1H NMR 
(CDCl3, ppm) δ 1.75 (s, NH); 4.05, 3.85 (d, C(1)H, H’); 3.40 (m, C(2)H, H’); 2.13, 1.62 
(m, C(3)H,H’); 1.26, 1.10 (m, C(4)H, H’); 4.15(s, C(6)H);6.85-7.68 (m, 28H, C6H5). 13C 
NMR (CDCl3, ppm) δ 49.56 C(1), 59.10 C(2), 31.58 C(3), 24.34 C(4); 206.35 (C=S); 





[Au2(C44H44N2P2)(C4H10NCS2)2] (16)  
This complex was synthesized with sodium diethyldithiocarbamate trihydrate (112.7 mg, 
0.5 mmol) by steps similar to (3). An orange solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in a vacuum. Yield 0.277 g, (82 %). Anal. 
Calc. for C54H64 Au2N4P2S4 (1353.25 g/mol): C, 47.92; H, 4.76; N, 4.14; S, 9.47. Found: C, 
47.25; H, 4.27; N, 3.89; S, 9.01. IR (cm-1) ν(N-H) 3428, ν(=CH2) 3055; ν(CH2) 2927asym, 
2855sym, ν(C-H) 1475bend, ν(Ar-C=C) 1613, ν(N-C) 1485, ν(C=S) 1039. 1H NMR (CDCl3, 
ppm) δ 2.55 (s, NH); 4.00, 3.79 (d, C(1)H, H’); 3.64 (m, C(2)H, H’); 2.00, 1.75 (m, 
C(3)H,H’); 1.59, 1.12 (m, C(4)H, H’); 4.25 (t, C(6)H); 1.25 (q, C(7)H); 6.65-7.75 (m, 28H, 
C6H5). 13C NMR (CDCl3, ppm) δ 51.25 C(1); 60.21 C(2); 29.95 C(3); 25.15 C(4); 206.24 
(C=S); 48.51 C(6); 12.18 C(7) 127.11-143.23 C(C6H5). 31P NMR (CDCl3, ppm) δ 25.50. 
 
[Au2(C44H44N2P2)(C14H14NCS2)2] (17)  
This complex was synthesized with sodium dibenzyldithiocarbamate trihydrate (153.6 mg, 
0.5 mmol) by steps similar to (3). A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.332 g (83%). Anal. calc. 
for C74H72 Au2N4P2S4 (1601.53 g/mol): C, 55.49; H, 4. 53; N, 3.49; S, 8.00. Found: C, 
55.03; H, 4.11; N, 2.99; S, 7.69. IR (cm-1) ν(N-H) 3438, ν(=CH2) 3057, ν(CH2) 2925, 
2851sym; ν(C-H) 1473bend, ν(Ar-C=C) 1635, ν(N-C) 1403, ν(C=S) 1019. 1H NMR (CDCl3, 
ppm) δ 2.52 (s, NH); 4.50, 4.35 (d, C(1)H, H’); 4.12 (m, C(2)H, H’); 2.61, 1.79 (m, 
C(3)H,H’); 1.55, 1.26 (m, C(4)H); 5.14, 5.07 (d, C(6)H,H’); 7.11-7.71 (m, 38H, C6H5). 13C 
NMR (CDCl3, ppm) δ 52.19 C(1); 62.75 C(2); 29.30 C(3); 23.81 C(4); 208.15 (C=S); 





3.3 Synthesis of gold(I) complexes with mono-phosphine and 
dithiocarbamate ligands 
 






Scheme 16. Synthesis of gold(I) polymers (19-21) and gold(I) monophosphine complexes 





[C14H16NPAuCl) complex (18) 
This complex was synthesized with 2-(diphenylphosphino)ethylamine (114.6 mg, 0.5 
mmol) by a procedure similar to (2). The chlorido(2-(diphenylphosphino)ethylamine)- 
gold(I) was obtained as a white solid, recrystallized from acetone/dichloromethane and 
dried overnight in vacuum. Yield 0.196 g (85%). Anal. calc. for C14H16NPAuCl (461.68 
g/mol): C, 36.42; H, 3.39; N, 3.03. Found: C, 35.90; H, 2.84; N, 3.36. IR (cm-1) ν(N-H) 
3431, 3354; ν(CH2) 2917asym, 2857sym, ν(C-H) 1310bend; ν(Ar-C=C) 1603; ν(N-C) 1432. 1H 
NMR (CDCl3, ppm) δ 4.03 (s, NH); 3.31, 3.17 (m, C(1)H, H’); 2.97, 2.73 (m, C(2)H, H’); 
7.45-7.65 (m, 10H, C5H5). 13C NMR (CDCl3, ppm) δ 37.65 C(1), 31.50 C(2), 
129.28-133.26 C(C5H5). 31P NMR (CDCl3, ppm) δ 21.39. 
 
[Au2(C2H6NCS2)2]n polymer (19) 
Intermediate (18), (231 mg, 0.5 mmol) in 10 mL of dichloromethane was added to sodium 
dimethyldithiocarbamate monohydrate (74.5 mg, 0.52 mmol) in 10 mL of ethanol at room 
temperature with continuous stirring for 6h. A colorless solid (2-(diphenylphosphino)- 
ethylamine) that formed was filtered off, and the clear pale yellow solution was stored for 
low evaporation. A yellow solid was obtained. IR (cm-1) ν(C-H) 2990, ν(C-H) 1375bend; 
ν(N-C) 1483; ν(C=S) 1100, 993. 1H NMR (CDCl3, ppm) δ 3.55 (s, 6H, CH3). 13C NMR 
(CDCl3, ppm) δ 196.12-NCS2(1), 46.64 C(2). 
 
[Au2(C4H10NCS2)2]n polymer (20)  
This polymer was synthesized with sodium diethyldithiocarbamate trihydrate (117.2 mg, 





obtained. A suitable crystal was selected for X-ray diffraction analysis. IR (cm-1) ν(C-H) 
2970, ν(C-H) 1377bend; ν(-CH2) 2925asym, 2856sym; ν(-CH2)bend 1264; ν(N-C) 1480; ν(C=S) 
1098, 1067. 1H NMR (CDCl3, ppm) δ3.92 (t, 6H, CH3), (t, 4H, CH2CH3). 13C NMR 
(CDCl3, ppm) δ 205.58 -NCS2 (1), 49.35 C(2), 12.20 C(3). 
 
[Au2(C14H14NCS2)2]n polymer (21)  
This polymer was synthesized with sodium dibenzyldithiocarbamate trihydrate (159.7mg, 
0.52 mmol) by a procedure similar to (18). A yellow solid was obtained. IR (cm-1) ν(CH2) 
2923asym, 2850sym, ν(C-H) 1265bend; ν(Ar-C=C) 1602; ν(N-C) 1433; ν(C=S) 1100, 1072. 1H 
NMR (CDCl3, ppm) δ 4.85, 4.78 (d, 4H, CH2), 7.17-7.77(m, 10H, C5H5). 13C NMR 
(CDCl3, ppm) δ 210.80 -NCS2 (1), 54.27 C(2), 128.58-140.93 C(C6H5). 
 
[Au(C14H16NP)2]Cl complex (22) 
 Intermediate (18), (231 mg, 0.5 mmol) in 10 mL of dichloromethane was added to 
2-(Diphenylphosphino)ethylamine (114.6 mg, 0.5 mmol) in 10 mL of dichloromethane  at 
ambient  room temperature with continuous stirring for 6h. A colorless solution was 
filtered off and stored for slow evaporation. A colorless solid was obtained.  Yield 0.3g 
(87%). Anal. calc. for [Au(C28H32NP)2]Cl (690.68 g/mol): C, 48.67; H, 4.67; N, 4.05. 
Found: C, 47.89; H, 5.52; N, 4.04. IR (cm-1) ν(N-H) 3421, 3332; ν(CH2) 2909asym, 2852sym, 
ν(C-H) 1275bend; ν(Ar-C=C) 1566; ν(N-C) 1496. 1H NMR (CDCl3, ppm) δ 4.04, 3.13 (s, 
2H, NH); 3.02, 2.85 (m, C(1)H, H’); 2.56, 1.26 (m, C(2)H, H’); 7.33-7.74 (m, 20H, C5H5). 
13C NMR (CDCl3, ppm) δ 36.63 C(1), 28.57 C(2), 129.17-133.08 C(C6H5). 31P NMR 






ne)Au(I) with dialkyl and dibenzyl-dithiocarbamate complexes (23-26) 
Scheme 17. Synthesis of gold(I) mono-phosphine complexes (23-26). 
 
[Au(C21H20NP)Cl] complex (23) 
 This complex was synthesized with (1R,2R)-2-(diphenylphosphino)-2,3-dihydro 
-1H-inden-1-amine)(158.7mg, 0.5 mmol) by a procedure similar to (2). A white solid was 
obtained, it was recrystallized from acetone/dichloromethane and dried overnight in a 





3.66; N, 2.54. Found: C, 45.27; H, 3.13; N, 2.18. IR (cm-1) ν(N-H) 3461, 3334; ν(CH2) 
2935 asym, 2850sym, ν(C-H) 1280bend, ν(Ar-C=C) 1628, ν(C-N) 1475. 1H NMR (CDCl3, 
ppm) δ1.56 (s, NH), 4.20 (d, C(1)H); 2.17 (m, C(2)H); 3.33, 2.75 (m, C(3)H,H’), 7.20-7.89 
(m, 14H, C6H5). 13C NMR (CDCl3, ppm) δ 56.5 C(1), 46.7 C(2), 30.8 C(3), 126.3-139.8 
C(C6H5). 31P NMR (CDCl3, ppm) δ 36.18. 
 
[Au(C21H20NP)(C2H6NCS2] (24) 
This complex was synthesized with sodium dimethyldithiocarbamate monohydrate (71.6 
mg, 0.5 mmol) by a procedure similar to (3).  Pale yellow solid was obtained, 
recrystallized from acetone/dichloromethane and dried overnight in a vacuum. Yield 0.238 
g (75%). Anal. calc. for C24H26AuN2PS2= 634.55 g/mol: C, 45.78; H, 4.12; N, 4.41; S, 
10.10. Found: C, 45.37; H, 4.55; N, 3.89; S, 9.83. IR (cm-1) ν(N-H) 3447, 3342; ν(CH2) 
2927asym, 2851sym, ν(C-H) 1244bend, ν(Ar-C=C) 1615, ν(C-N) 1486, ν(C=S) 1099,1134. 1H 
NMR (CDCl3, ppm) δ 1.63 (s, NH), 4.48 (d, C(1)H); 2.16 (m, C(2)H); 3.43, 3.17 (m, 
C(3)H,H’), 3.40 (s, C(4)H), 7.40-8.57 (m, 14H, C6H5). 13C NMR (CDCl3, ppm) δ 56.9 
C(1), 32.5 C(2), 29.7 C(3), 184.0 C=S(4), 34.7 C(5), 125-140 C(C6H5). 31P NMR (CDCl3, 
ppm) δ 33.67. 
 
[Au(C21H20NP)(C4H10NCS2)] (25)  
This complex was synthesized with sodium diethyldithiocarbamate trihydrate (112.7 mg, 
0.5 mmol) by a procedure similar to (3). An orange solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.262 g (79%). Anal. calc. 





H, 4.10; N, 3.87; S, 9.13. IR (cm-1) ν(N-H) 3417, 3321; ν(CH2) 2926asym, 2865sym, ν(C-H) 
1264bend, ν(Ar-C=C) 1610, ν(C-N) 1492, ν(C=S) 984,1068. 1H NMR (CDCl3, ppm) δ 4.05 
(s, NH), 4.47 (d, C(1)H); 2.15 (m, C(2)H), 3.92 (t, C(3)H,H’), 3.55 (q,C(4)H), 1.32 
(t,C(5)H), 7.42-7.75 (m, 14H, C6H5). 13C NMR (CDCl3, ppm) δ 54.5 C(1), 33.4 C(2), 29.6 




This complex was synthesized with sodium dibenzyldithiocarbamate trihydrate (153.6 mg, 
0.5 mmol) by a procedure similar to (3). An orange solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.262g (79%). Anal. calc. 
for C35H34AuN2PS2 (774.73 g/mol): C, 54.96; H, 4.44; N, 3.56; S, 8.15. Found: C, 54.37; 
H, 4.11; N, 3.17; S, 7.83. IR (cm-1) ν(N-H) 3406, 3319; ν(CH2) 2921asym, 2851sym, ν(C-H) 
1224bend, ν(Ar-C=C), ν(C-N) 1492, ν(C=S) 973,1099. 1H NMR (CDCl3, ppm) δ 1.7 (s, 
NH), 4.46 (d, C(1)H); 2.14 (m, C(2)H), 4.62 (t, C(3)H,H’); 4.82, 4.69 (d, C(4)H), 7.38-7.80 
(m, 24H, C6H5). 13C NMR (CDCl3, ppm) δ 53.6 C(1), 34.5 C(2), 29.7 C(3), 199.5 C=S(4), 











with dialkyl and dibenzyl-dithiocarbamates complexes (27-30) 
 
 
Scheme 18. Synthesis of gold(I) mono-phosphine complexes (27-30). 
 
[(C18H22NP)AuCl] complex (27) 
This complex was synthesized with (1R, 2R)-2-(diphenylphosphino)-1-aminocyclohexane 
(142 mg, 0.5 mmol) by a procedure similar to (2). A colorless solid was obtained, 





crystal was chosen for X-ray diffraction analysis. Yield 0.224 g (87%). Anal. calc. for 
C18H22NPAuCl (515.77 g/mol): C, 41.92; H, 4.30; N, 2.72. Found: C, 39.97; H, 3.55; N, 
2.34. IR (cm-1) ν(N-H) 3461, 33324; ν(CH2) 2935asym, 2850sym, ν(C-H) 1315bend, 
ν(Ar-C=C) 1572. 1H NMR (CDCl3, ppm) δ 1.97 (s, NH), 3.15 (m, C(1)H), 2.54 (m, 
C(2)H), 1.22 (m, C(3)H), 1.42 (m, C(4)H), 1.33 (m, C(5)H), 1.74 (m, C(6)H), 7.47-7.94 
(m, 10H, C6H5). 13C NMR (CDCl3, ppm) δ 56.01 C(1), 43.54 C(2), 24.73 C(3), 28.10 C(4), 
25.65 C(5), 37.65 C(6), 128.96 -134.84 C(C6H5). 31P NMR (CDCl3, ppm) δ 41.84. 
 
[Au(C18H22NP)(C2H6NCS2)] (28) 
This complex was synthesized with sodium dimethyldithiocarbamate monohydrate (72 
mg, 0.5 mmol) by a procedure similar to (3). A yellow solid was obtained, recrystallized 
from acetone/dichloromethane and dried overnight in a vacuum. Yield 0.255 g (85%). 
Anal. calc. for C22H18NPAuC2H6NS2 (600.53 g/mol): C, 42.00; H, 4.69; N, 4.66; S, 10.67. 
Found: C, 41.64; H, 4.77; N, 4.40; S, 10.40. IR (cm-1) ν(N-H) 3461, 3334; ν(CH2) 2927asym, 
2851sym, ν(C-H) 1246bend, ν(Ar-C=C) 1615, ν(C-N) 1486, ν(C=S)2 1134, 1099. 1H NMR 
(CDCl3, ppm) δ 1.92 (s, NH), 3.38 (m, C(1)H), 3.35 (m, C(2)H), 3.48 (m, C(3)H),1.87 (m, 
C(4)H),1.45 (m, C(5)H),1.29 (m, C(6)H), 3.52 (m, C(6)H),7.47-8.06 (m,10H, C6H5). 13C 
NMR (CDCl3, ppm) δ 54.55 C(1), 45.29 C(2), 24.04 C(3), 30.92 C(4), 25.18 C(5), 40.96 










This complex was synthesized with sodium diethyldithiocarbamate trihydrate (133 mg, 0.5 
mmol) by a procedure similar to (3). An orange solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.270 g (86%). Anal. calc. 
for C18H22NPAuC4H10NCS2 (600.53 g/mol): C, 42.00; H, 4.69; N, 4.66; S, 10.67. Found: 
C, 41.64; H, 4.77; N, 4.40; S, 10.40. IR (cm-1) ν(N-H) 3461, 3334; ν(CH2) 2927asym, 
2851sym, ν(C-H) 1264bend, ν(Ar-C=C) 1610, ν(C-N) 1496, ν(C=S)2 1068, 984. 1H NMR 
(CDCl3, ppm) δ1.93 (s, NH), 3.46 (m, C(1)H), 2.32 (m, C(2)H), 2.93 (m, C(3)H), 1.83 (m, 
C(4)H), 1.41 (m, C(5)H), 1.35 (m, C(6)H),  3.54 (s, C(8)H), 1.33 (s, C(9)H) 7.46-8.12 (m, 
10H, C6H5). 13C NMR (CDCl3, ppm) δ 54.87 C(1), 44.12 C(2), 24.15 C(3), 29.65 C(4), 
25.11 C(5), 39.55 C(6), 204.16 C=S(7), 52.25 C(8), 12.1 C(9), 128.38-134.65 C(C6H5). 31P 
NMR (CDCl3, ppm) δ 40.15. 
 
[Au(C18H22NP)(C14H14NCS2)] (30) 
This complex was synthesized with sodium dibenzyldithiocarbamate trihydrate (154 mg, 
0.5 mmol) by a procedure similar to (3). A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.326 g (88%). Anal. calc. 
for C18H22AuC14H14NCS2 (600.53 g/mol): C, 51.88; H, 4.89; N, 3.78; S, 8.65. Found: C, 
51.24; H, 4.25; N, 3.81; S, 8.06. IR (cm-1) ν(N-H) 3461, 3334; ν(CH2) 2923asym, 2852sym, 
ν(C-H) 1210bend, ν(Ar-C=C) 1600, ν(C-N) 1437, ν(C=S)2 1099, 973. 1H NMR (CDCl3, 
ppm) δ 1.7 (s, NH), 3.88 (m, C(1)H), 2.02 (m, C(2)H), 3.25 (m, C(3)H), 1.84 (m, C(4)H), 
1.46 (m, C(5)H), 0.88 (m, C(6)H), 5.11, 4.71 (d, C(7)H), 7.48-8.11 (m, 10H, C6H5). 13C 





C(6), 210.17 C=S(7), 58.40 C(8), 127.82-135.92 C(C6H5). 31P NMR (CDCl3, ppm) δ 
39.18. 
 
3.3.4 Chlorido(2-(di-i-propylphosphino)ethylamine)Au(I) with dialkyl and 
dibenzyldithiocarbamates complexes (31-34) 
 
[Au(C8H20NP)Cl] complex (31)  
This complex was synthesized with 2-(di-i-propylphosphino)ethylamine (81 mg, 0.5 
mmol) by steps similar to (2). A white solid was obtained and it was recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.138 g (70%). Anal. calc. 
for C8H20AuClNP = 393.64 g/mol: C, 24.40; H, 5.12; N, 3.55. Found: C, 23.97; H, 5.00; N, 
3.15. IR (cm-1) ν(N-H) 3443, 3325; ν(CH2) 2937asym, 2853sym, ν(C-H) 1375bend, ν(C-N) 
1485. 1H NMR (CDCl3, ppm) δ 1.52 (s, NH), 2.73 (m, C(1)H), 2.78 (m, C(2)H), 1.75 (m, 
C(3)H), 1.11 (d, C(4)H). 13C NMR (CDCl3, ppm) δ 61.4 C(1), 35.51 C(2), 24.64 C(3), 






Scheme 19. Synthesis of gold(I) mono-phosphine complexes (31-34). 
 
[Au(C8H20NP)(C2H6NCS2] (32) 
This complex was synthesized with sodium dimethyldithiocarbamate monohydrate (72 
mg, 0.5 mmol) by steps similar to (3). A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.191 g (80%). Anal. calc. 
for C8H20NPAuC2H6NCS2 (478.41 g/mol): C, 27.61; H, 5.47; N, 5.85; S, 13.40. Found: C, 
27.04; H, 4.97; N, 5.30; S, 12.80. IR (cm-1) ν(N-H) 3451, 3343; ν(CH2) 2928asym, 2849sym, 





2.85 (m, C(1)H), 2.97 (m, C(2)H), 1.87 (m, C(3)H), 1.21 (m, C(4)H), 3.53 (s, C(6)H). 13C 
NMR (CDCl3, ppm) δ 60.3 C(1), 34.2 C(2), 24.1 C(3), 19.3 C(4), 193.9  C=S(5), 55.5 
C(6). 31P NMR (CDCl3, ppm) δ 47.72. 
 
[Au(C8H20NP)(C4H10NCS2] (33)  
This complex was synthesized with sodium diethyldithiocarbamate trihydrate (113 mg, 0.5 
mmol) by steps similar to (3).  A yellow solid was obtained, it was recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.191 g (80%). Anal. calc. 
for C8H20AuC4H10NCS2 (506.46 g/mol): C, 30.82; H, 5.97; N, 5.53; S, 12.66. Found: C, 
30.24; H, 5.37; N, 5.30; S, 12.18. IR (cm-1) ν(N-H) 3451, 3345; ν(CH2) 2931asym, 2852sym, 
ν(C-H) 1283bend, ν(C-N) 1486, ν(C=S) 1024, 996. 1H NMR (CDCl3, ppm) δ 1.82 (s, NH), 
2.81 (m, C(1)H), 2.93 (m, C(2)H), 1.86 (m, C(3)H), 1.22 (m, C(4)H), 3.55 (s, C(6)H). 13C 
NMR (CDCl3, ppm) δ 59.53 C(1), 33.7 C(2), 23.7 C(3), 20.1 C(4), 203.7 C=S(5), 48.5 
C(6), 12.1 C(7). 31P NMR (CDCl3, ppm) δ 43.25. 
 
[Au(C18H22NP)(C14H14NCS2)] (34)  
This complex was synthesized with sodium dibenzyldithiocarbamate trihydrate (154 mg, 
0.5 mmol) steps similar to (3). A yellow solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0. 254 g (82%). Anal. calc. 
for C8H22NPAuC14H14NCS2 (618.59 g/mol): C, 42.71; H, 5.54; N, 5.52; S, 10.36. Found: 
C, 42.24; H, 5.23; N, 4.98; S, 10.06. IR (cm-1) ν(N-H) 3441, 3336; ν(CH2) 2929asym, 
2851sym, ν(C-H) 1370bend, ν(Ar-C=C) 1588, ν(C-N) 1477, ν(C=S) 1059, 993. 1H NMR 





C(4)H), 5.03, 4.75. (d, C(6)H), 7.43-7.78 (m, 10H, C6H5). 13C NMR (CDCl3, ppm) δ 58.6 
C(1), 35.3 C(2), 23.7 C(3), 20.1 C(4), 207.5 C=S(7), 54.5 C(8), 128.12-142.67 C(C6H5). 
31P NMR (CDCl3, ppm) δ 46.6. 
 
3.3.5 Gold(I) with mixed tri(o-methoxyphenyl)phosphine and 
triphenylphosphine complexes (35-37). 






This complex was synthesized with tri(o-methoxy- phenyl)phosphine (176 mg, 0.5 mmol) 
by a procedure similar to (2). A colorless solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.234 g (80%). Anal. calc. 
for C21H21AuClO3P= 584.78 g/ mol: C, 43.13; H, 3.61. Found: C, 42.94; H, 3.11. IR (cm-1) 
ν(CH2) 2932asym, 2855sym, ν(C-H) 1370bend, ν(Ar-C=C) 1623.  1H NMR (CDCl3, ppm) δ 
3.58 (s, C(1)H), 6.73-7.35 (m, 12H, C6H5). 13C NMR (CDCl3, ppm) δ 55.56 C(1), 
121.87-160.45 C(C6H5). 31P NMR (CDCl3, ppm) δ 36.18. 
 
[Au(C21H21O3P)2]Cl (36)  
This complex was synthesized with tri(o-methoxyphenyl)phosphine (131 mg, 0.5 mmol) 
following a procedure similar to (22). A colorless solid was obtained, recrystallized from 
acetone/dichloromethane and dried overnight in vacuum. Yield 0.398 g (85%). Anal. calc. 
for C42H42O6P2AuCl (937.15 g/ mol): C, 53.82; H, 4.51. Found: C, 53.34; H, 5.10. IR 
(cm-1) ν(CH2) 2935asym, 2853sym, ν(C-H) 1360bend, ν(Ar-C=C) 1589. 1H NMR (CDCl3, 
ppm) δ 3.45 (s, C(1)H), 6.95-7.56 (m, 24H, C6H5). 13C NMR (CDCl3, ppm) δ 55.77 C(1), 
111.62-160.95 C(C6H5). 31P NMR (CDCl3, ppm) δ 4.92. 
 
[Au(C39H36O3P2)]Cl (37)  
This complex was synthesized with triphenylphosphine (176 mg, 0.5 mmol) and 
tri(o-methoxyphenyl)phosphine (131 mg, 0.5 mmol) by a procedure similar to (22). A 
colorless solid was obtained, recrystallized from acetone/dichloromethane and dried 





mol): C, 55.29; H, 4.28. Found: C, 54.84; H, 4.11. IR (cm-1) ν(CH2) 2937asym, 2856sym, 
ν(C-H) 1365bend, ν(Ar-C=C) 1585. 1H NMR (CDCl3, ppm) δ 3.56 (s, C(1)H), 7.00-7.76 (m, 
27H, C6H5). 13C NMR (CDCl3, ppm) δ 55.79 C(1), 111.62-160.98 C(C6H5). 31P NMR 
(CDCl3, ppm) δ 12.57, 29.61. 
3.4. Single crystal structure determination 
 
Suitable crystals of complex (27) were obtained as colorless rods from dichloromethane/ 
ethanol. The X-ray data were collected at 173K (-100°C) on a STOE IPSD 2 Image Plate 
Diffraction System [127] connected with a two-circle goniometer and using MoK 
graphite monochromator (= 0.71073 Å). The structure was solved by  SHELXS-2014 
program [128]. The refinement and  further calculations were carried out with 
SHELXL-2014 [128].  
The water H atoms were located in a difference Fourier map and refined with distance 
restraint of O-H = 0.84(2) Å and with Uiso(H) = 1.5Ueq(O). It was not possible to locate 
both H atoms on water molecules O7W and O8W. The non-hydrogen atoms were refined 
using least-squares matrix on F2. A semi-empirical absorption correction was applied 
using the MUL scan ABS routine in PLATON [129].  The crystal structure and crystal 
packing were drawn using Mercury software [130]. The symmetry of crystal data and 
structure refinement is demonstrated in Table 3.23.  
3.5 MTT assay for in vitro cytotoxicity of gold(I) complexes 
 
Gold(I) complexes (2-17), (19-22), (24-26) and (36, 37)  were tested for their in vitro 





adenocarcinoma) and A549 (human lung carcinoma) cell lines as previously reported 
method [131]. The cells were seeded at 3 x 103 cells/well in 100 μL of DMEM containing 
10% fetal bovine serum (FBS) in a 96-well tissue culture plate and incubated for 72 h at 37 
oC, 5% CO2 and 90% relative humidity in a CO2 incubator. After incubation, 100 μL of 50, 
25 and 12.5 μM solutions of cisplatin, gold(I) complexes (2-17), (19-22), (23-26) and (36, 
37) prepared in Dulbecco's Modified Eagle's Medium (DMEM), was added to the cells and 
the cultures were incubated for 24 h.  The medium in the wells was casted off and 100 μL 
of DMEM containing MTT (0.5 mg/ml) was added to the wells, with subsequent 
incubation in the CO2 incubator at 37 o C in the dark for 4 h. After incubation, 
purple-colored formazan produced by the cells appeared as dark crystals in the bottom of 
the wells. The culture medium was carefully removed from each well to prevent disruption 
of the monolayer and 100 μL of dimethyl sulfoxide (DMSO) was added in each well. The 
solution in the wells was thoroughly mixed to dissolve the formazan crystals which 
produce a purple solution. The absorbance of the 96 well-plates was measured at 570 nm 
with Labsystems Multiskan EX ELISA reader against a reagent blank. The experimental 
results are calculated as micro-molar concentration of 50% cell growth inhibition (IC50) of 










3.6 Results and Discussion 
3.6.1 Gold(I) complexes with mixed bis-phosphine and dithiocarbamates 
ligands (2-17)  
 3.6.1.1 Spectroscopic analysis  
 
The synthesized gold(I) complexes with mixed bis-phosphine dithiocarbamate ligands 
(2-17) are shown in (Schemes 12, 13, 14 and 15) were characterized by 1H, 13C and 31P 
NMR, mid/far FT-IR spectroscopy, elemental analysis and melting point. The FT-IR data 
of free ligands and complexes (2-17) are summarized in Table 3.1. 
The spectra present the characteristic ν(C—N) and ν(C—S) absorbance bands. The region 
around 1500 cm-1 is associated with a thioureido ion (RN+=CS2) intermediate between the 
C-N single bond (1250-1360 cm-1) and the C=N double bond (1640-1690 cm-1) in the 
dithiocarbamate complexes.  The strong ν(C—N) absorbance bands of the complexes 
(2-17) were assigned in the range (1403-1480) cm-1, suggesting partial double bond 








      









DMDTC - 2924 1360 - - - 1488 926 
DETDC - 2925 1358 - 1397 - 1445 986 
DBDTC - - - 2922 1347 1600 1467 985 
2 3442 - - 2923, 2854  1436 1633 1478 - 
3 3434 - 1372 2923, 2852  1435 1629 1478 1099 
4 3424 2923 1355 2925, 2853  1435 1587 1480 1099 
5 3418 2920 - 2923, 2853  1443 1639 1203 1099 
6 3429 - - 2936, 2852  1315 1625 1435 1104 
7 3420 2920 1374 2931, 2851  1242 1629 1490 1108 
8 3425 2970 1355 2930, 2825  1265 1624 1480 1103 
9 3425 2970 1355 2929, 2825  1365 1224 1480 1103 
10 3434 - - 2934, 2847  - - 1446 1000 
11 3420 2920 1374 2928, 2845  1242 - 1490 1108 
12 3436 2934 1342 2929, 2847  1273 - 1446 1118 
13 3425 2970 1355 2925, 2825  1256 - 1480 1103 
14 3445 - - 2921, 2855  1439 1630 1481 - 
15 3430 2920 - 2923, 2855 1445 1632 1488 1035 
16 3428 - - 2927, 2855  1475 1613 1485 1039 








The ν(C—H) sp3 stretching band was observed at 2924 and 2925 cm-1 for free methyl and 
ethyl dithiocarbamate ligand, respectively, and after coordination, it was observed at 2934 
and 2970 cm-1. The ν(C=S) stretching band for free ligand was observed at 926-986 cm-1, 
and after coordination it was observed at 1099-1118 cm-1. The ν(C=C) band observed in 
the region 1587–1635 cm-1 of these complexes, which were assigned to the presence of 
aromatic ring. 
The comparison of 1H NMR spectra between free dithiocarbamate ligand and their 
complexes (2-17) showed significant shifts that indicate complexation of dithiocarbamate, 
as shown in Table 3.2.  
The 13C NMR chemical shifts (Table 3.3) for these complexes showed significant shift to 
higher fields with respect to free dithiocarbamate ligands. For example, C=S chemical 
shifts for dimethyldithiocarbamate, diethyldithiocarbamate or dibenzyldithiocarbamate 
were observed in the range 206-213 ppm compared to their gold(I) complexes, with a range 
of 198-210 ppm due to back donation from metal to ligand. In addition, 31P NMR chemical 
shifts for gold(I) complexes showed significant shift to lower field at (23.00 to 39.20 ppm), 
relatively to their precursors (2, 6, 10 and 14) with a range (-11.26 to 21.90 ppm) as shown 











1H, 1H’ 2H 3H, 3Hʹ 4H,4Hʹ 6H 7H, 
7Hʹ 
NH Aromatic-Hs 
DMDTC - - - - 3.35 s -   
DEDTC - - - - 3.93 q 1.13 t - - 
DBDTC     5.31, 4.77 d    
2 4.79, 3.84 d 4.11 m 2.31, 2.14 m 1.85, 1.32 m - - 1.60 8.25 m-6.77m 
3 4.00, 3.81 d 3.46 m 2.13, 1.62 m 1.26, 1.10 m 4.35 s - 1.61, 1.08 7.58m -6.80 m 
4 4.07,3.89 d 3.74m 2.08, 1.78 m 1.49, 1.02 m 4.19 q 1.30 t 2.35, 1.02 8.03m-6.74m 
5 4.90,4.45d 4.22 m 2.81, 2.19 m 1.59, 1.19 m 5.24, 5.07d - 2.62, 2.16 7.91m-6.81m 
6 3.67,3.17m 2.81, 2.16m - - - - 10.10 7.70m -7.42m 
7 3.92,3.12m 2.99, 2.10 m - - 3.56 s - 9.45 7.75m-7.50 m 
8 3.92, 3.12m 2.56, 2.43m - - 3.55 q 1.26 t 9.45 7.75m-7.28m 
9 3.64, 3.19m 2.56, 2.18m - - 5.08, 4.47d - 9.03 7.76m-7.30m 
10 3.79, 3.65m 2.51, 2.18m 3.47 m 1.90 m - - 1.76 - 
11 3.88, 3.74m 3.35, 2.64 3.48 m 1.87 4.17 s - 1.65 - 
12 3.88, 3.02m 2.02 m 3.25 m 1.84 m 3.46 q 1.30 t 1.70 - 
13 3.07m 2.02 m 3.14 m 1.84 m 5.24, 4.45 d - 1.67 7.34 m- 7.28 m 
14 4.65, 4.04d 4.15 m 2.35, 2.17 m 1.83, 1.30 m - - 9.45 8.30 m-6.65 m 
15 4.04, 3.85d 3.40 m 2.13, 1.62 m 1.26, 1.10 m 4.15 s - 1.75 7.68 -6.85 m 
16 4.00, 3.79 m 3.64 m 2.00, 1.75 m 1.59, 1.12 m 4.24 q 1.25 t 2.55 7.75 m-6.65 m 









Table 3.3. 13 C and 31P NMR chemical shifts for free ligands and complexes (2-17) in CDCl3 along with DMTC, DETC and    
DBTC in D2O. 
Ligand/ 
complex 
C1 C2 C3 C4 C5 C6 C7 C8 
 
C9 Aromatic Cs 31P 
DMDTC - - - - - - 208.3 45.7 - - - 
DEDTC - - - - - - 206.4 49.5 12.1 - - 
DBDTC - - - - - - 213.1 56.9 - - - 
2 46.2 63.9, 59.1 29.7, 29.4 23.6, 23.0 - - - - - - -11.29 
3 49.7 49.1 31.5, 30.9 24.8, 22.6 - - 207.4 45.4 - 134.7-127.2 29.11 
4 50.8 61.2 30.9 24.9 - - 205.7 49.3 12.3 145.0-126.7 26.80 
5 51.2 64.0 29.4 24.0 - - 198.5 56.1 - 136.7-127.9 23.00 
6 44.0 25.2 - - - - - - - 133.5-127.0 21.90 
7 43.8 22.7 - - - - 201.5 45.7 - 132.7-124.6 27.50 
8 42.3 27.4 - - - - 200.1 52.3 11.3 133.4-129.0 29.49 
9 44.1 25.8 - - - - 209.6 58.7 - 135.7-127.8 24.68 
10 46.2 30.0 34.5 29.2 26.5 25.5 - - - - -11.26 
11 45.1 30.1 34.8 29.8 26.2 25.8 202.6 45.2 - - 38.36 
12 47.0 32.0 34.5 28.4 26.6 25.7 205.9 49.0 12.0 - 39.18 
13 47.3 29.5 34.5 28.5 26.6 25.7 210.1 55.8 - 135.9-127.8 39.20 
14 45.2 62.8 29.4 23.7 - - - - - 162.6-128.2 -13.25 
15 49.6 59.1 31.6 24.3 - - 206.4 45.2 - 135.6-126.2 25.56 
16 51.3 60.2 30.0 25.2 - - 206.2 48.5 12.2 143.2-127.1 25.50 





3.6.1.2 In vitro cytotoxic activities for gold(I) bisphosphine complexes (2-17) 
 
In the present study, the synthesized gold(I) bis-phosphine complexes (2, 5, 6, 9, 10, 13, 
17) compared to cisplatin (standard classical anticancer drug) were tested in vitro 
cytotoxicity against A549, MCF7 and HCT15 human cancer cell lines using an MTT 
assay.  
The study of the dose-dependent inhibition of cell proliferation was obtained by increasing 
cisplatin and complex (2-17) concentrations against a fixed number of three human cancer 
cell lines as shown in Figures 3.1-3.3. IC50 values were obtained from the plot of the 
cisplatin and gold(I) complexes (2-17) concentration against the percentage of cell 
viability as shown in Table 3.4. For the A549 cell line, the complexes (2, 6) exhibited IC50 
values 42 ± 0.5 and 43 ± 0.3 μM, respectively, similar to cisplatin (42 ± 2 μM). These data 
clearly show that the complexes (2-17) inhibit cell proliferation and have potency levels 
similar to cisplatin, suggesting that the presence of the P-Au-S moiety enhanced the 
activity of these complexes [135]. For HCT15 and MCF7 cell lines, all complexes showed 













Table 3.4. IC50 values (μM) of gold(I) complexes (2-17) against HCT15, A549 and HeLa 
cancer cell lines. 
Complex HCT15 A549 MCF7 
Cisplatin 32 ± 2 42 ± 2 23 ± 4 
2 76 ± 0.5 42 ± 0.5 82 ± 2 
5 53 ± 3 291 ± 5 116 ± 3 
6 46 ± 1 43 ± 0.3 36 ± 2 
9 44 ± 3 206 ± 2 121 ± 3 
10 58 ± 2 74 ± 1 53 ± 1 
13 51 ± 3 280 ± 4 133 ± 2 
17 51 ± 1 379 ± 8 142 ± 4 
 Figure 3.1. Graph of cytotoxic effect of series concentrations of complexes (2, 5, 6, 9, 10, 13, 






Figure 3.3. Graph of cytotoxic effect of series concentrations of complexes (2, 5, 6, 9, 10, 
13, and 17) on cell viability of MCF7 cell line. 
 
 
Figure 3.2. Graph of cytotoxic effect of series concentrations of complexes (2, 5, 6, 9, 10, 





















3.6.2 Gold(I) complexes with mixed mono-phosphine and dithiocarbamate 
ligands (18-22), (23-26), (27-30) and (31-34) 
 
3.6.2.1 Spectroscopic analysis 
 
The synthesized of complexes (18-22), (23-26), (27-30) and (31-34) are shown in 
(Schemes 16, 17, 18 and 19) and were characterized by 1H, 13C and 31P NMR and mid 
FT-IR spectroscopy, elemental analyses and single crystal X-ray diffraction analysis. 
The FT-IR spectra for free ligands and their complexes (18-22), (23-26), (27-30) and 
(31-34) are summarized in Tables 3.5-3.6, 3.8 and 3.10. The formation of the complexes 
was confirmed by the presence of the ν(C—N) and ν(C—S) absorbance bands. The region 
around 1500 cm-1 is associated with thioureido ion (RN+=CS2) between the C─N single 
bond (1250-1360 cm-1) and the C=N double bond (1640-1690 cm-1) in the dithiocarbamate 
complexes [136, 132]. The strong ν(C—N) absorbance bands of the complexes (19, 24, 28 
and 32-34) were assigned in range of (1499-1433 cm-1), suggesting partial double bond 
character due to a partially delocalized electron density [136].  
For the (CS2) stretching, two bands were observed for the complexes (19, 24, 28 and 
32-34) in the range of (1134, 1099 cm-1) to (1098, 973 cm-1) with medium intensity. The 
presence of these two bands confirmed (CS2)as and (CS2)s of the dithiocarbamate ligand 
having bidentate nature [137-138].  
The bands showed in the region of 1533 to1629 cm-1, which were assigned to ν(C=C) of 
the aromatic ring [134]. 
In Far IR spectra, two bands of Au—Cl are observed at 220 and 250 cm-1 for intermediates 





bands are observed in the range of 272 and 278 cm-1 attributed Au─S band as shown in 
Tables 3.7 and 3.9. 
 
Table 3.5. Mid FT-IR frequencies (cm-1) for free ligands and complexes (18-22). 
Free ligand/                    




N─C    
Stretch 
C=S 
DMDTC - 2924 1360 - - 1488 926 
DEDTC - 2925 1358 2979 1379 1466 986 
DBDTC - - - 2922 1347 1445 985 
18 3431,3354 - - 2927,2857 1310 1432 - 
19 - - - 2990 1485 1483 1100,993 
20 - 2970 1377 2926,2856 1264 1480 1098,1067 
21 - 2923 - 2923,2850 1265 1433 1100,1072 
22 3421,3332 - - 2909,2852 1275 1496 - 
 
Table 3.6. Mid FT-IR frequencies (cm-1) for free ligands and complexes (23-26). 
Free ligand/    
Complex 
Stretch 
NH    
                                                                                                           
 
Stretch 
N─C       
Stretch 
C=S 
DMDTC - 2924 1360 - - - 1488 926 
DEDTC - - - 2979 1379 - 1466 986 
DBDTC - - - 2922  1347 1600 1445 985 
23 3461,3334 2993 1315 2916, 2850 1280 1628 - - 
24 3447,3342 2940 1376 2918, 2842 1244 1575 1499 1050,993 
25 3417,3321 2968 1346 2926, 2852 1264 1629 1492 1068,997 




Table 3.7. Far FT-IR frequencies (cm-1) of complexes (23-26). 
Complex Au—Cl Au—P Au—S 
23 220 301 - 
24 - 311 277 
25 - 310 275 






Table 3.8. Mid FT-IR frequencies (cm-1) for free ligands and complexes (27-30). 
Free ligand/     
Complex            
Stretch 
NH   
 Stretch 
N─C      
Stretch 
C=S 
DMDTC - 2924 1360 - - 1488 926 
DEDTC - 2925 1358 2979 1379 1466 986 
DBDTC - - - 2922 1347 1445 985 
27 3451,3360 - - 2935,2850 - 1475 - 
28 3441,3340 2940 1372 2927,2852 1246 1487 1134,1099 
29 3414,3322 2969 1345 2923,2849 1264 1492 1068, 984 
30 3411,3317 2967 1351 2923,2850 1210 1437 1099, 973 
 
    
 
  Table 3.9. Far FT-IR frequencies (cm-1) of complexes (27-30). 
 
Complex Au—Cl Au—P Au—S 
27 250. 298 - 
28 - 304 278 
29 - 302 276 





Table 3.10. Mid FT-IR frequencies (cm-1) for free ligands and complexes (31-34). 
Free ligand/  
Complex          
Stretch  
NH     
 Stretch 
 N─C      
Stretch 
C=S 
DMDTC - 2924 1360 - - 1488 926 
DEDTC - 2925 1358 2979 1379 1446 986 
DBDTC - - - 2922 1347 1445 985 
31 3443,3325 2945 1365 2937,2851 1375 1485 - 
32 3451,3343 2940 1372 2928,2849 1286 1496 1099, 973 
33 3451,3345 2959 1345 2931,2852 1283 1486 1034, 998 






The comparison of the 1H NMR spectra between free dithiocarbamate ligands and their 
gold(I) complexes (18-34) showed significant shifts that indicated complexation of 
dithiocarbamate, as shown in Tables 3.11-3.14. 
 




1H, 1H’ 2H, 2H’ 4H 5H NH Aromatic-Hs 
DMDTC - - - -   
DEDTC - - - - - - 
DBDTC      7.39 m-7.24 m 
L0 2.78, 2.77m 2.19,2.16m - - 1.30 7.40 m-7.25m 
18 3.31, 3.17 m 2.97, 2.73 - - 4.03 7.56m -7.45 m 
19 - - 3.55 s - - - 
20 - - 3.92 q 1.32 t - - 
21 - - 4.85,4.78 - - 7.77m -7.23 m 








1H 2H 3H, 3H’ 4H 5H NH Aromatic-Hs 
DMDTC - - - 3.35 s - - - 
DEDTC - - - 3.93 q 1.13 t - - 
DBDTC - - - 5.31,4.77d - - 7.39 m-7.24 m 
L1 4.20 d 2.17 m 3.12, 2.96 m - - 2.00 7.79m-7.49m 
23 4.65 d 2.71 m 3.33, 2.75 m  - 1.56 7.89 m -7.20 m 
24 4.48 d 2.16 m 3.43, 3.17m 3.40 s - 1.63 8.57m- 7.70 m 
25 4.47 d 2.15 m 3.92, 2.19 m 3.55 q 1.32 t 4.05 7.75m-7.42 m 












1H 2H 3H 7H 8H NH Aromatic-Hs 
DMDTC - - - 3.35 s - - - 
DEDTC - - - 3.93 q 1.13 t - - 
DBDTC - - - 5.31, 4.77 d - - 7.39 m-7.24 m 
L2 2.63 m   2.16 m   1.23 m - - 1.97 7.79m-7.49m 
27 3.15 m   2.54 m 1.22 m - - 1.92 7.89 m -7.20 m 
28 3.38 m   3.35 m 3.48 m 3.52 s - 1.93 8.06m- 7.47 m 
29 3.41 m   3.37 m 3.49 m 4.11 q 1.31 t 1.95 7.95m-7.41 m 









1H 2H 3H 6H 7H NH Aromatic-Hs 
DMDTC - - - 3.35 s -   
DEDTC - - - 3.93 q 1.13 t - - 
DBDTC - - - 5.31, 4.77d - - 7.39 m-7.24m 
31 2.73 m   2.78 m   1.75 m - - 1.52 - 
32 2.85 m     2.97 m 1.85 m 3.53 s - 1.72 - 
33 2.81 m   2.93 m 1.86 m 3.55 s 1.21 t 1.82 - 
34 2.88 m                   2.98 m 1.85 m 5.03, 4.75d - 1.83 7.78m-7.35 m 
 
The 13C NMR chemical shifts for the complexes (18-34) showed significant shifts to up 
fields with respect to free dithiocarbamate ligands. For instance, C=S chemical shifts for 
dimethyldithiocarbamate, diethyldithiocarbamate and dibenzyldthiocarbamate were 
observed in the range 206—213 ppm compared to their coordinated complexes in the range 
184—210 ppm. 31P NMR chemical shifts for precursors 18, 31 and ligands L1, L2, 





downfield, due to back donation from filled d-orbitals of gold atom to empty π* of S─C 
bond of dithiocarbamate moiety as shown in Tables 3.15-3.18.  
The crystal structure of the gold(I) polymer (19) [Au2(C4H10NCS2)2]n. xCH2Cl2 has been 
recently published [139]. 
 
Table 3.15. 13C and 31P NMR chemical shifts (ppm) for free ligands and gold(I) complexes 
(18-22) in CDCl3. 
Free ligand/ 















DMDTC - - 208.3 45.7 - - - 
DEDTC - - 206.4 49.5 12.1 - - 
DBDTC - - 213.1 56.9 - 137.2- 127.7 - 
18 37.6 31.5 - - - 138.4-128.0 -23.46 
19 - - 196.1 46.6 - -        - - 
20 - - 205.7 49.4 12.2 - - 
21 - - 210.8 54.3 - - - 





Table 3.16. 13C and 31P NMR chemical shifts (ppm) for free ligands and gold(I) complexes 


















DMDTC - - - 208.3 45.6 - - - 
DEDTC - - - 206.4 49.5 12.1 - - 
DBDTC - - - 213.1 56.9 - 137.2-127.5 - 
L1 57.4 47.5 31.9 - - - 140.0-124.1 -8.75 
23 56.5 46.7 30.8 - - - 139.9-126.3 36.18 
24 56.9 32.6 29.7 184.0 34.7 - 140.9-125.0 36.67 
25 54.5 33.4 29.6 203.6 48.3 12.2 135.3-126.4 35.55 







Table 3.17. 13C and 31P NMR chemical shifts (ppm) for free ligands and gold(I) complexes 









DMDTC - - - - - 208.3 45.7 - - - 
DEDTC - - - - - 206.4 49.5 12.1 - - 
DBDTC - - - - - 213.1 56.9 - 137.2-127.5 - 
L2 52.3 43.3 24.5 26.7 25.9 - - - 134.3-129.0 -9.80 
27 56.1 43.5 24.7 28.1 25.7 - - - 134.3-128.9 41.81 
28 54.5 43.5 24.0 30.0 25.2 207.5 50.5 - 134.0-128.9 41.68 
29 54.9 44.1 24.2 29.6 25.1 204.2 52.3 12.3 134.7-128.4 40.15 







Table 3.18. 13C and 31P NMR chemical shifts (ppm) for free ligands and gold(I) complexes 
(31-34) in CDCl3. 
Free ligand/ 
Complex 
C1 C2 C3 C4 C=S C6 
 
C7 Aromatic Cs 31P 
DMDTC - - - - 208.3 45.7  - - 
DEDTC - - - - 206.4 49.5 12.1 - - 
DBDTC - - - - 213.1 56.9 - 137.2-127.5 - 
31 61.4    35.5 24.6 18.9 - - - - 25.5 
32 60.3    32.4 24.1 19.3 207.5 55.5 - - 47.72 
33 59.5    33.7 23.7 20.1 203.7 48.5 12.3 - 43.25 







3.6.2.2 Gold(I) phosphine complexes (35-37) 
 
The synthesized of complexes (35-37) are shown in (Scheme 20) and were characterized 
by 1H, 13C and 31P NMR and mid FT-IR spectroscopy, elemental analyses. 
The ν(C—H) sp2 bending of precursor 35 was observed at 1370 cm-1 which is shifted to 
lower region in complexes 36 and 37 at 1360 and 1365 cm-1, respectively. The ν(C=C) 
stretching appears at 1623 cm-1 in precursor 35, whereas for 36- 37 it is observed at 1589 
and 1585 cm-1, respectively, as shown in Table 3.19. 
1H NMR spectra shows a significant shift for precursor 35 with respect to complexes 36-37 
Table 3.20. 31P NMR resonance of complexes 36-37 observed at 4.96 and (12.57, 29.61) 
ppm were shifted upfield with respect to precursor 35 (36.18 ppm) due to back donation 
from gold center atom to empty π* of P─C bond as illustrated in Table 3.21. 
 
    Table 3.19. Mid FT-IR frequencies (cm-1) for complexes (35-37). 
Complex        Bend 
(CH2) 
Stretch     
Ar(C=C)    
35 2932, 2855  1370 1623      
36 2935, 2853  1360 1589     
37 2937, 2865  1365 1585         
 
   Table 3.20. 1H NMR chemical shifts (ppm) of gold(I) complexes (35-37) in CDCl3. 
Complex 1H Aromatic-Hs 
35 3.58 s 7.35 m - 6.73 m 
36 3.45 s 7.56 m- 6.95 m 















35 55.6 160.5 - 121.9 36.18 
36 55.8 161.0 - 111.6 4.92 
37  55.8   161.0 - 111.6 12.57, 29.61 
 
3.6.3 Single crystal X-ray structure of complex 27 
 
The molecular structure of complex [Au(C18H22NP)Cl] (27) is depicted  in Figures 3.4- 
and 3.5. Selected bond lengths and bond angles for complex 27 are shown in Table 3.22 
and structure refinement & the crystal data are given in Table 3.23. The coordination 
geometry around the gold central atom is close to linearity, with (P1—Au—Cl1) 176.8 (1)º. 
The Au1—P1 and Au1—Cl1 bond lengths are 2.24 (2) and 2.28 (3) Å, respectively. The 
bond lengths and bond angles are similar to that reported for similar compounds  














Figure 3.5. Crystal packing of complex 27 viewed along b-axis 
 
 
Table 2.22. Selected bond lengths and bond angles for complex 27. 
 
 
Bond Length (Å) Bond Angles (°) 
Au1—Cl1                   2.28 (3) P1—Au1—Cl1           176.81 (1) 
Au1—P1                         2.24 (2) Au1—P1—C1            113.12 (3) 
P1—C1                          1.82 (1) Au1—P1—C7            114.83 (3) 
P1—C7                  1.84 (9) Au1—P1—C13           110.64 (3) 
P1—C13                       1.86 (9) C1—P1—C7             102.15 (4) 
C14—N1                       1.36 (1) C1—P1—C13            106.76 (4) 
  C7—P1—C13            108.95 (4) 





Table 3.23. Summary of crystal data and details of the structure refinement for complex 
27. 
Complex Experimental details 
Crystal data  
Empirical formula      C18H22AuClNP 
Formula weight                       515.76 g/mol 
Wavelength/Å                        0.71073 
Temperature/K                       173 
Crystal symmetry                     Monoclinic 
Space group                          P 21 
Cell lengths (Å)                     a=9.5364(5) b=17.3845(11) c=10.9433(5) 
Cell Angles (°)                      α=90, β=91.417(4), γ =90 
Dx 1.889 Mg/ m-3 
μ   8.34 mm-1 
Radiation type                       MoK\α 
Cell volume (Å3)                     1813.69 (17) 
Z 4 
Data collection  
Radiation source                     Fine-focus sealed tube 
Radiation monochromator Plane graphite 
(sin θ/λ)max (Å−1)                     0.609 
Refinement   
R[F2 > 2σ(F2)], wR(F2), S               0.025, 0.054, 0.88 
∆ρmax                                            1.18 e Å−3 
∆ρmin −1.01 e Å−3 
H-atom treatment:              H atoms treated by a mixture of independent and       
constrained refinement 
 
3.6.4 In vitro cytotoxic activities of gold(I) monophosphine complexes (18-22, 
35 and 37) 
  
In the present study, the precursors (18, 35), gold(I) polymers (19-21) and complexes (22, 
37) were tested for in vitro cytotoxicity against A549, MCF7 and HCT15 human cancer 
cell lines using an MTT assay and compared to that of cisplatin. 
The dose-dependent inhibition of cell proliferation was obtained by specific increase of 
complex concentrations against a fixed number of three human cancer cell lines Figures 





the percentage of cell viability (Table 3.24). For the A549 cell line, the IC50 values for 
polymers (20, 21) and complex (22) were 20 ± 1, 29 ± 2, 34 ± 1 μM, respectively, 
compared to cisplatin at 42 ± 2 μM. These data clearly show that polymers (20, 21) and 
complex (22) have inhibition of cell proliferation and potency levels one to two times 
better than that exhibited by cisplatin, suggesting  the presence of the labile 
dithiocarbamate in (20, 21) and two phosphine ligands around gold ion in complex 22 
enhanced the activity of these complexes [135]. Polymer (20) was the most active among 
the series, exhibiting IC50 =20 ± 1 μM due to the labile diethyldithiocarbamate ligand 
bonded to the gold(I) center. Gold(I) polymer (20) and complexes (22, 37) showed 
moderate IC50 values with respect to cisplatin and the other gold(I) dithiocarbamate 
complexes reported for their activity against HCT15 cell line [126]. For the MCF7 cell 





Table 3.24. IC50 values (μM) of gold(I) complexes (18-22, 35 and 37) against HCT15, 
A549 and HeLa cancer cell lines. 
Complex HCT15 A549 MCF7 
Cisplatin 32 ± 2 42 ± 2 23  ± 4 
18 51 ± 1 54 ± 1 38 ± 1 
19 257 ± 4 304 ± 6 139 ± 5 
20 39 ± 2 20 ± 1 49 ± 2 
21 69 ± 3 29 ± 2 76 ± 3 
22 34 ± 2 34 ± 1 52 ± 2 
35 92 ± 2 97 ± 1 95 ± 3 







Figure 3.6. Cytotoxic effects of various concentrations of complexes (18-22, 35 and 37) on 














 Figure 3.8. Cytotoxic effects of various concentrations of complexes (18-22, 35 and 37) on 
the cellular viability of the A549 cell line. 
Figure 3.7. Cytotoxic effects of various concentrations of complexes (18-22, 35and 37) on 








SYNTHESIS, CHARACTERIZATION AND IN VITRO 
CYTOTOXIC EVALUATION OF GOLD(I) CARBENE 




Gold complexes bearing N-Heterocyclic carbene (HNC) ligands have gained much 
attention due to their important applications in medicine, catalysis, anticancer and 
antimicrobial activity [142-145]. Since these ligands were first synthesized by Arduengo, a 
number of NHCs metal complexes are extensively used for catalysis, biochemistry and 
anticancer treatments [146-149]. NHC ligands form stable complexes with metal ions via 
σ-donation stronger than π-back donation [150]. 
Selenocysteine is the active side of selenoenzymes such as glutathione peroxidase (GPx), 
which is used to protect different organisms from damage due to catalytic cycle to reduce 
harmful peroxidase [151-153]. Spectroscopic properties of selenocyanide ligand with 
some transitional metals have been investigated [154]. The interaction of Au(III) 
compound with two equivalents of this ligand resulted in reduction of Au(III) to Au(I). In 





Ni(II), Pd(II) and Au(III) compounds [155]. A number of seleno-metal compounds were 
reported as potentially a promising new class of drugs for instance, gold antimalarial 
drug [156], Cd/Hg antibacterial [157,117], ruthenium antitumor agent [158] and Pt(II) 
/Pd(II) anticancer agents [159].  
4.2. Experimental Section 
 
4.2.1 Materials and Instrumentation 
 
All chemicals and solvents are analytical grade, they were used without further 
purification. AgPF6, selenourea, N,N-dimethylthiourea, 1,3-bis(2,6-di-isopropylphenyl)- 
imidazol-2-ylidenegold(I)chloride [Au(Ipr)Cl], and all organic solvents were purchased 
from Sigma -Aldrich St. Louis, Missouri United States and Stream Chemicals, 
Massachusetts, United States. ImSe, Diaz-Se, Diap-Se and their derivatives were 
synthesized according to methods in the literature [160-161]. 
 1H, 13C NMR and FTIR spectroscopy along with elemental analysis instruments were 
mentioned previously in section 3.1.  
77Se NMR spectra were recorded on a LAMBDA 500 spectrophotometer operating at 
200.0 MHz. 13C (MAS) NMR results were recorded on a Bruker 400 MHz spectrometer 
at ambient room temperature of 25 oC. Samples were packed into 4 mm zirconium oxide 
rotors. Pulse delay of 7.0 s and a contact time of 5.0 ms.  The magic angle spinning rates 







4.2.2 Synthesis of gold(I) carbene complexes with selones (39-50) 
 





















          
  
 
                    










    
Scheme 21C. Synthesis of gold(I)-selone complex 50.  
            
[Au(Ipr)(SeCN2C4H10)]PF6 (39) 
This complex was synthesized using a modified previously reported method [138]. 
AgPF6 (127 mg, 0.5 mmol) was dissolved in 5 mL of ethanol and added to 
1,3-Bis(2,6-di-isopropylphenyl)imidazol-2- ylidenegold(I)chloride [Au(Ipr)(Cl)] (311 
mg, 0.5 mmol) in 5 mL of CH2Cl2. Then stirred for 5 min at room temperature and 
filtered off.  N-ethyl,-1,3-imidazolidine-2-selone (N-EtImSe) (88.6 mg, 0.5 mmol) was 
added to the filtrate, stirred for 1 hour and filtered. The formed complex was kept in 
undisturbed area, after three days bright gray crystals were obtained and a suitable crystal 
was selected for single crystal diffraction analysis. Yield 0.264 g (60%). Anal calc. for 










[Au(Ipr)(SeCN2C3H8)]PF6 (40)  
This complex was synthesized with 1,3-diazinane-2-selone (DiazSe) by a procedure 
similar to (39). After four days a yellowish-white solid was obtained. The yield was 0.180 
g (50%). Anal. calc. for C31H44AuN4SePF6 (893.60 g/mol): C, 41.71; H, 4.97; N, 6.28. 
Found: C, 41.92; H, 5.14; N, 6.82. 
 
[Au(Ipr)(SeCN2C4H10)]PF6 (41) 
This complex was synthesized using 1,3-diazepine-2-selone (DiapSe) by a procedure 
similar to (39). After five days white solid was obtained. The yield was 0.275 g (65%). 
Anal. calc. for C32H46AuN4Se.PF6 (907.62 g/mol): C, 42.39; H, 5.11; N, 6.18. Found: C, 
41.93; H, 5.26; N, 6.08. 
 
[Au(Ipr)(SeCN2C5H12)]PF6 (42)  
This complex was synthesized with N-propyl-1,3-imidazolidine-2-selone (N-Pr-Imse) by 
a procedure similar to (39). After three days a gray solid was obtained. The yield was 
0.240 g (55%). Anal. calc. for C33H48AuN4SePF6 (921.65g/mol): C, 43.05; H, 5.25; N, 
6.09. Found: C, 42.57; H, 5.51; N, 5.81. 
 
[Au(Ipr)(SeCN2C4H10)]PF6 (43) 
 This complex was synthesized using N-methyl-1,3-diazinane-2-selone (N-MeDiazSe) 
by a procedure similar to (39). After four days a pale red solid was obtained. The yield 
was 0.274 g (60%). Anal calc. for C32H46AuN4SePF6 (907.63g/mol): C, 42.39; H, 5.11, N 






This complex was synthesized with selenourea by a procedure similar to (39). After four 
days colorless crystals were obtained and a suitable crystal was selected for single crystal 
diffraction analysis. The yield was 0.313 g (75%). Anal. calc. for C28H40AuN4SePF6 
(853.53 g/mol): C, 39.40; H, 4.72; N, 5.56. Found: C, 41.04; H, 5.23; N 6.04. 
 
[Au(Ipr)(SeCN2C2H6)]PF6 (45)  
This complex was synthesized using 1,3-imidazolidine-2-selone by a procedure similar to 
(39). After four days a white solid was obtained. The yield was 0.248 g (56%). Anal. 
calc. for C30H42AuN4SePF6 (879.57 g/mol): C, 40.97; H, 4.81; N, 6.37. Found: C, 41.38; 
H, 4.64; N, 6.28. 
 
[Au(Ipr)(SeCN2C4H10)]PF6 (46)  
This complex was synthesized using N,N′-dimethyl-1,3-imidazolidine-2-selone 
(N,N’-ImSe) by a procedure similar to (39). After four days, brick-red crystals were 
obtained and a suitable crystal was selected for single crystal diffraction analysis. The 
yield was 0.265 g (60%). Anal. calc. for C32H46AuN4SePF6 (907.63 g/mol): C, 42.35; H, 
5.11; N, 6.17. Found: C, 42.68; H, 5.21; N 5.91. 
 
[Au(Ipr)(SeCN2C3H7(OH))]PF6 (47) 
This complex was synthesized using 5-hydroxy-1,3-diazepine-2-selone by a procedure 






Anal. calc. for C31H44AuN4SePF6 (909.60 g/mol): C, 41.67; H, 4.96; N, 6.30. Found: C, 
41.60; H, 4.92; N. 5.99. 
 
[Au(Ipr)(SCN2C2H8]PF6 (48) 
This complex was synthesized using N,N′-dimethyl-thiourea by a procedure similar to 
(39). After five days colorless crystals were obtained and the suitable crystal was selected 
for single crystal diffraction analysis. The yield was 0.245g (61%). Anal. calc. for 
C30H44AuN4S. PF6= 881.59 g/mol: C, 41.69; H 5.10; N, 6.94; S, 3.97. Found: C, 41.26; 
H, 5.57; N, 7.20; S, 3.66. 
 
 [Au(Ipr)(SeCN2C5H12]PF6 (49).  
This complex was synthesized with N-isopropyl-1,3-imidiazolidine-2-selone (N-isopr- 
ImSe) by a procedure similar to (39). After four days gray crystals were obtained and a 
suitable crystal was selected single crystal diffraction analysis. The yield was 0.220g 
(50%). Anal. calc. for C33H48AuN4SePF6 (921.65 g/mol): C, 43.00; H, 5.25; N, 6.08. 
Found: C, 42.93; H, 5.56; N, 6.20. 
 
[Au(Ipr)(SeCN2C6H14]PF6 (50) 
This complex was synthesized using N,N′-diethyl-1,3-imidiazolidine-2-selenone by a 
procedure similar to (39). After four days yellow solid was obtained. The yield was 0.284 
g (61%). Anal. calc. for C34H50AuN4SePF6 (935.68 g/mol): C, 43.64; H, 5.39; N, 5.99. 






4.3 Results and Discussion 
 
4.3.1 Spectroscopic characterizations 
 
The synthesized of complexes (39-50) are shown in (Scheme 21) and were characterized 
by 1H, 13C and 31P NMR and mid FT-IR spectroscopy, elemental analyses and single 
crystal X-ray diffraction analysis. 
FT-IR spectra for free ligands and gold(I) complexes (39-50) clearly show a significant 
shift between the ligands and their complexes (39-50) inconsistence with complexation as 
shown in Table 4.1. For instance, ν(C=Se) for free ligands is in the range of (588-636) 
cm-1, while for the complexes (39-50) it is in the range (554-557) cm-1. This is consistent 
with back donation to π* C=Se [103-105].  
The stretching bands of ν(N─H) and ν(O─H) were shifted to higher frequency in 
complexes relative to the free ligands due to increase C-N π bond character [64]. 
1H NMR data for the ligands and their complexes (38-50) are shown in Table 4.2.   
13C NMR chemical shift of Au=C in the precursor (38) was observed at 175.3 ppm and it 
is shifted downfield in complexes (39-50) in the range of (181.1-185.3) ppm. This 
deshielding is related to back donation from d-orbital of Au atom to π* C=Se [92]. The 
chemical shift of C=Se in all free ligands was observed in the range of (167.4-182.1 
ppm), with an up-field shift in their complexes (39-50) in the range of (159.8-178.3 ppm) 
due to more electron shielding C=Se by back donation from d-orbital of gold atom 






     
 





      Stretch 
C=Se 
38 - 3073 1109 2960 1366 1258 1462 - 
EtImSe 3198 - - 2961 - - - 588 b 
39 3396 3166 1114 2956 1325 1272 1441 556 
DiazSe 3198 - - - - - - 602b 
40 3351 3165 1057 2957, 2867 1464 1205 1554 554 
DiapSe 3224 - - - - - - 613 
41 3351 3167 1061 2962, 2867 1469 1218 1553 556 
42 3400 - - 2960, 2871 1327 1294 1467 557 
43 3375 3164 1116 2958, 2872 1313 1210 1461 555 
44 3468,3363 3160 1055 2960, 2873 1463 1406 1643 606 
ImSe 3250 - - - - - - 558b 
45 3382 3161 1053 2960, 2872 1463 1323 1531 559 
Me2ImSe - - - - - - - 636 
46 3143 - 1108 2965, 2870 1413 1288 1563 556 
HOdiazSe 3345 - - - - - - 578 
47 3561(OH)3370 3159 1112 2957, 2874 1464 1208 1581 555 
48 3377 3162 1133 2931, 2873 1371 1371 1462 985 
iPrImSe 3395 - - - - - - 597 
49 3404 3157 1060 2959, 2874 1468 1287 1529 556 
Et2IMSe - - - - - - - 602, 626 








    
.3) in CDCl50-38H NMR chemical shifts (ppm) for free ligands and gold(I) complexes (1. Table 4.2   
Ligand/ 
complex 
3H 4H 5H 6H 7H 8H 9H 10H 11H 12H 13H NH 
38 7.39 d 7.55 t 2.46 m 1.33 d 1.21 d 7.98 s     - - 
EtImSe       3.62 m 3.69 m 3.72 m 1.21 m - 6.95 
39 7.36 d 7.61 t 2.54 m 1.31 d 1.26 d 7.33 s 3.46 m 3.54 m 3.76 m 1.15 m - 5.35 
DiazSe - - -  - - 3.31 t 1.98 p    1.71 
40 7.37 d 7.58 t 2.56 m 1.33 d 1.23 d 7.50 s 3.14 t 1.85 t - - - 2.93 
DiapSe       3.28 t 1.81 t - - - 7.19 
41 7.36 d 7.57 t 2.54 m 1.31 d 1.24 d 7.30 s 3.22 d 1.77 d - - - 1.61 
Pr ImSe - - - - - - 3.67 t 3.63 t 3.60 p 1.65 p 0.96 t 6.70 
42 7.38 d 7.62 t 2.55 m 1.31 d 1.26 d 7.37 s 3.76 t 3.48 t 3.28 t 1.56 d 0.86 t 4.62 
MeDiazSe       3.48 s 3.37 t 3.24 m 2.06 p - 2.15 
43 7.37 d 7.59 t 2.54 m 1.31 d 1.26 d 7.35 s 3.15 s 3.36 t 2.99 m 1.96 p - 1.77 
USe          -  2.01 
44 7.36 d 7.57 t 2.56 m 1.32 d 1.26 d 6.91 s - - - - - 3.48 
ImSe           - 8.35 
45 7.39 d 7.57 t 2.56 m 1.33 d 1.28 d 7.65 s 3.60   - - 3.15 
Me2ImSe       3.48 s 2.91 s  - - - 
46 7.35 d 7.59 t 2.51 m 1.26 d 1.25 d 7.30 s 3.66 s 2.85 s   - - 
HODiazSe       3.17 dd 4.08 m   - 2.50 
47 7.37 d 7.59 t 2.58 m 1.32 d 1.27 d 7.73 s 3.11 dd 4.01 m - - - 2.15 
Me2Tu          -  6.62 
48 7.36 d 7.57 t 2.52 m 1.30 d 1.26 d 7.27 s - - - - - 1.72 
iPrImSe       3.53 t 3.57 t 4.85 p 1.18 d - 6.63 
49 7.39 d 7.63 t 2.54 m 1.32 d 1.26 d 7.36 s 3.48 t 3.69 t 4.16 p 1.15 d - 4.75 
Et2ImSe       3.56 d 3.77 m 1.19dd - - - 





13C (MAS) solid state NMR for all complexes showed significant downfield shits (6-11 
ppm) for all carbon bonded to gold atom (Au=C) and up-field shift (~8 ppm) for all carbon 
bonding to selenium atom (C=Se). This attributed to back donation from gold to Se atom 
and indicating all complexes formed through binding to the selenium atom of the ligand. 
These phenomena were also observed in sulfur gold(I) complexes [102]. For all 
complexes, solid and liquid state chemical shift were consistent indicating the stability of 
the synthesized complexes in solid and liquid states. 13C (MAS) NMR Chemical shifts of 
complexes (38-50) are given in Table 4.4. 
77Se NMR chemical shift in all complexes is more shielded than that of free ligands. This 
phenomenon is attributed to (Au→Se=C) back bonding and the transferred electron 
density of N→C resulting a partial double character in C—N bond which confirms the 
coordination is done  through binding to the selenium atom [105]. 77Se NMR studies 
showed that DiapSe and DiazSe and their derivatives ligate more strongly than ImSe along 
with their derivatives. The selenol form be as a higher contribution for DaipSe and DaizSe 
relatively to ImSe due to ring strain hindering the rehybridization of N culminating in 
DaipSe as shown in Table 4.5. A linear correlation between 13C NMR chemical shifts of 
13C=Se and 77Se NMR chemical shift of complexes (40,41, 43-45 and 49) due to decrease 











Figure 4.1. Plot of 13C=Se NMR chemical shift against observed 77Se chemical shifts for 






   
.3) in CDCl50-38C NMR chemical shifts (ppm) for free ligands and gold(I) complexes (13. Table 4.3 
Ligand/ 
complex 
C1 C2 C3 C4 C5 C6 C7 
 
C8 Au=C C=Se C11 C12 C13 C14 C15 
38 145.5 130.7 133.9 123.0 28.8 24.5 24.0 124.2 175.3 - - - - - - 
EtImSe - - - - - - - - - 178.7 43.3 47.9 42.5 12.1 - 
39 145.9 131.3 133.5 123.9 28.8 24.5 23.9 124.4 182.0 171.8 43.9 49.0 43.4 12.0 - 
DiazSe - - - - - - - - - 171.0 40.8 18.9 - - - 
40 145.7 130.8 133.4 123.8 28.6 24.3 23.7 124.1 183.2 162.5 40.8 18.1 - - - 
DiapSe - - - - - - - - -    - - - 
41 145.8 131.0 133.4 123.7 28.8 24.6 23.9 124.4 183.2 174.4 46.8 25.8 - - - 
PrImSe - - - - - - - - - 179.6 42.6 48.6 50.2 20.4 11.0 
42 146.0 131.2 133.5 123.9 28.8 24.5 23.9 124.4 182.4 170.5 43.6 49.7 50.7 20.2 10.9 
MeDiazSe          173.3 44.9 20.5 47.9 40.4 - 
43 145.8 131.3 133.3 123.9 28.8 24.6 23.9 124.4 183.1 165.5 44.6 19.8 49.5 41.2 - 
Selenourea - - - - - - - - - 182.2 - - - - - 
44 145.8 131.6 133.9 123.5 28.8 24.5 23.8 124.2 185.3 173.2 - - - - - 
ImSe - - - - - - - - - 175.8 43.7 - - - - 
45 145.1 130.0 132.7 123.2 27.8 23.5 23.0 123.4 181.6 168.7 44.8 - - - - 
Me2ImSe - - - - - - - - - 181.2 36.7 49.1 - - - 
46 141.7 131.2 133.5 123.7 28.8 24.4 23.9 123.7 181.2 170.4 36.5 49.9 - - - 
HO-DiazSe - - - - - - - - - 167.4 45.1 56.2 - - - 
47 145.5 130.5 133.3 123.9 28.4 24.1 23.6 124.3 182.7 159.8 46.8 56.6 - - - 
Me2Tu - - - - - - - - - 182.3 30.8 - - - - 
48 145.9 131.1 133.3 124.0 28.8 24.5 23.9 124.4 181.1 176.4 32.3 - - - - 
iPr-ImSe - - - - - - - - - 178.4 42.6 42.9 48.9 19.4 - 
49 146.0 131.3 133.4 123.9 28.8 24.5 23.9 124.5 182.5 170.1 43.5 44.1 50.5 19.5 - 
Et2ImSe - - - - - - - - - 179.3 43.9 46.1 12.0 - - 







Table 4.4. 13C (MAS) Solid State NMR chemical shifts (ppm) for gold(I) complexes (38-50). 
Ligand/ 
complex 
C1 C2 C3 C4 C5 C6 C7 
 
C8 Au=C C=Se C11 C12 C13 C15 
38 145.5 130.7 133.9 123.0 28.7 24.4 24.0 124.2 175.3 - - - - - 
39 144.8 131.4 133.1 122.1 28.0 24.1 22.1 125.1 184.6 169.5 - 48.6 43.7 - 
40 146.9 133.0 134.8 123.6 28.6 24.4 23.7 124.6 186.6 165.5 42.4 19.4 - - 
41 146.7 133.2 134.6 123.6 27.6 24.9 24.1 126.0 186.4 172.9 49.7 26.0 - - 
42 147.4 131.8 134.4 123.8 30.3 25.5 23.5 124.7 188.5 171.5 45.2 50br - 12.6 
43 144.5 - 132.4br 121.7 28.0 25.8 23.4 124.6 183.1 165.5 44.6 19.8 49.9 - 
44 147.0 134.1 133.5 123.6 29.4 26.9 24.3 126.9 186.7 165.1 - - - - 
45 145.1 130.0 132.7 123.2 27.8 23.5 23.0 123.4 181.6 168.7 44.9 - - - 
46 144.9 132.6 br 135.2 - 28.0 25.3 22.7 124.0br 181.2 164.4 38.5 50.8 - - 
47 145.0 131.3 132.9 - 28.1 24.1 22.2 124.0 br 186.0 164.7 46.6 57.0 - - 
48 143.9 - 133.2 br 123.2 27.8 24.7 23.3 125.1 183.7 171.8 31.3 - - - 
49 146 131.3 133.4 123.9 28.8 24.5 23.9 124.5 182.5 170.1 43.5 44.1 50.5 - 








Table 4.5. 77Se NMR chemical shifts (ppm) for gold(I) complexes (39-50) in CDCl3. 
Compound 77 Se δ(ppm) ∆ 
EtImSe 80.89 5.53 
39 75.36 
DiazSe 199.93 33.46 
40 166.47 
DiapSe 292.00 134.26 
41 139.74 
PrImSe 85.50 6.10 
42 79.40 
MeDiazSe 193.60 80.96 
43 112.64 
Selenourea 200.70 46.53 
44 154.17 
ImSe 73.53 30.45 
45 42.78 
ImSe2Me 101.00 12.56 
46 88.44 
HO-DiazSe 208.00 45.27 
47 168.73 
iPrImSe 69.29 12.34 
49 56.92 
ImSe2Et 114.10 12.67 
50 101.43 













4.3.2 Single crystal X-ray structure determination 
 
X-ray data of 39, 44, 46, 48 and 49 were collected on a Stoe Mark IPD-2 System [163]  
with a two-circle goniometer and using MoKα graphite monochromator. The distance 
between the imaging plate and the sample was 100 mm. Structures were solved using the 
program SHELXS-97 [164]. The non-H atoms were refined using least-squares matrix on 
F2.  Crystal data and refinement details for complexes 39 and 49 are given in Table 4.8. 
The structures of these complexes were drawn using the programs PLATON and 
MERCURY [130].  
 
The molecular structure of complex [Au(Ipr)(SeCN2C4H10)]+ (39) is depicted in Figure 
4.2. Selected bond lengths and angles are given in Table 4.6. The coordination geometry 
around the gold ion is close to linearity, with (C—Au—Se) 176.8(7)º. The Au—C and 
Au—Se bond lengths are 2.40(4) and 2.00(2) Å, respectively. The bond lengths and bond 






















Bond Length (Å) Bond Angles (°) 
Au1—Se1               2.40 (4) Se1—Au1—C6       176.8 (7) 
Au1—C6                   2.00 (2) Au1—Se1—C1        98.62 (8) 
Se1—C1                    1.86 (3) C1—N1—C2         112.1 (3) 
N1—C1              1.32 (4) C1—N1—C3         110.9 (2) 
N2—C2                    1.45 (5) Se1—C1— N2        126.4 (2) 
N3—C6                    1.33 (3) Se1—C1—N2        122.7 (2) 
N4—C6                      1.35 (3) Au1—C6—N3        129.9 (2) 
 Au1—C6—N4        124.6 (2) 





The molecular structures of complexes 44, 46 and 48 are shown in Figures 4.3, 4.4 and 
4.5 respectively.  
 
 
Figure 4.3. Molecular structure of complex [Au(Ipr)(SeCN2H4)]PF6 (44), with partial 

















Figure 4.4. Molecular structure of complex [Au(Ipr)(SeCN2C4H10)]PF6 (46), with partial 














Figure 4.5. Molecular structure of complex [Au(Ipr)(SCN2C2H8]PF6 (48), with partial 
labelling atoms and 50% probability ellipsoids. 
 
The molecular structure of complex [Au(Ipr)(SeCN2C5H12]PF6 (49) is shown in Figure 
4.6. Selected bond lengths and angles are illustrated in Table 4.7. The geometry of the 
coordination around gold ion formed by carbon of NHC ligand and Selenium ligand, is 
close to linearity, with (C—Au—Se) angle of 177.1(5)º. The Au—C and Au—Se bond 
lengths are 2.11(2) and 2.38(3) Å, respectively. The bond lengths and bond angles are 







Figure 4.6. Molecular structure of complex 49, with partial labelling atoms and 50% 


















Bond Length (Å) Bond Angles (°) 
Au2—Se8                2.38 (3) Se8—Au2—C9            177.1 (5) 
Au2—C9                    2.11 (2) Au2—Se8—C11           102.1 (6) 
Se8—C11                   1.80 (2) Au2—C9—N11           123.0 (1) 
C9—N11             1.24 (3) Au2—C9—N15           122.0 (1) 
C9—N15                  1.31 (2) N11—C9—N15           115.0 (2) 
N12—C11                 1.40 (3) Se8—C11—N12          123.0 (1) 





Table 4.8. Summary of crystal data and details of the structure refinement for complexes 
(39 and 49). 
Complex 39 49 
Empirical formula C32 H46 Au F6N4PSe C33 H48 AuF6N4PSe 
Formula weight 907.62 921.65 
Crystal symmetry Monoclinic Triclinic 
Space group P 21/c P 1 
Crystal color Colorless Colorless 
Crystal size / mm 0.4x 0.31 x 0.13 Not given 
Wavelength/Å 0.71073 0.71073 
Temperature/K 173(2) 293  
a (Ǻ) 13.3698 (6) 9.9945 (6) 
b (Ǻ) 17.3635 (5) 13.7841 (8)   
c (Ǻ) 16.0631 (6) 14.1416 (8) 
α (ᵒ) 90 100.394 (5) 
β (ᵒ) 102.411 98.683 (5) 
γ (ᵒ) 90 95.727 (5) 
Cell volume (Å3) 3641.8 (2) 1890.31 (19) 
Dx 1.686 Mg m−3 1.686 Mg m−3  
μ 5.14 mm−1 4.96 mm−1 
Radiation type Mo Kα Mo Kα 
Z 4 1 
Diffractometer STOE IPDS 2 STOE IPDS 2 
Absorption correction Multi-scan (MULABS in 
PLATON; Spek, (2009) 
Multi-scan (MULABS in 
PLATON,( 2009) 
Radiation source Plane graphite Plane graphite 
R[F2 > 2σ(F2)], wR(F2), S 0.018, 0.043, 1.01 0.36, 0.087, 0.96 
∆ρmax 0.68 e Å−3 4.29 e Å−3 
∆ρmin −0.58 0 e Å−3 −3.25 e Å−3 
H-atom treatment: Treated by a mixture of 
independent  and 
constrained refinement 
Treated by a mixture of 
independent and constrained 









4.3.3 In vitro cytotoxic activities of gold(I) complexes (38-50) 
 
Gold(I) complexes labeled (38-50) were tested for in vitro cytotoxicity against A549 
(human lung carcinoma), MCF7 (human breast adenocarcinoma) and HCT15 human 
cancer cell lines (human colon cancer) using MTT assay and compared with cisplatin 
(standard anticancer drug). IC50 values (μM) of complexes (38-50) against HCT15, A549 
and MCF7 cancer cell lines are shown in Table 4.9. 
The dose-dependent inhibition of cell proliferation was obtained by specific increase of 
cisplatin and complexes (38-50) concentrations against a fixed number of three human 
cancer cell lines Figures 4.7(a, b and c)- 4.9(a, b and c). IC50 values were obtained from 
the curve of the concentration of cisplatin, and complexes (38-50) against percentage of 
cell viability.  For HCT15 cell line, the IC50 values for complexes (38-50) are in the 
range of (54 ± 1─ 51 ± 2 μM), respectively, compared to cisplatin 32 ± 2 μM. The data 
showed the complex 48 (28 ± 2 μM) has inhibition of cell proliferation and potency 
levels batter than that exhibited by cisplatin (32. ± 2 μM), suggesting S containing ligand 
is more labile than Se containing ligand and enhanced the cytotoxic activity of this 
complex Au(Ipr)(SCN2C2H8]PF6. The complex 45 (33 ± 1 μM) has similar IC50 value to 
cisplatin. However, for A549 and MCF7 cell lines, complexes (38-50) exhibited 










Table 4.9. IC50 values (μM) of gold(I) complexes (38-50) against HCT15, A549 and 
MCF7 cancer cell lines. 
Complex HCT15 A549 MCF7 
Cisplatin 32 ± 2 42 ± 2 23 ± 4 
38 54 ± 1 62 ± 2 60 ± 2 
39 45 ± 1 56 ± 1 42 ± 1 
40 70 ± 1 77 ± 1 67 ± 1 
41 69 ± 1 81 ± 1 45 ± 1 
42 62 ± 1 75 ± 1 53 ± 1 
43 43 ± 1 54 ± 1 62 ± 2 
44 76 ± 2 82 ± 1 75 ± 3 
45 33 ± 1 47 ± 1 43 ± 2 
46 42 ± 1 58 ± 1 51 ± 1 
47 72 ± 2 76 ± 1 58 ± 1 
48 28 ± 2 44 ± 1 39 ± 1 
49 44 ± 2 49 ± 1 49 ± 1 
50 51 ± 2 71 ± 1 51 ± 1 
 
 
Figure 4.7a. Graph of cytotoxic effect of series complexes (38-42) concentrations on cell 






Figure 4.7b. Graph of cytotoxic effect of concentrations complexes (38, 43-47) on cell 
viability of HCT15 cell line. 
 
Figure 4.7c. Graph of cytotoxic effect of concentrations of complexes (38, 48-50) on cell 






Figure 4.8a. Graph of cytotoxic effect of concentrations of complexes (38-42) on cell 




Figure 4.8b. Graph of cytotoxic effect of concentrations of complexes (38, 43-47) on cell 






Figure 4.8c. Graph of cytotoxic effect of concentrations of complexes (38, 48-50) on cell 
viability of A549 cell line. 
 
Figure 4.9a. Graph of cytotoxic effect of concentrations of complexes (38-42) on cell 







Figure 4.9b. Graph of cytotoxic effect of concentrations of complexes (38, 43-47) on cell 
viability of MCF7 cell line. 
 
 
Figure 4.9c. Graph of cytotoxic effect of concentrations of complexes (38, 48-50) on cell 









SYNTHESIS AND CHARACTERIZATION OF 
(TRI-TERT-BUTYLPHOSPHINO)GOLD(I)THIONE 
COMPLEXES 
5.1 Introduction  
 
Auranofin is a linear Au(I) complex of triethyl phosphine and tetracetylthiogulcose 
ligands, which has been used as anti-arthritis drug. Later in 1980s it was investigated 
clinically as anticancer drug in mice [166]. A series of analogues, mainly Au(I) phosphine 
complexes showed promising in vitro and in vivo anticancer tests [167-169]. Recently, 
studies on gold complexes with phosphine and sulfur donor ligands in cancer 
chemotherapy are growing rapidly. Some water soluble gold(I) phosphine derivatives have 
tested against in vitro and in vivo against colon cancer [170]. Zou et al. reviewed the 









5.2 Experimental Section 
 
5.2.1 Materials and instrumentation 
  
All solvents were of analytical grade, used without further purification. Ethanol, diethyl 
ether, dichloromethane, acetone, were purchased from Fluka AG (St. Gallen, Switzerland). 
Chloro(tri-tert-butylphosphine)gold(I) complex from Stream Chemicals Inc. 
(Newburyport, Massachusetts. United States). AgPF6 was purchased from Sigma-Aldrich, 
United States. 1,3-diazinane-2-thione (Diaz), N-hydroxyethyl, 1,3-imidazolidine-2-thione 
(2-EtOH-Imt), 1,3-diazepine-2-thione (Diap) and N-ethyl-1,3-diazinane-2-thione 
(N-Et-Diaz) were prepared as reported [171]. 1H, 13C, 31P NMR, FT-IR spectroscopy and 
elemental analyses were described in section 3.1.  
5.2.2 Synthesis of (tri-tert-butylphosphino)gold(I) thione complexes (52-55) 
   











 [Au{P(t-Bu)3}( SN2C3H6)]PF6 (52) 
AgPF6 (0.127 g, 0.500 mmol) was dissolved in 7 mL of ethanol and then added to a 
solution of (t-Bu)3PAuCl (0.217 g, 0.500 mmol) in acetone (7 mL). The resulting mixture 
was stirred at ambient temperature for 30 mins. and filtered off. 1, 3-diazinane-2-thione 
(0.058 g, 0.50 mmol) was then added to the filtrate, the mixture was stirred for 2 hours, 
filtered and stored in undisturbed area. After four days bright yellowish-white crystals 
were obtained and a suitable crystal was selected for single crystal diffraction analysis. 
Yield 0.268 g (81%). Anal. calc. for C16H35AuN2P2SF6 (660.43 g/mol): C, 29.09; H, 5.34; 
N, 4.24; S 4.85. Found: C, 31.26; H, 3.99; N 3.01; S 3.03. 
 
[Au{P(t-Bu)3}(SN2C5H9-OH)]PF6 (53)  
Complex 53 was prepared using N-hydroxyethyl-1,3-imidazolidine-2-thione (0.073 g, 
0.50 mmol) by a procedure similar to (52). After three days a colorless solid was obtained. 





Yield 0.213 g (62%). Anal. calc. for C17H37AuN2OP2SF6 (690.46 g/mol): C, 29.57; H, 
5.40; N, 4.05; S, 4.64. Found: C, 30.39; H, 4.52; N, 4.13; S, 4.55. 
 [Au{P(t-Bu)3}(SN2C5H10]PF6 (54) 
Complex 54 was prepared using 1,3-diazepine-2-thione (0.065 g, 0.50 mmol) by a 
procedure similar to (52). After three days the colorless crystals were obtained. A suitable 
crystal was selected for single crystal diffraction analysis.  Yield 0.192 g (57%). Anal. 
Calc. for C17H37AuN2P2SF6 (674.46 g/mol): C, 30.27; H, 5.52; N, 4.15; S, 4.75. Found: C, 
30.91; H, 4.16; N, 4.70; S, 4.94. 
 
[Au{P(t-Bu)3}(SN2C5H10]PF6 (55) 
Complex 55 was prepared using N-ethyl-1,3-diazinane-2-thione (0.072 g, 0.50 mmol) by a 
procedure similar to (52). After three days the yellow crystals were obtained. A suitable 
crystal was selected for X-ray diffraction analysis. Yield 0.213 g, (62 %). Anal. Calc. for 
C18H39AuN2P2SF6 (688.49 g/mol): C, 31.40; H, 5.70; N, 4.06; S, 4.65. Found: C, 31.52; H, 
4.24; N, 4.57; S, 4.97. 
 
5.3 Results and discussion 
 
 
5.3.1 Spectroscopic characterization  
 
The synthesized chloro(tri-tert-butylphosphino)gold(I) with thione complexes (52-55) are 
shown in (Scheme 22) and were characterized by 1H, 13C and 31P NMR and mid FT-IR 





FT-IR spectroscopy data of free ligands and complexes (52-55) are summarized in Table 
5.1. 
The formation of complexes (52-55) was confirmed by the significant shift in frequencies 
of free ligands to their complexes. For instance, ν(C=S) band in free ligands is in the 
range of (1001-1191 cm-1), however for complexes (52-55) it is in the range of (830-875 
cm-1) due to C=S weaken upon coordination [133]. In the complexes (52-55) the strong 
ν(C—N=S) absorbance bands were assigned in the range (1443-1480) cm-1 due to 
increasing double character in C─N bond.  
Table 5.1. Mid FT-IR frequencies (cm-1) of free ligand and (tri-tert-butylphosphino)gol(I) 









Diaz - - - 2924  1360 1488 1066 
2EtOHImt - 2979 1379 2925  1358 1466 1065 
Diap - - - 2922  1347 1445 1001 
EtDiaz - - - 2935  1315 1448 1191 
52 3402 (NH) 3000 1370 2954, 2870  1319 1480 875 
53 3600 (OH) 2999 1368 2953, 2895  1328 1476 830 
54 3379 (NH) 3005 1370 2952, 2861 1223 1480 846 
55 3409 (NH) 2952 1375 2904, 2870  1258 1443 852 
 
The comparison of the 1H NMR spectra of free thione ligands and their complexes 
(52-55) showed significant shifts that indicate complexation. For example, 1H NMR data 
for the complex 52 display a doublet at 1.48 ppm, triplet at 3.23 ppm, and triplet at 1.77 








butylphosphino) -tert-H NMR chemical shifts (ppm) for free ligands and (tri1. Table 5.2
gold(I) thione complexes (51-55) in DMSO. 
Ligand/ 
complex 
1H 4H 5H 6H 7H 8H NH 
 
OH 
t-Bu3PAuCl 1.51 d - - - - - - - 
Diaz - 3.07 t 1.70 m - - - 7.76 - 
52 1.48 d 3.23 t 1.77 m - - - 8.93 - 
2-EtOHImt - 3.48 t 3.67 t 3.52 t 3.37 t - 7.93 4.75 
53 1.48 d 3.52 t 3.89 t 3.62 t 3.45 t - 8.95 4.98 
Diap - - - - - - - - 
54 1.48 d 3.48 t 1.85 m - - - 7.20 - 
EtDiaz - 3.05 t 1.80 m 3.26 t 3.71 q 1.04 t 7.71 - 
55 1.47 d 3.21 t 1.86 m 3.44 t 3.77 q 1.17 t 8.97 - 
 
The chemical shifts of 13C and 31P NMR for free ligand and their Au(I) compounds (51-55) 
are shown in Table 5.3. 
13C NMR spectra support the proposed structure of the synthesized complexes. The C=S 
resonance shifted to upfield in all complexes by 4-7 ppm most likely due to back donation 
from gold ion to the π* C=S [171-172]. The C4 (C—N) resonance was shifted downfield in 
all complexes relatively to the free ligand likely due to the increase of sp2 character of 
nitrogen upon coordination.  
31P NMR spectra are in agreement with 1H and 13C NMR results. The 31P resonance 
appears at -10.69 ppm for t-Bu3PAuCl, thus being shifted downfield upon coordination in 
all complexes. A linear correlation between 31P NMR chemical shift and 13C=S NMR 














Table 5.3. 13C and 31P NMR chemical shifts (ppm) for free ligands and 




C1 C2 C=S C4 C5 C6 C7 
 
C8 31P 
t-Bu3PAuCl 32.2 39.5 - - - - - - -10.69 
Diaz - - 173.9 40.1 18.6 - - - - 
52 31.8 40.9 166.8 41.2 18.4 - - - -8.21 
2-EtOHImt - - 182.4 40.9 48.5 49.1 58.8 - - 
53 32.2 40.4 175.3 42.5 49.8 50.3 58.5 - -7.0 
Diap - - 183.9 45.9 26.9 - - - - 
54 32.3 39.7 179.5 46.5 26.1 - - - -7.23 
EtDiaz - - 175.9 40.2 20.9 45.0 47.6 12.1 - 





5.3.2 Signal crystal X-ray structure determination 
 
The structures of complexes 54 and 55 were determined at 173 K (–100 °C) using a STOE 
IPDS 2 with a two-circle goniometer and MoKα graphite monochromator [127]. 
Diffraction data collected using a detector image plate (34 diameter) and sealed X-ray tube 
diffraction source 12 x 0.4 mm long fine-focus. The structures were solved  using the 
programs SHEXLX97, SHELXS-2014 [173]. The non-hydrogen atoms were refined using 
least-squares matrix on F2. The structure of complex 54 and 55 were drawn using the 
programs PLATON and MERCURY [174]. A summary of crystal data and refinement 
details for complexes 54 and 55 are given in Table 5.6.    
The molecular structure and crystal backing of compound [Au{P(t-Bu)3}(SN2C5H10]PF6 
(54) are shown in Figures 5.2 and 5.3 respectively. The selected bond lengths and bond 
angles for complex 54 is shown in Table 5.4. 
The coordination geometry around gold ion with is close to linearity, with (P1—Au—S1) 
178.1(7)º. The Au1—P1 and Au1—S1 bond lengths are 2.23(2) and 2.27(2) Å, 
respectively. The bond lengths and bond angle are similar to those reported for other 
compounds [126, 175].  
The molecular structure and crystal packing of complex [Au{P(t-Bu)3}(SN2C5H10]PF6 
(55) are shown in Figures 5.4 and 5.5 respectively. The selected bond lengths and bond 
angles for complex 54 are shown in Table 5.5. 
The coordination geometry around gold ion is close to linearity, with (P1—Au—S1) 





respectively. These bond lengths and bond angle are similar to those reported for 




Figure 5.2. Molecular structure of complex 54, with partial labelling atoms and 50% 






















Bond Length (Å) Bond Angles (°) 
Au1—S1            2.32 (2) S1—Au1—P1          178.1 (7) 
Au1—P1             2.27 (2) Au1—S1—C1          100.8 (2) 
S1—C1               1.74 (7) S1—C1—N1           119.6 (5) 
N1—C1          1.32 (8) S1—C1—N2           117.1 (5) 







Figure 5.4. Molecular structure of complex 55, with partial atom labelling atoms and 50% 




















Bond Length (Å) Bond Angles (°) 
Au1—S1                 2.32 (1) S1—Au1—P1            178.0 (5) 
Au1—P1                     2.29 (1) Au1—S1—C1            103.8 (2) 
S1—C1                       1.74 (5) S1—C1—N1             121.0 (4) 
N1—C1               1.31 (7) S1—C1—N2             120.3 (4) 





Table 5.6. Summary of crystal data and details of the structure refinement for complexes 
(54 and 55). 
Complex 54 55 
Crystal data   
Empirical formula C17 H37 AuF6N2P2S C18 H39 AuF6N2P2S 
Formula weight       674.46 g/ mol 688.49 g/mol 
Crystal symmetry                     Monoclinic Monoclinic 
Space group                P 21/c  P 21/c  
Crystal color                            Colorless Colorless 
Crystal description          - Block 
Crystal size / mm      - 0.40 x 0.33 x 0.19 
Wavelength/Å                                    0.71073 0.71073 
Temperature/K              293(2) 233(2) 
Cell length a (Ǻ) 16.053(4) 24.9014(16) 
Cell length b (Ǻ) 11.756(3) 13.0453(5)   
Cell length c (Ǻ)                      26.392(4) 16.0089(9) 
Cell angles α (ᵒ)                                           90 90 
Cell angles β (ᵒ)                                     90 90 
Cell angles γ (ᵒ)                                        90.97 90.764 (5) 
Dx   1.686 Mg m−3  1.686 Mg m−3 
μ 6.16 mm−1   5.92 mm−1 
Radiation type               Mo Kα Mo Kα 
Cell volume (Å3) 4979.96(3)  5197.9 (5) 
Z - 8 
Data collection   
Diffractometer   STOE IPDS 2 STOE IPDS 2 
Absorption correction         - Multi-scan (MULABS in 
PLATON; 2009   
Radiation source Plane graphite  Fine-focus sealed tube 
Refinement   
R[F2>2σ(F2)],wR(F2),S      - 0.36, 0.087, 0.96 
∆ρmax                                 1.01 e Å−3  1.14 e Å−3 
∆ρmin −1.50 e Å−3 −1.38 e Å−3 
H-atom treatment             Treated by a mixture of 
independent and constrained         
refinement.     
Treated by a mixture of 
independent and constrained 












SYNTHESIS AND CHARACTERIZATION OF GOLD(I) 




N-heterocyclic carbene (NHC) is versatile ligand with unique properties. Their metal 
complexes have potential applications in the field of medicinal inorganic chemistry and 
industry are currently a focus of the interest [119-121, 176]. Horvath et al. prepared a 
series of gold(I) N-heterocyclic carbene complexes with bisphosphine ligands and 
evaluated for their in vitro and in vivo anticancer activity [177].  
6.2 Experimental Section 
 
6.2.1 Materails and Instrumentation 
 
All solvents were of analytical grade and used without further purification. Ethanol, 
diethyl ether, dichloromethane, acetone, were purchased from Fluka AG (St. Gallen, 
Switzerland). 1,3-Bis(2,6-di isopropylphenyl)imidazol-2-ylidenechloridogold(I) 





-aminocyclohexane, (1R, 2R)-2-(diphenylphosphino)-1,2-diphenylethylamine, 
(R)-2-(diphenylphosphino)-1-phenylethylamine, (R)-1-(diphenylphosphino)-2-amino-3, 
3-dimethylbutane, tricyclohexylphosphine, 3-(diphenylphosphino)propylamine, 
1,3-bis(Diphenylphosphino)propane, 1,2-bis(Diphenylphosphino)ethane and 
bis[2-(Dicyclohexyl(phosphino)ethyl]amine were purchased from Stream Chemicals Inc. 
(Newburyport, Massachusetts. United States). AgPF6 was purchased from Sigma-Aldrich, 
United States. 1H, 13C, 31P NMR, FT-IR spectroscopy and elemental analysis were 
described in section 3.1.  
 
6.2.2 Synthesis of gold(I) N-heterocyclic carbene with mono and 
bis-phosphine complexes (56-65) 
   
 





















































AgPF6 (0.127 g, 0.500 mmol) was dissolved in 5 mL of ethanol was added to a solution 
of 1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidenechloridogold(I) [Au(Ipr)Cl] (0.311 g, 
0.500 mmol) in acetone (5 mL). The resulting mixture was stirred at ambient temperature 
for 10 min and then the mixture was filtered off. Bis(2-cyanoethyl) phenylphosphine 
(0.108 g, 0.500 mmol) was added to the filtrate, stirred for 30 min, filtered and stored in 
undisturbed area. After five days colorless crystals were obtained and a suitable crystal 
was selected for X-ray diffraction analysis. Yield 0.313 g (66%). Anal. calc. for 
C39H49AuN4P2F6 (946.75 g/mol): C, 49.42; H, 5.31; N, 5.91. Found: C, 55.28; H, 5.31; N, 
6.73. 
[Au(Ipr)(C18H22NP)]PF6 (57)  
Complex 57 was prepared using (1R,2R)-2-(diphenylphosphino)-1-aminocyclohexane 
(0.142 g, 0.500 mmol) following a procedure similar to (56). After three days a colorless 
solid was obtained. Yield 0.344 g (68%). Anal. calc. for C45H59AuN3P2F6= (1014.87 
g/mol): C, 49.42; H, 5.31; N, 4.14. Found: C, 53.61; H, 6.06; N, 4.15 
 
[Au(Ipr)(C26H24NP)]PF6 (58)  
Complex 58 was prepared using (1R,2R)-2-(diphenylphosphino)-1,2-diphenylethylamine 
(0.159 g, 0.500 mmol) following a procedure similar to (56). After five days a yellow 
solid was obtained. Yield 0.363 g (65%). Anal. calc. for C53H61AuN3P2F6 (1112.98 





[Au(Ipr)(C20H20NP)]PF6 (59)  
Complex 59 was prepared using (R)-2-(diphenylphosphino)-1-phenylethylamine (0.153 
g, 0.500 mmol) following steps similar to (56). After five days a yellow solid was 
obtained. Yield 0.402 g (78%). Anal. calc. for C53H61AuN3P2F6 (1036.88 g/mol): C, 
54.44; H, 5.54; N, 4.05. Found: C, 53.47; H, 5.93; N, 3.99. 
 [Au(Ipr)(C18H24NP)]PF6 (60)  
Complex 60 was prepared using (R)-1-(diphenylphosphino)-2-amino-3,3-dimethylbutane 
(0.143 g, 0.500 mmol) following a procedure similar to (56). After four days a colorless 
solid was obtained. Yield 0.357 g (77%). Anal. calc. for C39H49AuN3P2F6 (932.73 g/mol): 
C, 50.22; H, 5.29; N, 4.50. Found: C, 45.96; H, 5.80; N, 3.72. 
 [Au(Ipr)(C18H33P)]PF6 (61)  
Complex 61 was prepared using tricyclohexyl-phosphine (0.140 g, 0.50 mmol) by a 
procedure similar to (56). After five days colorless solid was obtained. Yield 0.411 g 
(81%). Anal. calc. for C45H69AuN2P2F6 (1010.95 g/mol): C, 53.46; H, 6.87; N, 2.77. 
Found: C, 56.42; H, 8.34; N, 3.02 
[Au(Ipr)(C15H18NP)]PF6 (62)  
Complex 62 was prepared using 3-(diphenyl- phosphino)propylamine (0.122 g, 0.5 
mmol) following a procedure similar to (56). After three days a colorless solid was 
obtained. Yield 0.310 g (64%). Anal. calc. for C42H54AuN3P2F6 (973.80 g/mol): C, 51.80; 





[(Au(Ipr))2(C27H26P2)](PF6)2 (63)  
AgPF6 (0.127 g, 0.500 mmol) was dissolved in 5 mL of ethanol and the solution was 
added to a solution of 1,3-Bis(2,6-di-isopropylphenyl)imidazol-2-ylidenegoldchlorido(I) 
[Au(Ipr)Cl] (0.311 g, 0.500 mmol) in dichlormethane 5 mL. The resultant mixture was 
stirred at ambient temperature for 10 min and then filtered off. 1,3-Bis(Diphenyl- 
phosphino)propane (0.103 g, 0.250 mmol) in dichloromethane 5 mL was added to the 
filtrate. The mixture stirred for 30 min, filtered and the filtrate stored in a undisturbed 
area. After five days the colorless crystals were obtained and a suitable crystal was 
selected for X-ray diffraction analysis. Yield 0.332 g, (71%). Anal. Calc. for 
C81H98Au2N4P4F12 (1873.48 g/mol): C, 51.92; H, 5.27; N, 2.99. Found: C, 44.85; H, 5.04; 
N, 3.02. 
[(Au(Ipr))2(C26H24P2)](PF6)2 (64)  
Complex 64 was prepared using 1,2-Bis(Diphenylphosphino)ethane (0.100 g, 0.250 
mmol) by a procedure similar to (63). After five days a colorless solid was obtained. 
Yield 0.308 g, (66 %). Anal. Calc. for C80H96Au2N4P4F12 (1873.48 g/mol): C, 51.67; H, 
5.20; N, 3.01. Found: C, 56.42; H, 6.22; N, 3.32. 
[(Au(Ipr))2(C28H24P2)](PF6)2 (65) 
Complex 65 was prepared using Bis[2-(Dicyclohexylphosphino)ethyl]amine (0.117 g, 
0.250 mmol) by a procedure similar to (63). After five days the colorless crystals were 





(60%). Anal. calc. for C82H125Au2N5P4F12 (1926.71 g/mol): C, 51.11; H, 6.53; N, 3.63. 
Found: C, 50.68; H, 6.52; N, 3.45. 
6.3 Results and Discussion 
 
6.3.1 Spectroscopic Characterization 
  
The ligands (L3-L12) and their gold(I) complexes (56-65) were synthesized (Scheme 23) 
and were characterized using by 1H, 13C and 31P NMR and mid FT-IR spectroscopy, 
elemental analyses and single crystal X-ray diffraction analysis.  
The FT-IR frequencies for free ligand and their complexes (56-65) are shown in Table 
6.1. FT-IR spectra showed weak absorbance in the region of (3049-3078 cm-1) assigned to 
benzene ring =C—H stretching for the free ligands and precursor 38. This absorbance was 
shifted to higher frequency in the range (3120 -3175 cm-1) in all complexes. The ν(C≡N) 
band for free ligand L2 appears at 2250 cm-1 and for it is complex 56 was shifted lower 







Table 6.1. Mid FT-IR frequencies (cm-1) of gold(I) with mixed carbene and phosphine complexes (56-65). 




   
 
    Stretch  
C≡N 
38 - 3037 1109 2960  1366 1258 1462 - 
L3 - 3073 1095 2933, 2911 1327 1426 - 2250 
56 - 3120 1108 2956, 2874  1327 1256 1467 2242 
L4 3334, 3259 3074 1099 2916, 2844  1327 1230 1478 - 
57 3433, 3358 3170 1103 2963, 2867  1328 1215 1466 - 
L5 3371, 3302 3063 1071 2903, 2854  1314 1238 1484 - 
58 3288, 3275 3171 1118 2960, 2869  1329 1214 1469 - 
L6 3376, 3350 3055 1066 2939, 2838 1399 1271 1485 - 
59 3400, 3392 3168 1104 2962, 2869  1329 1214 1467 - 
L7 3381, 3301 3055 1084 2955, 2867  1363 1184 1479 - 
60 3292, 3285 3172 1105 2958, 2870  1329 1217 1472 - 
L8 - - - 2932, 2849  - - 1444 - 
61 - 3167 1119 2927, 2853  1328 1272 1452 - 
L9 3367, 3292 3052 1095 2929, 2854  1306 1434 1586 - 
62 3392, 3326 3148 1103 2962, 2870  1329 1215 1497 - 
L10 - 3050 - 2920, 2850  1370 - 1455 - 
63 - 3175 1105 2962, 2870  1329 1215 1469 - 
L11 - 3049 - 2923, 2853 1365 - 1452 - 
64 - 3172 1106 2963, 2870  1329 1216 1467 - 
L12 3285 - - 2934, 2841 1324 1256 1442 - 







The 1H NMR chemical shifts of free ligands and their complexes (56-65) are given in 
Table 6.2.  1H NMR data showed significant shift in carbene moiety between precursor 38 
and their complexes (56-65). 1H NMR chemical shift of NH in free ligands (L2-L5 and 
L7) was observed in the range (1.09-2.02 ppm) and shifted downfield for their complexes 
(57-60 and 62) in range (1.17-2.21 ppm). For all free ligands, 1H MNR data of H—C—P 
moiety observed downfield to their complexes due to back donation from gold ion to π* 
P─C bond. 
 13C NMR chemical shifts for free ligands and their complexes are summarized in Table 
6.3. 13C NMR chemical shift (C=Au) for precursor 38 was observed at 175.3 ppm. 
whereas, for their complexes was shifted downfield in the range (187.9-207.2 ppm) likely 










.3) in CDCl65-56H NMR chemical shifts (ppm) for free ligands and gold(I) complexes (1 .Table 6.2 
Ligand/ 
complex 
3H 4H 5H 6H 7H 8H 9H 10H 11H 12H 13H NH 
38 7.39 d 7.55 t 2.46 m 1.33 d 1.21 d 7.98 s - - - - - - 
L3 - - - - - - 2.36 t 2.10 t 7.53 dd 7.45dd - - 
56 7.36 d 7.61 t 2.54 m 1.13 d 1.26 d 7.33 s 2.43 t 2.15 t 7.55 dd 7.51 dd - - 
L4 - - - - - - 2.59 m 1.69 m 2.06, 1.21 m 1.95 m 0.87 m 2.02 
57 7.35 d 7.55 t 2.63 m 1.33 d 1.24 d 7.50 s 3.08 m 1.64 m 2.51, 1.24 m 2.09 m 1.00 m 2.12 
L5 - - - - - - 4.41 d 4.40 dd 7.82 m 7.14 m 7.44m 1.8 
58 6.67 d 6.88 t 2.60 m 1.31 d 1.32 d 5.60 s 4.24 d 3.70 dd 7.92 m 6.95 m 7.75 m 2.17 
L6 - - - - - - 3.99 d 2.73,183 d 7.41 m 7.11 m - 1.99 
59 6.62 d 6.87 t 2.59 m 1.31 d 1.27 d 5.31 s 3.72 d 2.70, 240 d 7.54 m 7.08 m - 2.16 
L7 - - - - - - 2.90 dd 2.40,1.83 d 7.78 m 7.34 m 0.94 m 2.14 
60 6.81 d 6.91 t 2.87 m 1.35 d 1.27 d 5.79 s 3.09 s 2.47,1.87 d 7.68 m 7.53 m 0.71 m 2.18 
L8 - - - - - - 1.66 1.89, 1.22 1.80, 138 1.73, 1.58 - - 
61 7.34 d 7.49 t 2.46 m 1.25 d 1.20 d 5.24 s 1.41 1.76, 0.89 1.65, 1.04 1.60, 1.18 - - 
L9 - - - - - - 1.50 m 1.99 p 2.69 t 7.25 m 7.35 t 1.09 
62 7.50 d 7.59 t 2.33 m 1.24 d 1.20 d 7.13 s 1.27 m 1.92 p 2.54 t 7.33 m 7.41 t 1.17 
L10 - - - - - - 1.62 t 2.36 t 7.30 m 7.36 m - - 
63 7.39 d 7.64 t 2.49 m 1.17 d 0.91 d 8.20 s 1.21 t 2.20 t 6.96 m 7.59 m - - 
L11 - - - - - - 2.10 t 7.30 m 7.32 m - - - 
64 7.32 d 7.54 t 2.41 m 1.19 d 1.01 d 7.76 s 1.79 t 6.74 m 7.47 m - - - 
L12 - - - - - - 3.94, 378 m 2.97,2.14 m 3.18 m 1.76 m 1.56 m - 









.3) in CDCl65-56gold(I) complexes ( C NMR chemical shifts (ppm) for free ligands and13 Table 6.3. 
Ligand/ 
complex 
C1 C2 C3 C5 C6 C8 Au=C C10 
 
C11 C12 C13 C14 C15 C16 C17 C18 
38 145.5  130.7   133.9    28.8   24.5   124.2   175.3 -  -  - - - - - 
L3        119.1   14.1    23.9    133.2   132.6   129.2 - - - 
56 144.5   130.1 132.4 27.7 23.5 124.1 187.9 110.8 11.9 21.4 131.9 128.6 128.5 - - - 
L4        52.5                 43.8 24.8 27.3 26.2 36.6 135.6 132.3 128.3 
57 145.9           131.0 133.5 28.4 24.9 124.1 190.3 56.5 42.4 24.4 28.8 25.2 38.8 134.1 132.7 129.3 
L5        58.8      53.4 143.6 137.6 136.9 133.7 128.7 127.6 126.2 
58 145.3              131.7 132.9 28.7 24.4 124.5 207.2 60.7 52.7 146.0 134.9 133.5 133.2 128.6 127.2 125.1 
L6        53.7    39.4 145.6 138.4 132.9 128.7 126.2 - - 
59 145.9      131.1 133.0 28.7 24.6 124.6 189.1 45.1 37.0 143.8 133.6 132.2 127.9 126.1 - - 
L7        32.3   57.4 34.6 25.7 139.6 133.4 128.8 - - 
60 145.5     131.1 133.3 28.8 24.6 124.6 188.6 32.9 59.5 36.0 25.6 133.2 130.7 128.8 - - 
L8        31.0     35.5 27.6 26.5 - - - - - 
61 145.7   130.9 133.4 28.8 24.5 124.7 193.1 32.8 34.4 26.7 25.5 - - - - - 
L9        25.2      30.0 43.3 138.6 132.4 128.3 - - - 
62 145.9     131.2 133.3 28.9 24.7 125.0 190.6 24.5 28.5 41.9 132.8 129.4 128.8 - - - 
L10        29.6  22.4 138.6 132.7 128.4 - - - - 
63 145.2   130.9 132.5 28.8 23.5 125.6 188.9 26.4 19.1 132.9 129.5 127.7 - - - - 
L11        23.7       137.9 132.6 128.3 - - - - - 
64 145.2       130.8 132.2 28.3 24.3 125.2 188.7 22.8 132.7 129.5 126.0 - - - - - 
L12 - - - - - - - 46.9   







27.2 26.3 - - - 
65 145.7           131.0 133.2 29.5 24.4 124.5 193.1 47.0 29.5 










31P NMR chemical shifts (ppm) for free ligands and gold(I) complexes (56-65) are given 
in Table 6.4. The resonance values for free ligands are in the range (-25.14─ -9.22 ppm), 
whereas those of their complexes were observed downfield in the range (30.26─46.46 
ppm) due to back donation from gold ion to π* P─C bond. Expect for L8 appearing at 
9.33 ppm and complex 61 observed upfield at -44.54.    
 




































6.3.2 Signal crystal X-ray structure  
 
The structure of complexes 56, 61, 63 and 65 were determined using STOE IPDS 2 
system at 203-293K with a two-circle goniometer and MoKα graphite monochromatic 
radiation[127]. Structures were solved using the program SHELXS-97 [178-180]. The 
non-hydrogen atoms were refined using least-squares matrix on F2. The molecular 
structures of complexes are consistent with spectroscopic data and are illustrated in 
Figures (6.1─6.4). The coordination geometry around gold(I) ion is distorted from 
linearity with angle (C—Au—P) of 177.0(4)º, 179.9(3)º, (173.1(6) and 174.4(6)º [181]. 
The bond lengths and bond angles for complexes 56, 61 and 63 are illustrated in Tables 
6.5, 6.7 and 6.9. Summary of crystal data and details of the structure refinement for 
complex (56, 63 and 65) are shown in Tables 6.6, 6.8 and 6.10. 
The pronounced distortion in compound 63 (173.1(6). The C—Au and Au—P bond 
lengths (Å) are 2.052(14); 2.022 (11); 2.060(2) and 2.261(5); 2.295(3); 2.280(6) are similar 
to those reported [182].  
The hydrogen-bond (Å) for complex 61 is found to be PF6----H—CCl3 between (F1) of 
counter ion (PF6¯) and hydrogen of (CHCl3) as solvent. The hydrogen  bond length (Å) 









Figure 6.1. Molecular structure of complex 56, with partial labelling atoms and 50% 















Bond Length (Å) Bond Angles (°) 
P1—Au1             2.261 (5) C1—Au1—P1             177.0 (4)
C1—Au1           2.052 (14) C28—P1—Au1            115.0 (5)
C1—N1                 1.285 (17) C34—P1—Au1            112.0 (6)
C2—N2            1.353 (17) C37—P1—Au1            112.4 (6)
C28—P1               1.834 (15) N2—C1—Au1             126.5 (9) 
C34—P1                 1.827 (15) N1—C1—Au1            127.0 (11) 





Table 6.6. Summary of crystal data and details of the structure refinement for complex 56.
  
Complex 56 Experimental details 
Crystal data   
Empirical formula C39H49AuN4P2F6 
Formula weight 946.75 
Wavelength/Å 0.71073 
Temperature/K 293(2) 
Crystal symmetry Monoclinic 
Crystal color  colorless  
Space group Cc 
Cell lengths (Å)  a=17.053 (1), b=17.959 (2), c= 13.483 (1)    
Cell Angles (°) α= 90.000, β= 91.026 (7), γ= 90.000  
Dx 1.392 Mg m−3  
μ 3.64  mm−1 
Radiation type   Mo Kα 
Cell volume (Å3) 4128.6 (6) 
Z 4 
Data collection  
Diffractometer  STOE IPDS 2  
Absorpance correction Not given 
Radiation source fine-focus sealed tube 
Radiation monochromator  plane graphite 
(sinθ/λ)max (Å−1) 0.686 
Refinement  
R[F2 > 2σ(F2)], wR(F2), S 0.061, 0.173, 1.09 
∆ρmax  4.01 e Å−3 
∆ρmin  −1.63 e Å−3 























Bond Length (Å) Bond Angles (°) 
P1—Au1             2.295 (3) C1—Au1—P1        179.9 (3) 
C1—Au1            2.022 (11) C15—P1—Au1        110.7 (3) 
N1—C1                 1.355 (8) C21—P1—Au1        110.1 (3) 
P1—C15                1.386 (7) N1—Au1—C1         128.2 (4) 





Table 6.8. Summary of crystal data and details of the structure refinement for complex 61. 
Complex 61 Experimental details 
Crystal data   
Empirical formula  C46H70AuCl3N2P2F6 
Formula weight 1130.29 
Wavelength/Å 0.71073 
Temperature/K 203  
Crystal symmetry Orthorhombic 
Crystal color Plate, colorless  
Crystal size/ mm 0.40 x 0.22 x 0.03 
Space group Cmc21 
Cell lengths (Å) a=17.2904 (7), b=18.2392 (11), c= 16.1154 (7)   
Cell Angles (°)  α= 90.000 (5), β= 90.000 (5), γ= 90.000 (5) 
Dx 1.477 Mg m−3  
μ 3.17 mm−1 
Radiation type   Mo Kα 
Cell volume (Å3) 5082.2(4) 
Z 4 
Data collection  
Diffractometer  STOE IPDS 2  
Absorpance correction Multi-scan (MULABS; Spek, 2009) 
Radiation source fine-focus sealed tube 
Radiation monochromator  plane graphite 
Tmin, Tmax 0.746, 1.000 
(sin θ/λ)max (Å−1) 0.622 
Refinement   
R[F2 > 2σ(F2)], wR(F2), S 0.024, 0.047, 0.90 
∆ρmax  0.95 e Å−3 
∆ρmin −0.61 e Å−3 










Figure 6.3. Molecular structure of binuclear complex 63, with partial labelling atoms and 
50% probability ellipsoids. Hydrogen atoms have been omitted for clarity. 
 
 








Bond Length (Å) Bond Angles (°) 
Au01—P6              2.28 (6) P6—Au01—C181         174.4 (6) 
Au01—C181              2.06 (2) P8—Au04—C186          173.1 (6) 
Au04—P8                 2.27 (7) Au01—C181—N42        122.0 (2) 
Au08—C186          1.97 (2) Au01—C181—N53        130.0 (2) 
N42—C181               1.32 (3) N42—C181—N53         107.0 (2) 
N53—C181               1.31 (3) Au04—C186—N54        134.0 (2) 
N54—C186               1.37 (3) Au04—C186—N55        124.0 (2) 





Table 6.10. Summary of crystal data and details of the structure refinement for complex 
63. 
Complex 63 Experimental details 
Crystal data   
Empirical formula C81H98 Au2F12N4P4 
Formula weight 1873.48 
Wavelength/Å 0.71073 
Temperature/K 293(2) 
Crystal symmetry monoclinic 
Space group P 21/c 
Cell lengths (Å) a=18.819 (5), b=22.480 (5), c= 42.175 (5)    
Cell Angles (°) α= 90.000 (5), β= 94.936 (5), γ= 90.000 (5) 
Dx 1.686 Mg m−3  
μ 385.24 mm−1 
Radiation type   Mo Kα 
Cell volume (Å3) 17776(7) 
Z 4 
Data collection  
Radiation source fine-focus sealed tube 
Radiation monochromator  graphite 
Tmin, Tmax 0.39, 1.000 
(sin θ/λ)max (Å−1) 0.577 
Refinement   
R[F2 > 2σ(F2)], wR(F2), S 0.164, 0.429, 2.47 
∆ρmax 10.15 e Å−3 
∆ρmin −7.65 e Å−3 









Figure 6.4. Molecular structure of binuclear complex 65, with 50% probability ellipsoids. 













SPECTROSCOPIC STUDIES OF INTERACTIONS OF THE 
POTENTIAL ANTICANCER AGENTS [Au(cis-DACH)Cl2]Cl 
AND [Au(cis-DACH)2]Cl3 WITH BIOLOGICALLY  
RELEVENT THIONES 
 7.1 Introduction.  
  
The study of metallo-drugs, containing sulfur donor ligands, with interesting physical, 
chemical, biological and pharmacological properties have attracted attention [183-184].  
Among these, gold complexes are a new class of metal-based drugs with promising 
potential antitumor properties [23]. Notably, a number of gold(I) and gold(III) complexes 
are reported to possess cytotoxic effects against selected human cancer cell lines [185], 
gold(I)-thiolates as anti-arthritic [186-187] and antitumor drugs [8,138,188]. In contrast, 
the pharmacological behavior of gold(III) derivatives containing thiols and thiones is 
unclear and is an underdeveloped field in modern inorganic chemistry [133]. These 





and square planar structure similar to Pt(II), and the interaction of their complexes with 
thiols and thiones have been widely reported [189]. 
Ghosh et al. studied kinetics of the interaction of Pd(II) imidazole derivative and 
2-aminopyrimidine and they concluded their study with a proposed mechanism [190]. 
Moreover, the kinetic and mechanistic studies were carried out for the interaction of 
cis-[Pt(en)(H2O)2](ClO4)2 and cis-[Pt(dmen)(H2O)2](ClO4)2, where en = ethylenediamine 
and dmen = N,N-dimethyl-ethylenediamine, with glycine under pseudo fist-order 
conditions as a function of  temperature, pH and ligand concentration [191]. Ray et al. 
evaluated activation parameters of kinetics for the substitution reactions of 
cis[Pt(cis-DACH)(H2O)2]2+, DACH=1,2-diaminocyclohexane, with dipeptides containing 
glycine, glutathione and penicillamine under pseudo first-order conditions dependent on 
pH, ligand [192].   
The oxidation of thiols and thioether groups that are part of amino acids, via metal ions, 
has been investigated for decades due to their important role in function and structure of 
proteins [193]. The interaction of [Au(CN)4]-, [Au(terpy)Cl]2+, [Au(bpma)Cl]2+, 
[Au(dien)Cl]2+ and [AuCl4]‾, where terpy =2,2ˈ, 6ˈ,2ˈˈ-terpyridine, bpma = bis(pyridyl 
methyl)amine, dien = diethylene-triamine, with the biologically relevant thiols and 
thioether, such as L-Cysteine, glutathione and L-methionine, has been studied [106,194]. 
These studies were conducted by cyclic voltammetry (CV), ESI-MS, 1H NMR and 
UV-Vis spectroscopy. In addition, researchers extensively studied kinetics and 
mechanism of redox reactions of Au(I) and Au(III) complexes to investigate their ligand 
exchange reactions and metabolism [195-196]. The kinetics of the formation and 





a two-term rate law [197]. The study showed that their hydrolysis are faster than the 
analogous Pt(II) complexes.  
 The preparation and characterization of new gold(III) compounds with DACH was 
reported [198], the effect of stereochemistry of DACH on tumor activity, and the 
cis-DACH isomer showed the highest activity against human cancer cell lines such as 
prostate cancer (PC-3) and gastric carcinoma (SGC-7901). We report the interaction of 
[Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with enriched thiourea (Tu) and 
1,3-diazinane-2-thione (DIAZ)  by 1H, 13C and 15N NMR spectroscopy, UV-Vis 
spectroscopy, and electrochemistry. We also present the kinetics of these interactions.  
7.2 Experimental Section 
 
7.2.1 Materials and Instrumentation 
 
NaAuCl4.2H2O and cis-DACH were purchased from Sigma-Aldrich, USA; absolute 
EtOH from Merck, D2O from Alfa-Aesar, and thiourea from Cambridge Isotope Lab. Inc. 
DIAZ was prepared as described [171]. Deionized water with a resistivity of 18.6 MΩ 
cm−1 was used to prepare all solutions. It was obtained directly from a PURELABs Ultra 
Laboratory Water Purification System. 
7.2.2 Spectroscopic techniques 
 
1H NMR spectra were recorded on a JEOL-LA 500 MHz NMR spectrophotometer. The 
spectral conditions were: 32k data point, 3.2 s acquisition time, and 5.75 μs pulse width. 
13C NMR measurements were recorded at 125.65 MHz with 1H broadband decoupling. 





5.12 μs pulse width. 15N NMR spectra were recorded at 50.53 MHz with benzamide as 
external reference (932.56 ppm) relative to internal reference NH4NO3 (375.11 ppm). All 
spectra were recorded at 297 K in D2O using tetramethylsilane (TMS) as internal 
standard. 
7.2.3 Electrochemical technique 
 
A CHI660 potentiostat was used for all square wave stripping voltammetric (SWSV) 
measurements. The electrochemical cell contained a glassy carbon electrode (GCE; 3.0 
mm diameter, Model CHI104, CH Instruments, Austin, TX) as a working electrode, 
Ag/AgCl (sat. KCl) reference electrode (Model CHI111, CH Instruments, Austin, TX), 
and a platinum wire counter-electrode were inserted into a 2-mL glass cell through holes 
in its Teflon cover. Prior to each SWSV measurement, the GCE was polished with 3.0 
and 0.05 µm alumina slurries and washed with double-distilled water. Each SWSV 
measurement was performed at room temperature in a quiescent 0.2 M KCl aqueous 
solution, and with an initial potential of 0.0V and final potential of +1.6V. 
7.2.4 Synthesis of [Au(cis-DACH)Cl2]Cl 
 
[Au(cis-DACH)Cl2]Cl was synthesized as described in the literature [199]. λmax = 305 
nm. 1H NMR, ppm, δ: 3.59 m, 2.02 m, 1.76 m, 1.47 m, and 1.29 m. 13C NMR, ppm, δ: 
63.3, 26.8, and 21.4. Anal. Found (calculated) for C6H14AuCl3N2 (417.51 g/mol): C, 
17.22 (17.26); H, 3.38 (3.35); N, 6.67 (6.71). 






[Au(cis-DACH)2 ]Cl3 was synthesized as described in the literature [199]. λmax  = 344 
nm. 1H NMR, ppm, δ: 3.58 m, 1.94 m, 1.74 m, 1.54 m, 1.38 m. 13C NMR, ppm, δ:  61.7, 
61.6, 26.3, 26.1 and 20.6. Anal. Found (calculated) for C12H28AuCl3N4 (531.70 g/mol): C, 
27.02 (27.11); H, 5.28 (5.31); N, 10.61 (10.54). 
7.2.6 Kinetic Measurements 
 
The kinetic measurements were carried out on a Cary 100 UV-Vis spectrophotometer 
(Agilent Technologies) connected with a Cary temperature controller (accuracy = ± 0.1 
°C). The working wavelengths were determined over the wavelength range (200 -500 
nm) (Fig. 7.11). The reactions were started by mixing the complex in 30 mM KCl 
solution and ligand solutions in equal volumes directly in a vial kept inside the 
instrument.  The kinetic measurements were made under pseudo first-order conditions, 
where concentration of the complex is 0.2 mM with excess ligands (2-10 mM).  The 
reactions were carried out at different temperatures of 288.2, 298.2 and 310.2 K. The 
pseudo firs-order rate constant kobsd was calculated as an average value of seven 
independent kinetic runs. All calculations were maintained using Microsoft Excel, Origin 
8. 
7.3 Results and Discussion 
 
7.3.1 Interaction of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with 
enriched Tu and DIAZ 
 
Interactions of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with enriched 10 % Tu 





DIAZ. The reaction products were monitored by 1H, 13C and 15N NMR, UV-Vis 
spectroscopy and electrochemistry. The interaction of [Au(cis-DACH)Cl2]Cl and 
[Au(cis-DACH)2]Cl3 with Tu was monitored by 13C NMR as shown in (Fig. 7.1). Fig. 
7.1a shows the 13C NMR spectrum of 1 mg Tu (13C enriched), and Fig. 1b shows the 13C 
NMR spectrum of the oxidation reaction of Tu by H2O2, which resulted in the formation 
of urea (NH2)2CO and Tu dioxide, (NH2)2CO2S [200-201]. When enriched Tu (0.25 eq.) 
was added to 1 eq. of [Au(cis-DACH)Cl2]Cl, their solution changed to yellow colour 
(Fig. 7.1A-c) and the 13C NMR peak of enriched Tu was observed up-field at 179.68 ppm 
due to complexation, similar to previous observations [96]. Whereas, no peak was 
observed for [Au(cis-DACH)2]Cl3 at the same conditions.  Figure 7.1A-d shows the 
formation of [Au(cis-DACH)Tu2]3+ at 164.59 ppm, which is consistent with Fig. 7.1B-c 
of [Au(cis-DACH)2]Cl3  at the same mole ratio (1: 0.5). Upon addition of enriched Tu to 
the solutions complex: Tu (1:1) and (1:4) of [Au(cis-DACH)Cl2]Cl and 
[Au(cis-DACH)2]Cl3 respectively, a colourless solution was observed with yellow 
precipitation due to the reduction of Au(III) to Au(I) [202], as shown in  Fig.7.1(A-e), 
Fig. 7.1(A-f) and Fig. 7.1(B-d). The signal at 164.59 ppm remained constant and two new 
intense signals at 182.04 ppm and 184.87 ppm, which appeared as triple due to 15N 
coupling [203-204]. The 13C NMR chemical shifts of different species in the interaction 










Table 7.1. 1H, 13C NMR chemical shifts of the free ligand enriched (Tu), the [Au(cis-DACH)Cl2]Cl (A) and 





1H, 13C(δ in ppm) 
C=S (C1) C2,C3 C4,C7 C5,C6 2H, 3H 4H, 7H eq 4H, 7H ex 5H, 6Heq 5H, 6H ex 
A B A B A B A B A B A B A B A B A B 
Tu 185.6 - - - - - - - - - - - - - - - - - 
Tu + 
H2O2 
169.5 164.5 158.5 - - - - - - - - - - - - - - - 



















































































































































































Figure 7.1. (A) 13C NMR spectra for: free Tu (a), oxidation of Tu by H2O2 (b), the reaction of [Au(cis-DACH)Cl2]Cl 
and Tu, 1:0.25 (c), at 1:0.5 (d), at 1:1 (e), and at 1: 4 (f). (B) 13C NMR spectra for: free Tu (a), oxidation of Tu by H2O2 






15N NMR spectrum of the reaction of enriched Tu (13C, 15N) with [Au(cis-DACH)Cl2]Cl 
(Fig. 7.2-A) shows a peak for free Tu at 583.26 ppm. An up-field shift to 409.17 ppm and 
244.55 ppm at complex: Tu (1:1) and (1:2) mole ratio, respectively, indicates consecutive 
replacement of chloride.  At complex: Tu (1:4 eq.), [Au(cis-DACH)Cl2]Cl was reduced 
to colourless [Au(Tu)2]+, which was confirmed by a peak at 538.07 ppm [101]. Similarly, 
the reaction of the same ligand with [Au(cis-DACH)2]Cl3  showed three peaks: 403.56 
ppm at (1:1), as well as 277.15 ppm and 538.58 ppm at (1:2), which are indicative for the 
presence of [Au(cis-DACH)2Tu]3+, [Au(cis-DACH)(Tu)2]3+ and [Au(Tu)2]+, respectively 
(Fig. 7.2 B). 
The substitution reaction of [Au(cis-DACH)Cl2]Cl and Tu was studied by UV-Vis 
spectroscopy in aqueous solution containing 30 mM KCl at pH 3.5. Two bands at 390 nm 
and 249 nm, assigned to [Au(cis-DACH)(Tu)Cl]2+ and [Au(cis-DACH)(Tu)2]3+, 
respectively, were observed, which are attributed to charge transfer from metal to ligand 
(M→Tu). The bands at 237 nm and 230 nm represent a redox reaction, assigned to 
[Au(Tu)2]+  Fig. 7.3 [101].  
We then studied the interaction of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with 
Tu in aqueous solution containing 0.2 M KCl by square wave stripping voltammetry. 
Well-defined SWSV peaks are obtained at +0.82V and +1.35V (vs. Ag/AgCl) for 0.48 
mM [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3, respectively (Fig. 7.4 and Fig. 7.5). 
The obtained peak disappeared with the subsequent additions of Tu as in Fig. 7.4 (c-g) 
and Fig. 7.4 (c-h). The electrochemical results are in agreement with the 1H, 13C and 15N 













Figure 7.2. (A). 15N NMR spectra of free Tu (a), after the reaction with [Au(cis-DACH)Cl2]Cl at (1:1) (b), at (1:2) (c) and at  
(1: 4) (d) (B). 15N NMR spectra of free Tu (a), after the reaction with [Au(cis-DACH)2]Cl3 at (1:1) (b), at (1: 2) (c) and at (1:4) 






Figure 7.3. UV-Vis spectra for: ree Tu (0.1 mM) (a), after reaction with 
[Au(cis-DACH)Cl2]Cl (0.1 mM) (b), complex: Tu, 1:0.5 (c), (1:1) (d), (1:2) (e) and at (1:4) 




      
 
 
Figure 7.4. SWSV of ree (a) and presence (b) of 0.48 mM of [Au(cis-DACH)Cl2]Cl in 0.2 
M KCl solution. Subsequent additions of 0.24 mM Tu (c-g). Working conditions of the 









Figure 7.6. SWSV of free (a) and presence (b) of 0.24 mM of Tu in 0.2 M KCl solution. 
Subsequent additions of 0.48 mM Tu (b-f) at pH 3.5. Working condition of the pulse width 
(increment), 4 mV; pulse height (amplitude), 25 mV; frequency 15 Hz and in aqueous 
solution.  
Figure 7.5. SWSV of free (a) and presence (b) of 0.48 mM of [Au(cis-DACH)2]Cl3 in 
0.2 M KCl solution. Subsequent additions of 0.24 mM Tu (c-h). Working condition of 





We also monitored the interaction of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 
with DIAZ by 13C NMR in D2O, as shown in Fig. 7.7. Fig. 7.7a shows the 13C NMR 
spectrum of 5 mM of DIAZ, and Fig. 7.7b shows the 13C NMR spectrum of oxidation of 
DIAZ (RN2C=S) with H2O2, which produces RN2CSSCN2R. Reaction of both complexes 
with equimolar of DIAZ resulted in an up-field shift to 164.82 ppm in the 13C NMR (Fig. 
7.7 A-c and Fig. 7.7 B-c. Their solutions changed from yellow to orange after 1 hr, and 
later turned to colourless with white precipitation due to initial reduction of Au(III) to 
Au(I) and then oxidation of DIAZ to (DIAZ)2 [147, 205]. When [Au(cis-DACH)Cl2]Cl 
and [Au(cis-DACH)2]Cl3 reacted with 2 eq. of DIAZ (Fig. 7.7A-d and Fig. 7.7B-d, the 
chemical shift of (C=S) of DIAZ shifted down-field to 169.55 ppm, and the solutions 
changed to pale yellow with yellow precipitation. At higher concentration of DIAZ (4 
eq.), the 13C chemical shift of (C=S) shifted down-field to 172.32 ppm and 171.61 ppm, 
respectively, (Fig. 7.7A-c and Fig. 7.7B-c) in agreement with that reported [99]. The 
proof of total reduction of Au(III) specie to Au(I) is confirmed by disappearance of the 
solution color with yellowish white precipitation.   
The evidence for the coordination sulphur of the thione ligand is provided by 13C NMR 














Figure 7.7. (A) 13C NMR spectra for: free DIAZ (a), oxidation of DIAZ by H2O2 (b), reaction of [Au(cis-DACH)Cl2]Cl and DIAZ at 
(1:1)(c), at (1:2) (d) and at (1:4) (e); (B) 13C NMR spectra for: free DIAZ (a), oxidation of DIAZ by H2O2 (b), reaction 








Table 7.2. 13C NMR chemical shifts of the free ligand (DIAZ) and the [Au(cis-DACH)Cl2]Cl(A) and [Au(cis-DACH)2]Cl3 (B) 
complexes in D2O. 
Ligand/ 
Complex 
C=S (C2) C4,C6 C5 C7,C8 C9, C12 C10, C11 
A B A B A B A B A B A B 
Diaz 176.6 - 41.3 - 20.3 - - - - - - - 
Diaz + 
H2O2 
171.5 - 42.2, 41.6 
40.0, 39.8 
- 18.8, 18.6 
18.5, 17.5 
- - - - - - - 




- - - - 63.3 
- 
61.7, 61.6 26.7 
- 
26.3, 26.1 21.4 21.6 












[1: 2] - 167.8 40.2 40.5 18.7 18.5 - 50.3 - 27.7 - 20.9, 20.1 
[1: 4] 174.5 
 
171.6 41.6, 40.7 
40.1, 39.0 
- 20.1, 19.1 
19.6, 18.8 
18.4 51.4 49.9 27.1 27.4 21.7 20.5 
 





The 13C chemical shift of C=S (C2) shifted up-field by 2.1-11.8 ppm in all of the 
complexes according to reduction of double bond character in (C=S) thione group. 
(C4,C4’) and C(5) are shifted downfield by 0.44-0.88 ppm due to the increase in 
double bond character of C=N group [61]. The substitution reaction of 
[Au(cis-DACH)Cl2]Cl and DIAZ was studied by UV-Vis spectroscopy. It was 
carried out in aqueous solution containing 30 mM KCl at pH 3.5. Fig. 7.8 shows the 
UV-Vis spectra of the substitution reaction followed by redox reaction. Two bands 
at 235 nm and 245 nm correspond to the products substitution reaction referred to 
[Au(cis-DACH)Cl(DIAZ)]2+ and [Au(cis-DACH)(DIAZ)2]3+, respectively. They are 
due to back bonding from metal to ligand (M→DIAZ). The band at 207 nm 
represents redox reaction product [Au(DIAZ)2]+, which is due to reductive 
elimination through trans-effect [147].  
 
 
Figure 7.8. UV-Vis spectra for: free DIAZ (0.1 mM) (a), [Au(cis-DACH)Cl2]Cl (0.1 mM) 
(b), reaction of [Au(cis-DACH)Cl2]Cl and DIAZ 1:0.5 (c), 1: 1 (d), 1:2 (e), and 1:4 (f). All 





We then studied the interaction of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with 
DIAZ in aqueous solutions containing 0.2 M KCl by square wave stripping voltammetry. 
A well-defined SWSV peak is obtained at +0.82V (vs. Ag/AgCl) for 0.48 mM 
[Au(cis-DACH)Cl2]Cl (Fig. 7.9). Whereas for [Au(cis-DACH)2]Cl3 is obtained at 
+1.35V (Fig. 7.10 ). The obtained peak disappeared with the subsequent additions of 
DIAZ [Fig. 7.9(c-h). 





Figure 7.9. SWSV of free (a) and presence (b) of 0.48 mM of [Au(cis-DACH)Cl2]Cl in 
0.2 M KCl solution. Subsequent additions of 0.24 mM of DIAZ (c-h). Working 



































Figure 7.10. SWSV of free (a) and presence (b) of 0.48 mM of [Au(cis-DACH)2]Cl3 in 
0.2 M KCl solution. Subsequent additions of 0.24 mM DIAZ (c-h) at pH 3.5. Working 
condition of the pulse width (increment), 4 mV; pulse height (amplitude), 25 mV; 
frequency, 15Hz in aqoueous solution. 
Figure 7.11. SWSV of free (a) and presence (b) of 0.24 mM of DIAZ in 0.2 M KCl 
solution. Subsequent additions of 0.48 mM DIAZ (b-f) at pH 3.5. Working condition 
of the pulse width (increment), 4 mV; pulse height (amplitude), 25 mV; frequency, 15 





7.3.2 Kinetic Data 
 
The kinetics of substitution reactions of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 
with Tu and DIAZ were studied by following the change of absorbance at selected λmax. 
Pseudo first-order reaction conditions were employed for all kinetic runs at pH 3.5 using 
excess thione ligands with concentration of 2-10 mM. The reactions were carried out in 
the presence of 30 mM KCl to prevent the complex hydrolysis. All kinetic data are 
summarized in (Tables 7.3-7.6). 
Plots of ln(A ͚-At) versus time, at constant temperature, pH 3.5 and fixed concentration of  
complex (0.2 mM) with excess Tu or DIAZ, were observed as nonlinear as shown in Fig. 
7.12. The nonlinear plots, initially curved and subsequently plateaued (Figs.7.14-7.16), 
support that the interactions proceeded through two consecutive steps, as shown in 
Scheme 24.  
                             
        (A ͚- At) - a2 exp (-kobsd2 t) = a1 exp(-kobsd1 t)                (1)    
                             
        ∆ =   a1 exp(-kobsd1 t)                                      (2) 
 
Where, a1 and a2 are constants that are dependent on the rate constants and extinction 
coefficient (ε), and ∆ values are the difference of ln(A ͚-At) values between the observed 
and extrapolated part of the linear portion of the plot of ln(A ͚-At) versus time (t). The 
values of (A ͚-At) - a2 exp (-kobsd2 t) are obtained from the difference of X-Y values at 
different time (Fig. 7.12) when time is 0-10 seconds (A ͚ is the absorbance after reaction 






Figure 7.12. Kinetic plot of ln(A ͚-At) versus time (sec); [Au(cis-DACH)Cl2]Cl= 2.0 × 10-4 
M;[DIAZ]= 5.0×10-3 M; in aqeous solutions containging 30 mM KCl, at pH 3.5 and 15 °C. 
 
 
Scheme 24: Proposed reaction pathways for the substitution reaction of: (A) 






Table 7.3. Observed pseudo first-order rate constants as a function of nucleophile 
concentration and temperature for the substitution reaction between [Au(cis-DACH)Cl2]+ 
and Tu, in aqueous solution containing 30 mM KCl at pH 3.5. 





0.002 0.617           0.0325 
0.003 0.685           0.0376 
0.004 0.746           0.0427 
0.005 0.806           0.0482 
0.006 0.856           0.0536 
0.008 0.935           0.0633 
0.010 1.019           0.0688 
 
298.0 
0.002 0.715          0.0396 
0.003 0.795           0.0464 
0.004 0.858           0.0525 
0.005 0.947           0.0564 
0.006 0.997           0.0624 
0.008 1.183           0.0726 
0.010 1.288           0.0792 
 
310.0 
0.002 0.998           0.0426 
0.003 1.095            0.0485 
0.004 1.249           0.0589 
0.005 1.365           0.0652 
0.006 1.462           0.0712 
0.008 1.75            0.0824 















Table 7.4. Observed pseudo first-order rate constants as a function of nucleophile 
concentration and temperature for the substitution reaction between [Au(cis-DACH)2]3+ 
and Tu, in aqueous solution containing 30 mM KCl at pH 3.5. 
 





        0.002  0.652         0.0302 
0.003  0.695         0.0333 
0.004  0.722         0.0391 
0.005  0.762         0.0420 
0.006  0.815         0.0468 
0.008  0.881         0.0535 
0.010  0.995         0.0586 
 
298.0 
0.002  0.666         0.0345 
0.003  0.698         0.0384 
0.004  0.753         0.0428 
0.005  0.796         0.0502 
0.006  0.884         0.0543 
0.008  0.996         0.0626 
0.010  1.098         0.0687 
 
310.0 
0.002  0.679         0.0386 
0.003  0.729         0.0429 
0.004  0.829         0.0514 
0.005  0.886         0.0569 
0.006  0.967         0.0625 
0.008  1.084         0.0703 














Table 7.5. Observed pseudo first-order rate constants as a function of nucleophile 
concentration and temperature for the substitution reaction between [Au(cis-DACH)Cl2]+ 
and DIAZ in aqueous solution containing 30 mM KCl at pH 3.5. 





        0.002  0.536         0.0259 
0.003  0.596         0.0285 
0.004  0.619          0.031 
0.005  0.632         0.0325 
0.006  0.663         0.0343 
0.008  0.699         0.0392 
0.010  0.749         0.0466 
 
298.2 
0.002  0.722         0.0335 
0.003  0.761         0.0367 
0.004  0.802         0.0406 
0.005  0.834         0.0435 
0.006  0.866         0.0466 
0.008  0.922         0.0529 
0.010  0.976         0.0572 
 
310.2 
0.002  0.749         0.0372 
0.003  0.799         0.0423 
0.004  0.847         0.0473 
0.005  0.886         0.0514 
0.006  0.933         0.0554 
0.008  0.998         0.0621 














Table 7.6. Observed pseudo first-order rate constants as a function of nucleophile 
concentration and temperature for the substitution reaction between [Au(cis-DACH)2]3+ 
and DIAZ in aqueous solution containing 30 mM KCl at pH 3.5. 





        0.002   0.536         0.0198 
0.003   0.566         0.0212 
0.004   0.589         0.0232 
0.005   0.612         0.0255 
0.006  0.633         0.0272 
0.008  0.679         0.0322 
0.010  0.709         0.0342 
 
298.2 
0.002  0.588         0.0202 
0.003  0.627         0.0234 
0.004  0.656         0.0266 
0.005  0.673         0.0298 
0.006  0.708         0.0323 
0.008  0.754         0.0372 
0.010  0.798         0.0418 
 
310.2 
0.002  0.686         0.0356 
0.003  0.748         0.0409 
0.004  0.776         0.0444 
0.005  0.829         0.0471 
0.006  0.88         0.0511 
0.008  0.942         0.0569 















Evaluation of the rate constant k1 
The rate constant of the first step (A→B in Scheme 24) is dependent on the thione 
concentration, which is consistent with previous reports [61,192]. At constant temperature, 
the rate constant (kobsd1) for reaction of Tu or DIAZ with [Au(cis-DACH)Cl2]Cl and 
[Au(cis-DACH)2]Cl3 were obtained from the slopes of the plots of ln∆ versus time as 
illustrated in Figures (7.17-7.20).  
Typical calculations were made for each thione at concentrations of 2 -10 mM, 0.2 mM of 
[Au(cis-DACH)Cl2]+ or [Au(cis-DACH)2]3+, pH 3.5, in aqueous solutions containing 30 
mM KCl and at different temperatures of 288.2, 298.2 and 310.2 K. kobsd1 values were 
calculated by the Weyh and Hamm method [206]. 
A plot of kobsd1 versus thione concentration gives a straight line with an intercept = k-1 and 
a slope = k1. As illustrated in Eq. 3,  
kobsd1   =   k1[thione]   +  k-1[Cl-]                   (3) 
 
Evaluation of the rate constant k2  
The second step (B→C in Scheme 24) is a slower process than the first one due to 
competition between the second thione and the solvent. Kinetics showed that this step is 
independent on ligand concentration. The kobsd2 values were calculated from the slopes of 
the linear portion of the plots of ln(A ͚ -At) versus time.  
A plot of kobsd2 versus thione concentration gave a straight line with an intercept = k-2 and a 
slope = k2 as illustrated in Eq. 4.  
kobsd2   =   k2[thione]   +  k-2[Cl-]                   (4) 
Plots of pseudo first-order rate constants as a function of thione concentration at different 





[Au(cis-DACH)2]Cl3 with Tu and DIAZ are shown in Figs. (7.21-7.24). The rate 
constants (k1 and k2) are summarized in Table 7.7.  
Evaluation of activation parameters 
The activation parameters (ΔH#, ΔS#) for the reaction of [Au(cis-DACH)Cl2]Cl or 
[Au(cis-DACH)2]Cl3 with Tu and DIAZ were evaluated using Eyring plots. The Eyring 
plots for these substitution reactions at various temperatures are shown in Figures. 
(7.25-7.31). ΔH# and ΔS# values are summarized in Table 7.7. Enthalpies of activation are 
comparable to Ag-Cl and Ag-S bond energies and are consistent with previous studies 
[106]. Entropies of activations are all highly negatives, which support that all steps follow 
associative mechanisms. This is expected, at least for the Au(III) complexes. These d8 




Figure 7.13. UV-Vis spectra for the substitution reaction between [Au(cis-DACH)Cl2]+ 




















Figure 7.15. A typical Kinetic trace for the substitution reaction between 
[Au(cis-DACH)2]3+ (2.0 ×10-4 M) and Tu (2.0 ×10-3 M), in aqueous solution containing 30 
mM KCl, at pH 3.5, wavelength 245 nm and at 288 K. 
Figure 7.14. A typical kinetic trace for the substitution reaction between 
[Au(cis-DACH)Cl2]+ (10.0 × 10-4 M) and Tu (2.0 ×10-3 M), in aqueous 







Figure 7.16. A typical kinetic trace for the substitution reaction between 
[Au(cis-DACH)2]3+ (2.0 × 10-4 M) and DIAZ (6.0×10-3 M), in aqueous solution containing 
30 mM KCl, at pH 3.5, wavelength 251 nm and 288 K. 
 
Table 7.7 shows that the rate constant for the reaction of the two complexes with DIAZ and 
Tu. The reactivity of these thione ligands are shown to be slower than that for cyanide. It is 
also much faster than other nucleophiles as in these  order: L-Histidine ˃ guanosine-5ˈ- 
monophosphate˃ inosine-5ˈ-monophosphate˃ inosine towards the [Au(cis-DACH)Cl2]Cl 











Figure 7.17. A typical Kinetic plot of ln∆ versus time (sec); [Au(cis-DACH)Cl2]Cl= 2.0 × 





Figure 7.18. A typical Kinetic trace of the plot ln∆ versus time (sec) for the substitution 
reaction between [Au(cis-DACH)Cl2]+ (10.0 x 10-4 M) and Tu = 2.0×10-3 M, in aqueous 





Figure 7.19. A typical Kinetic trace of the plot ln∆ versus time (sec) for the substitution 
reaction between [Au(cis-DACH)2]3+ (2.0×10-4M) and Tu (2.0 ×10-3M), in aqueous 
















Figure 7.20. A typical kinetic trace of the plot ln∆ versus time (sec) for the substitution 
reaction between [Au(cis-DACH)2]+3(2.0 × 10-4 M) and DIAZ (6.0 ×10-3 M), in aqueous 






Figure 7.21. Plot of pseudo first-order rate constants for the first (kobsd1) and second 
(kobsd2) steps as a function of nucleophilic concentration and temperature of the 
substitution reaction between [Au(cis-DACH)Cl2]+ and Tu in aqueous solution containing 





Figure 7.22. Plot of pseudo first-order rate constants for the first (kobsd1) and second (kobsd2) 
steps as a function of nucleophilic concentration and temperature of the substitution reaction 










Figure 23. Plot of pseudo first-order rate constants for the first (kobsd1) and second (kobsd2) 
steps as a function of nucleophilic concentration and temperature of the substitution 
reaction between [Au(cis-DACH)Cl2]+ and DIAZ in aqueous solution containing 30 mM 
KCl. 
Figure 24. Plot of pseudo first-order rate constants for the first (kobsd1) and second (kobsd2) steps 
as a function of nucleophilic concentration and temperature of the substitution reaction between 






Figure 7.25. Eyring plots for forward substitution reactions of [Au(cis-DACH)Cl2]+ with 
Tu for the first (kobsd1) and second (kobsd2) step in aqueous solution containing 30 mM KCl 




Figure 7.26. Eyring plots for the reverse substitution reactions of [Au(cis-DACH)Cl2]+ 
with Tu for the first (kobsd1) and second (kobsd2) step in aqueous solution containing 30 mM 







Figure 7.27. Eyring plots for the forward substitution reactions of [Au(cis-DACH)2]3+ 
with Tu for the first (kobsd1) and second (kobsd2) step in aqueous solution containing 30 mM 














Figure 28. Eyring plots for the reverse substitution reactions of [Au(cis-DACH)2]3+ with Tu for 
















Figure 7.29. Eyring plots for the forward substitution reactions of [Au(cis-DACH)Cl2]+ 
with DIAZ for the first (kobsd1) and second (kobsd2) step in aqueous solution containing 30 














Figure 7.30. Eyring plots for the forward substitution reactions of [Au(cis-DACH)2]3+ with 
DIAZ for the first (kobsd1) and second (kobsd2) step in aqueous solution containing 30 mM 








Figure 7.31. Eyring plots for the reverse substitution reactions of [Au(cis-DACH)2]3+ with 
DIAZ for the first (kobsd1) and second (kobsd2) step in aqueous solution containing 30 mM 






Table 7.7. Rate constants for the substitution reactions of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with Tu 
 [Au(cis-DACH)Cl2]+ 
First step k1/M-1 s-1 ∆H1≠/kJmol-1 ∆S1≠/JK-1mol-1 k-1/M-1 s-1 ∆H-1≠/kJmol-1 ∆S-1≠/JK-1mol-1 
Tu 73.0 ± 3 22.4 ± 2.5 -133 ±  8 17.2 ± 0.3 7.4 ± 2.0 -196 ± 6.0 
Diaz 31.5 ± 1.2 16 ± 1 -164.3 ± 3.3 10.1 ± 0.2 - - 
Second step k2/M-1 s-1 ∆H2≠/kJmol-1 ∆S2≠/JK-1mol-1 k-2/M-1 s-1 ∆H-2≠/kJmol-1 ∆S-2≠/JK-1mol-1 
Tu 5 ± 0.2 7 ± 0.8 -208  ± 3 0.95 ± 0.4 6 ± 0.6 -227 ±7 
Diaz 3.0 ± 0.1 9.4 ± 1.4 -204 ± 5 0.84 ± 0.2 9 ± 2 -218 ±16 
[Au(cis-DACH)2]3+  
First step k1/M-1 s-1 ∆H1≠/kJmol-1 ∆S1≠/JK-1mol-1 k-1/M-1 s-1 ∆H-1≠/kJmol-1 ∆S-1≠/JK-1mol-1 
Tu 56 ± 2 9.2 ± 0.5 -181 ± 15 16.1 ± 0.4 - - 
Diaz 26 ± 1 16 ± 2 -164 ± 5 16.4 ± 0.2 4 ± 0.2 -209 ± 0.5 
Second step k2/M-1 s-1 ∆H2≠/kJmol-1 ∆S2≠/JK-1mol-1 k-2/M-1 s-1 ∆H-2≠/kJmol-1 ∆S-2≠/JK-1mol-1 
Tu 4.4 ± 0.2 6.6 ± 0.3 -211 ± 8 0.8 ± 0.1 5 ± 0.2 -232 ± 1 









NMR AND KINETIC STUDIES OF THE INTERACTION OF 
[Au(cis-DACH)Cl2]Cl AND [Au(cis-DACH)2]Cl3 WITH 




Recently, chemical and biochemical studies of Au(III) complexes containing N-chelating 
ligands have been reported showing biological activity [41, 68,210-215]. In addition, a 
number of other Au(III) complexes with N-ligands have been developed as promising 
anti-cancer and showed better cytotoxic activities. Gold(III) is analogue of the antitumor 
agent cis-diaminedichloroplatinum(II) (cisplatin) and in cis-1,2-diaminocyclohexane 
dichlorido- platinum(II) (DACH) complexes. The new gold(III) complexes may be 
attractive as anticancer drugs to overcome cisplatin side-effects [26, 188, 216-218]. 
Al-Maythalony et al. investigated the interaction of Au(III)–alkyldiamine complexes with  
L-histidine  and imidazole ligands by 1H, 13C NMR and UV spectrophotometry, and 
found that the rate of reaction is dependent on pH [101]. Zhu et al. reported the synthesis, 
structure and electrochemistry of Au(III) ethylenediamine complexes and their interactions 
with Guanosine5-phosphate [219].  Sanghvi et al. described antitumor properties of 
five-coordinate gold(III) complexes bearing substituted polypyridyl ligands, and  found 





metallotherapeutic cisplatin [220]. Ahmed et al. studied histological changes in kidney and 
liver of rats due to exposure of [Au(en)Cl2]Cl complex [8]. Al-Jaroudi et al. described the 
synthesis, characterization and cytotoxicity of gold(III) complexes with the ligand 
1,2-diaminocyclohexane, and showed the influence of stereochemistry on antitumor 
activity [198]. Monim-ul-Mehboob et al. prepared a series of Au(III)-alkanediamine 
complexes, with ligands ethylenediamine, propylenediamine, butylenediamine, and 
N-alkyl substituted ethylenediamine, those were characterized and tested against  gastric, 
prostate and ovarian cancer cells [221]. 
The interaction of Au(III) with cyanide ligand has interest in therapeutic values and 
pharmacological activity, due to the formation of [Au(CN)4] ̅, which is unstable in 
physiological condition and produces [Au(CN)2 ] ̅. Cyanide is naturally produced in the 
body by oxidation of SCN¯ by the enzyme myeloperoxidase (MPO) and released by 
phagocytic cells [50, 203, 222]. The [Au(CN)2]̅ has been extensively used in the treatment 
of rheumatoid arthritis since 1920s, while other Au(I) complexes showed activity against 
malaria and HIV [52, 109]. 
Canumalla et al. described redox and ligand exchange reactions of potential gold(I) and 
gold(III)-cyanide metabolites under biomimetic conditions [195]. Yangyuoru et al. studied 
the reduction of auricyanide using biological ligand glutathione (GSH) as reductant 
through two intermediates I230 and I290 [194]. Al-Maythalony et al. described 1H, 13C NMR 
and UV-Vis spectroscopy studies of gold(III)-tetracyanide complex with L-cysteine, 






8.2 Experimental section 
8.2.1 Materials and instrumentation 
NaAuCl4.2H2O, cis-DACH (C6H14N2) were purchased from Sigma-Aldrich- USA, 
absolute ethanol from Merck, CH3OD and D2O were purchased from Alfa-Aesar, KCN, 
99.9% enriched K13CN and 99% enriched K13C15N from Cambridge Isotope Lab. Inc. 
Deionized water with a resistivity of 18.6 MΩ cm−1 is used to prepare all solutions. The 
water is obtained directly from a PURELABs Ultra Laboratory Water Purification System. 
Spectroscopic and electrochemical techniques, synthesis of [Au(cis-DACH)Cl2]Cl and 
[Au(cis-DACH)2]CL3 were described in section 3.1. 
8.2.2 Kinetic Measurements 
The UV-Vis spectra of the complex and cyanide solutions were recorded over the range 
200-500 nm, Fig. 8.1 (five runs) and are showing λmax at 305 nm and 258 nm for 
[Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 respectively. The reactions were started 
by mixing the complex and cyanide solutions in equal volumes directly in a vial kept 
inside the instrument. The kinetic measurements were made under pseudo-first order 
conditions, where concentration of the complex is 0.1 mM and for the cyanide it was in 
the range 2-10 and 20 mM. The reactions were followed over 10 minutes and were 
carried out at ambient temperature of 25 °C. The pseudo-first order rate constant kobsd is 
calculated as an average value of eight independent kinetic runs [61]. Observed 






Figure 8.1. The UV-Vis spectra for the substitution reaction of [Au(cis-DACH)Cl2]Cl ( 1.0 
×10-4M) (a) before and (b) after addition of cyanide (5.0 ×10-3M) and (c) cyanide before 
reaction, the substitution reaction carried out at ambient temperature of 25°C. 
 
8.3 Results and Discussion 
8.3.1 Interaction of [Au(cis-DACH)Cl2]Cl With K13CN 
 
Interaction of [Au(cis-DACH)Cl2]Cl with enriched KCN was carried out in CH3OD by 
mixing the reactants at different ratios and monitored by 1H, 13C, 15N NMR, UV-Vis 
spectroscopy and electrochemistry.1H, 13C and 15N NMR chemical shifts for the species 
in this interaction are given in Tables (8.1-8.2, 8.4A) . 
When 13C NMR is used to monitor the reaction, (Fig.8.2a) shows the chemical shift of (5 
mM) 20% enriched K13CN at 160.48 ppm. The peak at 103 ppm in (Fig.8.2b) indicates 
the white precipitate [Au (13CN)4] ̅ . It is formed by interaction of [Au(cis-DACH)Cl2]Cl 







Table 8.1. 1H NMR chemical shifts of the reaction of [Au(cis-DACH)(Cl2]Cl complex 
with K13CN ligand in CH3OD solution. 
Specie 1H, 2H 3H, 6H eq 3H, 6H ex 4H, 5H eq 4H, 5H ex 
(1: 0) 3.59 m 2.02 m 1.76 m 1.47 m 1.29 m 
(1: 1) 3.56 m 2.00 m 1.75 m 1.48 m - 
(1: 2) 3.39 m 1.87 m 1.62 m 1.40 m 0.86 m 
(1: 4) 3.61 m 1.76 m 1.51 m 1.32 m 0.86 m 
 
The anionic complex, [Au(13CN)4]̅ is not stable and goes, through trans-effect, into 
reductive elimination to form cyanogen (NCCN), which appeared at 110.52 ppm, while 
Au(III) was reduced to [Au(13CN)2] ̅, which was shifted up-field at 152-157 ppm, due to 
the back donation of gold to cyanide ligand [205]. The [Au(CN)2] ̅ complex has higher 
stability due to its significant covalent bond than the corresponding [Cu(CN)2] ̅ and 
[Ag(CN)2] ̅  described by Wang et al [224]. 
Figure 8.2c shows the 13C spectrum, where the two peaks at 101.31 ppm and 96.50 ppm, 
indicate the rapid consecutive exchange of chloride ions by 13CN‾ ion to produce 
[Au(cis-DACH)(13CN)Cl] ̅ and [Au(cis-DACH)(13CN)2] ̅ respectively. The down-field 
shift at (1:1.5) ratio to 119.13 ppm, 120.52 ppm, and 121.34 ppm indicates the formation 
of [Au(CN)2Cl2]¯, [Au(CN)3Cl] ̅, and [Au(13CN)2(OH)Cl] ̅ respectively. While the peak at 








Table 8.2. 13C NMR chemical shifts of the 13CN  ̄ for different species during the reaction 
of [Au(cis-DACH)Cl2]Cl complex with cyanide in CH3OD solution. 
Species  13C(δ in ppm) Reference 
KCN 160 ppm [200] 
[Au(cis-DACH)(CN)Cl]Cl 101 ppm This work 
[Au(CN)4]  ̄ 103 ppm [195- 200] 
[Au(CN)2Cl2] ̄ 119 ppm [195] 
HCN 137 ppm This work 
NCCN 110 ppm [196] 
[Au(CN)2(OH)Cl]Cl 121 ppm [195] 
[Au(CN)2(OH)2]Cl 120 ppm [195] 






Scheme 25. Suggested mechanism reaction of [Au(cis-DACH)Cl2]Cl with K13CN in 








The 13C spectrum, fig.2d sheds a light on another reaction mechanism of the reduction of 
[Au(13CN)4]̅ to [Au(13CN)2]̅ through intermediate complexes [Au(13CN)2Cl2] ̅, 
[Au(13CN)3Cl] ̅, and [Au(13CN)2(OH)Cl] ̅  by displacement of cyanide by chloride 
through cis effect kinetics, unlike the behaviour of Pt(II) described by Skibsted [225]. 
 
Scheme 26. Suggested mechanism of conversion [Au(13CN)4]̅  to [Au(13CN)2] ̅. 
 
The above mechanism is the solvolytic pathway through reversible exchange of chloride 
and H2O. For instance, H2O is being the stronger compared to chloride and cyanide ions 






Figure 8.2. 13C NMR spectra of (a) free K13CN, (b) after reaction with [Au(cis-DACH)Cl2]Cl at (I: 0.25) ratio, (c) at (1: 0.5) ratio, (d) at 





The CN ̄ ion, being the strong π-acceptor rapidly displaces DACH at (1:2) ratio as shown 
by the resonance of free DACH at 53.03 ppm, 31.03 ppm, 22.95 ppm (Fig.2e) [194]. 
Table 8.1 shows 1H NMR chemical shifts of [Au(cis-DACH)Cl2]Cl complex interacting 
with CN ̄ ligand at different ratios. (Fig. 8.3a) shows a peak at 265 ppm assigned to (5 
mM) free 99.9 % enriched K13C15N. for the ration reaction (1:2) (Fig.3b) this peak shifted 
down-field at 281 ppm and it is assigned to [Au(13C15N)4] ̅ . While at (1:4) ratio, (Fig. 
8.3c) there are two resonances at 262 ppm and at 281 assigned to [Au(13C15N)2] ̅ and 
[Au(13C15N)4] ̅  respectively [205]. 
 
 
Figure 8.3.15N NMR spectra of (a) free K13C15N, (b) after reaction with 
[Au(cis-DACH)Cl2]Cl at (complex: ligand) (1:2) ratio, (c) after reaction with 
[Au(cis-DACH)Cl2]Cl at (complex: ligand) (1:4) ratio, in CH3OD. 
 
Moreover, the obtained electrochemical results came in a complete agreement with 1H, 
13C, and 15N NMR and UV spectroscopy, and confirmed the suggested mechanism 





(glassy carbon electrode) in a quiescent aqueous solution of 0.2 M KCl.  A well-defined 
SWV peak (Fig. 8.4b) was obtained at +0.82V (vs. Ag/AgCl) for 1.0 mM 
[Au(cis-DACH)Cl2]Cl. This peak showed a systematic decrease on its peak area with 
subsequent additions of CN- at different equivalents (1:0.5), (1:1) and (1:1.5) (Fig. 4 c-e).  
At (1:2) ratio, a complete peak disappearance was observed with the appearance of a new 
peak shoulder around +1.4V (Fig.8.4f), which became more defined at (1:3) and (1:4) 
ratios. The same additions of CN- to 0.2 M KCl solution in absence of the 
[Au(cis-DACH)Cl2]Cl complex showed no peaks (data not shown). 
 
 
Figure 8.4. SWVs in a 0.2 M KCl aqueous solution at a GCE in absence (a) and presence 
(b) of 1.0 mM [Au(cis-DACH)Cl2]Cl, and subsequent additions of 0.5 mM (c-f) and 1.0 
mM (g, h) of KCN aqueous solution. Working condition of the pulse width (increment), 
4mV; pulse height (amplitude), 25 mV; frequency, 15 Hz. Inset is the corresponding 







8.3.2 Interaction of [Au(cis-DACH)2]Cl3 with K13CN 
 
Interaction of [Au(cis-DACH)2]Cl3 with 20% enriched K13CN was carried out in D2O by 
mixing the reactants at different mole ratios and monitored by 1H, 13C ,15N NMR, UV-vis 
spectroscopy, and electrochemistry. The 1H, 13C and 15N NMR chemical shifts for this 
interaction are given in Tables (8.3-8.4B). 13C NMR is used to monitor the interaction, 
(Fig. 8.5a) shows a peak for (5 mM) 20% enriched K13CN assigned at 157.4 ppm. (Fig. 
8.5b) shows two new peaks up-field at 104.5 ppm and at 119.8 ppm corresponding to 
[Au(13CN)4]̅ and [Au(CN)2Cl2] ̅ respectively [101,195]. When the reaction is carried out at 
(1:1) ratio, the peak at 119.8 ppm is shifted down-field 120.47 ppm and a new peak is 
observed at 154.37 ppm, assigned to [Au(13CN)2]̅, which is the result of reductive 
elimination of [Au(13CN)4]̅   (Fig. 8.5c) [223]. 
Figure 8.5d shows a peak at 110.10 ppm of cyanogen (NCCN) due to an oxidation of 
CN‾ and reduction of Au(III) to Au(I) [101]. There is a significant down-field shift from 
119.8 ppm to 122.5 ppm corresponding to very fast consecutive two cyanide ligands 
exchanged by H2O due to solvolytic pathway [226]. 
Table 8.3. 1H NMR chemical shifts of DACH protons for the reaction of 
[Au(cis-DACH)2]Cl3 with (K13CN) in D2O. 
Species  1H, 2H 3H, 6H eq. 3H, 6H ex. 4H, 5H eq. 4H, 5H ex. 
(1:0) 3.58 m 1.94 m 1.74 m 1.56 m 1.38 m 
(1:1) 3.32, 3.20 m 1.86 m 1.65 m 1.53 m 1.33 m 
(1:2) 3.21, 3.06 m 1.80 m 1.62 m 1.49 m 1.26 m 






















Figure 8.5. 13C NMR spectra of (a) free K13CN, (b) after reaction with [Au(cis-DACH)2]Cl3 at( I: 0.25) ratio, (c)  at (1:1)  ratio, 





At higher concentration of 13CN‾ ion into (1:4) ratio, an up-field shift of DACH’s carbons 
was observed, which corresponds to the displacement of DACH ligands. The peak 
observed at 121 ppm is an indication of H2O being exchanged by chloride to form 
[Au(CN)2(OH)Cl] ̅ (Fig. 8.5d) [195]. Table 8.3 shows 1H NMR chemical shifts for 
[Au(cis-DACH)2]Cl3 reaction with K13CN in the range (1:1) to (1:4) ratio.  
 
Table 8.4(A-B). 15N NMR chemical Shifts of the 13C15N  ̄ for different species during the 
reactions of [Au(cis-DACH)Cl2]Cl (A) and [Au(cis-DACH)2]Cl3 (B) with K13C15N in 
CH3OD and D2O. 
Specie    A B 
K13C15N 265.03 ppm 271.82 ppm 
[Au(13C15N)2] ̄ 262.63 ppm 265.06 ppm 
 ̄]4N)15C13Au([      281.52 ppm              275.01 ppm    
 
 
The 15N NMR spectrum (Fig.8.6b) shows two resonances at 275.01 ppm and 265.06 ppm 
assigned to [Au(13C15N)4]̅  and [Au(13C15N)2]̅  respectively. 
Figure 8.7 shows a SWV peak for the [Au(cis-DACH)2]Cl3 at +1.35V (vs. Ag/AgCl). 
The peak area decreased systematically with the additions of CN-. However, and due to 
the relatively high potential peak position (+1.35V), the decrease was not easy to follow, 










Figure 8.6. 15N NMR spectra of (a) free K13C15N and (b) after reaction with  
 [Au(cis-DACH)2]Cl3 at (complex: ligand) (I:2) ratio in D2O. 
 
 
Figure 8.7. SWVs in a 0.2 M KCl aqueous solution at a GCE in absence of complex (a) and 
presence (b) of 1.0 mM [Au(cis-DACH)2]Cl3, and subsequent additions of 0.5 mM (c-f) and 
1.0 mM (g, h) of KCN aqueous solution. Working condition of the pulse width (increment), 





8.3.3 Kinetic Data 
 
The substitution reactions of these square-planar gold(III) complexes [(cis-DACH) 
AuCl2]Cl and [Au(cis-DACH)2]Cl3 with cyanide ion were investigated spectro- 
photometrically by the change of absorbance at the selected wavelengths as function of 
time under pseudo-first order conditions. The substitution reaction proceeds most likely 
through an associative mechanism. All reactions were studied in aqueous solution. An 
addition of 20 mM NaCl prevents hydrolysis of the complex. The suggested reaction 
mechanism of cyanide ion with [Au(cis- DACH)Cl2]Cl is shown in  Scheme 25. The 
rate constants are determined from the plot of linear dependence of kobsd versus total 
cyanide concentration (figure 8.8A) according to equation (1). The slope of the line 
represents kf, while the intercept indicates kb[Cl ̄ ]. All kinetic data are summarized in 
Table 8.5. 
kobsd =   kf[CN ̄ ] + kb[Cl ̄ ]                           (1) 
The Enthalpy, Entropy and Activation energy for the reaction of [Au(cis-DACH)Cl2]Cl 
with cyanide ion are calculated using Eyring equation (2) and Arrhenius equation (3)   
                         (2)                                                                                                                                   
                             
  
                                                                       
 
 





From the rate constant values, it can be clearly seen that the [Au(cis-DACH)Cl2]Cl  
reacts much faster than [Au(cis-DACH)2]Cl3 complex. The difference in reactivity can be 








Table 8.5. Rate constant k, for substitution reaction of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with cyanide ion, in the 
presence of 20 mM NaCl in aqueous solution at 298 K. 
 
λ max 
[Au(cis-DACH)Cl2]Cl  = 0.1 mM 
[CN-]/ M Kobsd / s-1 kf / M-1s-1 kb/ M-1s-1 ∆H≠/kJmol-1 ∆S≠/JK-1mol-1 Ea/kJmol-1 
305 nm 0.00200 0.1993 148 ± 1.00 (11 ±1)10-4 39 ± 3.0 -80 ± 4.0 42± 4.0 
 0.00300 0.3458 
 
    
 0.00400 0.5989 
 0.00500 0.7246 
 0.00600 0.9971 
 0.00800 1.3654 
 0.01000 1.7456 
 0.02000 2.8345 
λ max  [Au(cis-DACH)2]Cl3 = 0.1 mM    
258 nm 0.00200 0.0696 18 ±1.0 (94 ±1)10-4 11 ± 2.0 -185 ± 4.0 13 ± 2.0 
 0.00300 0.0797 
       
  
      
 0.00400 0.09478 
 0.00500 0.10739 
 0.00600 0.11663 
 0.00800 0.14978 
 0.01000 0.2552 





The reactive kinetics of the cyanide ligand is found to be much faster than the following 
nucleophiles: L-histidine (L-His), guanine-5ʹ-monophosphate (5ʹ-GMP), inosine (Ino), 
and inosine-5ʹ-monophosphate (5ʹ-IMP) towards the [Au(cis-DACH)Cl2]Cl complex 
[61-62]. 
The reactivity order of these ligands toward [Au(cis-DACH)Cl2]Cl complex is CN̄ >>> 
L-His >5ʹ-GMP > Ino > 5ʹ-IMP as shown in (Table 8.6). it is substitution reaction and 
absorbance band is 305 nm as shown in Fig. 8.9.  
 
 
Table 8.6. Rate constants for substitution reactions of [Au(cis-DACH)Cl2]Cl and 
[Au(cis-DACH)2]Cl3 complexes with cyanide in presence of 20 mM NaCl in aqueous 
solution at 298K. 
Specie  kf / M-1 s-1     Kb / M-1 s-1    ∆H≠/kJ mol-1   ∆S≠/JK-1mol-1   ∆Ea / kJmol-1   Reference  
[Au(cis-DCH)Cl2]+     
Cyanide 148 ± 3 (11± 1)10-4 39 ± 3.0 -80  ± 4.0 42 ± 4.0 This work 
       
L-His 75 ± 2 4.0 ± 0.1 12 ± 3 -160 ± 10 - [171] 
5′-GMP 66 ± 2 9.3 ± 0.2 10 ± 3 -180 ± 10 - [61, 62] 
5′-IMP 6. ± 0.3 0.6 ± 0.2 - - - [61] 
Ino 10 ± 1 0.6 ± 0.2 - - - [61] 
[Au(cis-DACH)2]3+ 
Cyanide  18 ±1    (94 ± 1)10-4 11 ± 2.0    -185 ± 4.0 13 ± 2.0      This work 
 
 
Figure 8.10 shows UV spectra of an oxidation reduction reaction of 
[Au(cis-DACH)Cl2]Cl with CN ‾ ion at (complex: ligand) (1:2) ratio. The bands observed 
at 204 nm and 211 nm, correspond to [Au(CN)2]̅, by the back donation from d-orbital(d8) 
in Au(III) ion to empty π̽ -acceptor in cyanide ligand, which strengthens Au-CN and 





[Au(cis-DACH)Cl2]Cl with CN‾ ion at (1: 4) ratio. The bands observed at 204, 211and 
240 nm assigned to [Au(CN)2]̅ ,  remains unchanged after 24 h, indicating completion of 
the oxidation reduction reaction [228-229]. Figure 8.12(A-B) show pseudo-first order rate 
constant as function of nucleophilic concentration and temperature for the reaction of 
[Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with cyanide ion. 
 
 
Figure 8.8A. Plot of pseudo-first order rate constant for the reaction between 







Figure 8.8B. Plot of pseudo-first order rate constant for the reaction between 




Figure 8.9. UV-Vis spectra for the substitution reaction of (a) [Au(cis-DACH)Cl2]Cl (1 
mM) before and (b) after addition of KCN(1 mM) at (complex: ligand) (1:0.5) ratio in the 






Figure 8-10. UV-Vis spectra for an oxidation reduction reaction of (a) 
[Au(cis-DACH)Cl2]Cl (0.1 mM) before and (b) after addition of KCN (0.1 mM) at 
(complex: ligand) (1:2) mole ratio in the range 200-350 nm at 25 °C. 
 
 
Figure 8.11. UV-Vis spectra for an oxidation reduction reaction of (a) 
[Au(cis-DACH)Cl2]Cl (0.1 mM) before and (b) after 30 min of addition of KCN (0.1 mM) 






Figure 8.12A: Plot of pseudo first order rate constants, as function of CN¯ concentration 
and temperature for the reaction between [Au(cis-DACH)Cl2]Cl and cyanide ion  in the 
presence of 20 mM NaCl in aqueous solution. 
 
 
Figure 8.12B: Plot of pseudo first order rate constants, as function of CN¯ concentration 
and temperature for the reaction between [Au(cis-DACH)2]Cl3 and cyanide ion in the 






CONCLUSION AND FUTURE STUDIES 
 
Gold(I) complexes belong to an emerging class of potential anticancer agents. During the 
past couple of decades many gold(I) compounds with versatile structures, showing 
promising cytotoxic effects against selected human cancer cell lines and acceptable 
stability under physiological conditions have been reported. All attributes make them 
good candidates as antitumor drugs. Herein, we report the synthesis, and characterization 
of gold(I) complexes [Au(R3P)(R2NCS2)] (2-34);[Au(R3P)2] (35-37); [Au(Ipr)-(Se=CR2)] 
(38-50); [Au(R3P)(S=CR2)], (51-55),[Au(Ipr)(R3P)] and [Au(Ipr)2(R6P2)] (56-65).  
Compounds (2-22), (35-37), and (38-50) were tested for their an in vitro cytotoxicity 
against three human cancer cell lines; HeLa (human cervical cell line), HCT 15(human 
colon cell line) and A549 (human lung carcinoma). Gold(I) compounds (20-22, 48) 
exhibited better cytotoxicity in terms of IC50 values against A549 cell line and HCT15 than 
the standard anticancer chemotherapy drug (cisplatin). Whereas, the other studied gold(I) 
compounds showed moderate to lower in vitro cytotoxicity against HCT15 and HeLa 
cancer cell lines. The significant cytotoxicity of gold(I) compounds against A549 and 
HCT15 human cancer cells has made them strong candidates as potential anticancer agents 
for further exploration against lung and colon cancer. 
The interaction of [Au(cis-DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with cyanide, Tu and 
DIAZ was studied using (1H, 13C and 15N) NMR and square wave stripping voltammetry. 
contribution for DaipSe and DaizSe relatively to ImSe due to ring strain hindering the 
rehybridization of N culminating in DaipSe NMR studies showed that DIAZ ligates more 





to Tu (evident from the magnitude of (C=S) chemical shift). Kinetic measurements 
revealed that the substitutive reaction [Au(cis-DACH)Cl2]Cl reacting faster than 
[Au(cis-DACH)2]Cl3. Also the trend of the rate constants for the ligands oder as 
following: cyanide >>> Tu > DIAZ. The negative values of ∆S≠ for these reactions lend 
support for an associative mechanism and these results may contribute to a better 
understanding of biochemical mechanism of [Au(cis-DACH)Cl2]Cl and 
[Au(cis-DACH)2]Cl3. 
For further future studies  
 In vitro cytotoxicity assay of the compounds (23-34), (51-55) and (56-65). 
 In vivo assay for gold(I) compounds with the significant cytotoxicity to explore 
their mechanism of action. 
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